Education and Career

Academic & Professional Experience

•   1998 04 ,  - 現在, Faculty of Medicine, Kindai University

Research Activities

Research Areas

• Life sciences, Medical systems
• Life sciences, Tumor diagnostics and therapeutics

Research Interests

• nodule-in-nodule HCC, Coded phase inversion harmonic, Pure arterial phase imaging, dysplastic nodule, nodule-in-nodule, Sonazoid

Published Papers

• Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma, Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M, J Hepatol, J Hepatol, 72, 307 - 319, 2020 , Refereed
• Possible involvement of autophagy in esophageal ulcers in anorexia nervosa., Masaki S, Watanabe T, Minaga K, Kamata K, Komeda Y, Kimura M, Kudo M, Clinical journal of gastroenterology, Clinical journal of gastroenterology, Jan. 2020 , Refereed
  DOI
• Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial., Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL, KEYNOTE, investigators, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO1901307, Dec. 2019 , Refereed
  DOI
• Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial., Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y, TACTICS study group, Gut, Gut, Dec. 2019 , Refereed
  DOI
• Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach., Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), Nov. 2019 , Refereed
  DOI
• Novel concept of bared type metallic stent for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction (with video)., Takenaka M, Nakai A, Kudo M, Journal of hepato-biliary-pancreatic sciences, Journal of hepato-biliary-pancreatic sciences, Nov. 2019 , Refereed
  DOI
• REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset., Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H, Journal of gastroenterology, Journal of gastroenterology, Nov. 2019 , Refereed
  DOI
• Revisionary antireflux metal stent placement for stent occlusion after endoscopic ultrasound-guided hepaticojejunostomy., Minaga K, Takenaka M, Okamoto A, Omoto S, Kamata K, Yamao K, Kudo M, Endoscopy, Endoscopy, Nov. 2019 , Refereed
  DOI
• Response to the letter to the editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study" by Dr. Peng Chen'., Yamao K, Watanabe T, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), Nov. 2019 , Refereed
  DOI
• The chances of hepatic resection curing hepatocellular carcinoma., Cucchetti A, Zhong J, Berhane S, Toyoda H, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Ercolani G, Mazzaferro V, Kudo M, Cescon M, Pinna AD, Kumada T, Johnson PJ, Journal of hepatology, Journal of hepatology, Nov. 2019 , Refereed
  DOI
• Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial., Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y, Liver cancer, Liver cancer, 8(6), 505 - 519, Nov. 2019 , Refereed
  DOI
• Can Localized Stenosis of the Main Pancreatic Duct be a Predictive Factor for Early Detection of Pancreatic Cancer?, Takenaka M, Yamao K, Kudo M, Clinical endoscopy, Clinical endoscopy, 52(6), 523 - 524, Nov. 2019 , Refereed
  DOI
• Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update., Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 49(10), 1109 - 1113, Oct. 2019 , Refereed
  DOI
• Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma., Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW, British journal of cancer, British journal of cancer, 121(7), 625, Oct. 2019 , Refereed
  DOI
• Report of the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan., Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, Oct. 2019 , Refereed
  DOI
• Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video)., Takenaka M, Minaga K, Kamata K, Yamao K, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Komeda Y, Sakurai T, Watanabe T, Nishida N, Chiba Y, Kwon CI, Jeong S, Lee TH, Kudo M, Surgical endoscopy, Surgical endoscopy, Oct. 2019 , Refereed
  DOI
• Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552]., Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M, Journal of hepatology, Journal of hepatology, Oct. 2019 , Refereed
  DOI
• A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE., Kudo M, Liver cancer, Liver cancer, 8(5), 299 - 311, Oct. 2019 , Refereed
  DOI
• Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients., Hiraoka A, Kumada T, Michitaka K, Kudo M, Liver cancer, Liver cancer, 8(5), 312 - 325, Oct. 2019 , Refereed
  DOI
• Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan., Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M, Liver cancer, Liver cancer, 8(5), 403 - 411, Oct. 2019 , Refereed
  DOI
• Long-term outcomes of EUS-guided transluminal stent deployment for benign biliary disease: Multicenter clinical experience (with videos)., Ogura T, Takenaka M, Shiomi H, Goto D, Tamura T, Hisa T, Kato H, Nishioka N, Minaga K, Masuda A, Onoyama T, Kudo M, Higuchi K, Kitano M, Endoscopic ultrasound, Endoscopic ultrasound, 8(6), 398 - 403, Sep. 2019 , Refereed
  DOI
• Effective use of the Japan Narrow Band Imaging Expert Team classification based on diagnostic performance and confidence level., Hirata D, Kashida H, Iwatate M, Tochio T, Teramoto A, Sano Y, Kudo M, World journal of clinical cases, World journal of clinical cases, 7(18), 2658 - 2665, Sep. 2019 , Refereed
  DOI
• Comparison of the efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy and hepaticogastrostomy for malignant distal biliary obstruction: Multicenter, randomized, clinical trial., Minaga K, Ogura T, Shiomi H, Imai H, Hoki N, Takenaka M, Nishikiori H, Yamashita Y, Hisa T, Kato H, Kamada H, Okuda A, Sagami R, Hashimoto H, Higuchi K, Chiba Y, Kudo M, Kitano M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(5), 575 - 582, Sep. 2019 , Refereed
  DOI
• Dual-frequency MR elastography to differentiate between inflammation and fibrosis of the liver: Comparison with histopathology., Sofue K, Onoda M, Tsurusaki M, Morimoto D, Yada N, Kudo M, Murakami T, Journal of magnetic resonance imaging : JMRI, Journal of magnetic resonance imaging : JMRI, Aug. 2019 , Refereed
  DOI
• Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need., Minami Y, Kudo M, Hepatobiliary surgery and nutrition, Hepatobiliary surgery and nutrition, 8(4), 414 - 416, Aug. 2019 , Refereed
  DOI
• Endoscopic sclerotherapy under balloon-assisted enteroscopy for hemorrhagic jejunal varices after choledocho-jejunostomy., Takashima K, Matsui S, Komeda Y, Nagai T, Toshiharu S, Kashida H, Kudo M, Endoscopy, Endoscopy, Aug. 2019 , Refereed
  DOI
• Biology and Significance of Alpha-Fetoprotein in Hepatocellular Carcinoma., Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman W, Chintharlapalli S, Abada P, Sherman M, Zhu AX, Liver international : official journal of the International Association for the Study of the Liver, Liver international : official journal of the International Association for the Study of the Liver, Aug. 2019 , Refereed
  DOI
• Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis., Uchida S, Oiso N, Komeda Y, Kudo M, Kawada A, European journal of dermatology : EJD, European journal of dermatology : EJD, 29(4), 444 - 445, Aug. 2019 , Refereed
  DOI
• Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study., Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N, Cancers, Cancers, 11(8), Jul. 2019 , Refereed
  DOI
• Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency., Yokomichi N, Nishida N, Umeda Y, Taniguchi F, Yasui K, Toshima T, Mori Y, Nyuya A, Tanaka T, Yamada T, Yagi T, Fujiwara T, Yamaguchi Y, Goel A, Kudo M, Nagasaka T, Liver cancer, Liver cancer, 8(4), 239 - 254, Jul. 2019 , Refereed
  DOI
• Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials., Kudo M, Liver cancer, Liver cancer, 8(4), 221 - 238, Jul. 2019 , Refereed
  DOI
• B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial., Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y, Ogawa C, Akazawa K, Liver cancer, Liver cancer, 8(4), 271 - 280, Jul. 2019 , Refereed
  DOI
• Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis., Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E, Liver cancer, Liver cancer, 8(4), 281 - 294, Jul. 2019 , Refereed
  DOI
• Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study., Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 58(14), 1993 - 2002, Jul. 2019 , Refereed
  DOI
• Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease., Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 58(14), 2029 - 2033, Jul. 2019 , Refereed
  DOI
• Novel concept using a plastic stent for endoscopic ultrasound-guided hepaticogastrostomy adjusting the length according to the patient's anatomy., Takenaka M, Minaga K, Yoshikawa T, Okamoto A, Nakai A, Omoto S, Kudo M, Endoscopy, Endoscopy, Jul. 2019 , Refereed
  DOI
• Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy by the intentional expansion method., Takenaka M, Kamata K, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(6), 718, Jul. 2019 , Refereed
  DOI
• Large balloon expansion method for re-intervention after endoscopic ultrasound-guided hepaticogastrostomy for stent obstruction., Takenaka M, Nakai A, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(5), e99 - e100, Jul. 2019 , Refereed
  DOI
• Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study., Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M, Cancers, Cancers, 11(7), Jul. 2019 , Refereed
  DOI
• Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells., Kamata K, Watanabe T, Minaga K, Hara A, Yoshikawa T, Okamoto A, Yamao K, Takenaka M, Park AM, Kudo M, International immunology, International immunology, 31(12), 795 - 809, Jul. 2019 , Refereed
  DOI
• Radiofrequency ablation for hepatocellular carcinoma: clinical value of US-US overlay fusion for optimal ablation and local controllability., Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, Jul. 2019 , Refereed
  DOI
• Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma., Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, Real-life Practice Experts for HCC, RELPEC) Study Group., HC, Group (hepatocellular carcinoma exper, s, fr, clinics in Ja, Oncology, Oncology, 97(5), 1 - 9, Jul. 2019 , Refereed
  DOI
• Response Evaluation Criteria in Cancer of the Liver (Version 5) (RECICL 2019 revised version)., Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, Jun. 2019 , Refereed
  DOI
• Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma., Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW, British journal of cancer, British journal of cancer, 121(3), 218 - 221, Jun. 2019 , Refereed
  DOI
• Recent Updates on the Relationship between Cancer and Autoimmune Pancreatitis., Okamoto A, Watanabe T, Kamata K, Minaga K, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 58(11), 1533 - 1539, Jun. 2019 , Refereed
  DOI
• Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan., Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S, Journal of gastroenterology, Journal of gastroenterology, 54(6), 558 - 570, Jun. 2019 , Refereed
  DOI
• Intracystic papillary neoplasm preoperatively diagnosed by high-quality cytology derived from endoscopic nasogallbladder drainage., Hara A, Kamata K, Takenaka M, Chikugo T, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 89(6), 1257 - 1259, Jun. 2019 , Refereed
  DOI
• Novel sphincterotomy device that orientates blade along the axis of the bile duct in patients with Roux-en-Y anastomosis., Takenaka M, Yoshikawa T, Okamoto A, Nakai A, Minaga K, Yamao K, Kudo M, Endoscopy, Endoscopy, 51(6), E132 - E134, Jun. 2019 , Refereed
  DOI
• The IFN-α-IL-33 Axis as Possible Biomarkers in IgG4-Related Disease., Minaga K, Watanabe T, Kamata K, Takenaka M, Yasukawa S, Kudo M, The American journal of gastroenterology, The American journal of gastroenterology, 114(6), 1002 - 1003, Jun. 2019 , Refereed
  DOI
• Switching from Entecavir to Tenofovir alafenamide versus maintaining Entecavir for chronic hepatitis B., Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M, Journal of medical virology, Journal of medical virology, Jun. 2019 , Refereed
  DOI
• Hemorrhage from metastasis of a 5-mm renal cell carcinoma lesion to the gallbladder detected by contrast-enhanced endoscopic ultrasonography., Takenaka M, Okabe Y, Kudo M, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 51(5), 743, May 2019 , Refereed
  DOI
• Autoimmune hepatitis and IgG4-related disease., Minaga K, Watanabe T, Chung H, Kudo M, World journal of gastroenterology, World journal of gastroenterology, 25(19), 2308 - 2314, May 2019 , Refereed
  DOI
• Pembrolizumab for the Treatment of Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 8(3), 143 - 154, May 2019 , Refereed
  DOI
• Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures., Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, Ishikawa T, Seike M, Katsube T, Ochiai T, Kimura K, Fukuhara T, Kano T, Nagata T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 17(6), 1192 - 1200, May 2019 , Refereed
  DOI
• Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: A prospective multicenter study., Itonaga M, Kitano M, Hatamaru K, Tamura T, Nuta J, Kawaji Y, Takenaka M, Minaga K, Kudo M, Ogura T, Higuchi K, Chiba Y, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(3), 291 - 298, May 2019 , Refereed
  DOI
• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial., Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, REACH, study investigators, The Lancet. Oncology, The Lancet. Oncology, 20(2), 282 - 296, Feb. 2019 , Refereed
  DOI
• New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode., Koizumi Y, Hirooka M, Tamaki N, Yada N, Nakashima O, Izumi N, Kudo M, Hiasa Y, PloS one, PloS one, 14(8), e0221548, 2019 , Refereed
  DOI
• Risk factors for local recurrence and appropriate surveillance interval after endoscopic resection, Komeda Y, Watanabe T, Sakurai T, Kono M, Okamoto K, Nagai T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Tsuji N, Kashida H, Kudo M, World J Gastroenterol, World J Gastroenterol, 25, 1502 - 1512, 2019 , Refereed
• Targeted and immune therapy for hepatocellular carcinoma: predictions for 2019 and beyond, Masatoshi Kudo, World J Gastroenterol, World J Gastroenterol, 25, 789 - 807, 2019 , Refereed
• [Systemic therapy for hepatocellular carcinoma:recent advances and future perspective]., Kudo M, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 116(1), 8 - 17, 2019 , Refereed
  DOI
• Liver damage related to immune checkpoint inhibitors., Nishida N, Kudo M, Hepatology international, Hepatology international, 13(3), 248 - 252, Jan. 2019 , Refereed
  DOI
• [Current status of radiation exposure to crystalline lens in ERCP (endoscopic retrograde cholangiopancreatography)]., Takenaka M, Hosono M, Nakai A, Omoto S, Minaga K, Kamata K, Yamao K, Hayashi S, Nishida T, Kudo M, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 116(12), 1053 - 1055, 2019 , Refereed
  DOI
• Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC., Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, Kudo M, Nakagawa K, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(12), e239 - e241, Dec. 2018 , Refereed
  DOI
• Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients., Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M, Investigational new drugs, Investigational new drugs, 36(6), 1072 - 1084, Dec. 2018 , Refereed
  DOI
• Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations., Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, Kudo M, Barr RG, Ultrasound in medicine & biology, Ultrasound in medicine & biology, 44(12), 2419 - 2440, Dec. 2018 , Refereed
  DOI
• Dual-energy computed tomography for non-invasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data., Sofue K, Tsurusaki M, Mileto A, Hyodo T, Sasaki K, Nishii T, Chikugo T, Yada N, Kudo M, Sugimura K, Murakami T, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 48(12), 1008 - 1019, Nov. 2018 , Refereed
  DOI
• Acute Pancreatitis with Disturbed Consciousness Caused by Hyperparathyroidism., Otsuka Y, Kamata K, Minaga K, Takenaka M, Watanabe T, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 57(21), 3075 - 3078, Nov. 2018 , Refereed
  DOI
• Novel metallic stent designed for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction., Takenaka M, Yamao K, Minaga K, Nakai A, Omoto S, Kamata K, Kudo M, Endoscopy, Endoscopy, Nov. 2018 , Refereed
  DOI
• Mechanistic Insights into Autoimmune Pancreatitis and IgG4-Related Disease., Watanabe T, Minaga K, Kamata K, Kudo M, Strober W, Trends in immunology, Trends in immunology, 39(11), 874 - 889, Nov. 2018 , Refereed
  DOI
• Systemic Therapy for Hepatocellular Carcinoma: Latest Advances., Kudo M, Cancers, Cancers, 10(11), Oct. 2018 , Refereed
  DOI
• Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 7(4), 305 - 311, Oct. 2018 , Refereed
  DOI
• A case of EUS-guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second puncture., Omoto S, Takenaka M, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(1), e20 - e21, Oct. 2018 , Refereed
  DOI
• Cytokines produced by innate immune cells in IgG4-related disease., Yoshikawa T, Watanabe T, Minaga K, Kamata K, Kudo M, Modern rheumatology, Modern rheumatology, 29(2), 1 - 18, Oct. 2018 , Refereed
  DOI
• Value of contrast-enhanced harmonic EUS with enhancement pattern for diagnosis of pancreatic cancer: a meta-analysis., Yamashita Y, Shimokawa T, Napoléon B, Fusaroli P, Gincul R, Kudo M, Kitano M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(2), 125 - 133, Oct. 2018 , Refereed
  DOI
• Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]., Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX, European journal of cancer (Oxford, England : 1990), European journal of cancer (Oxford, England : 1990), 100, 135 - 136, Sep. 2018 , Refereed
  DOI
• Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy., Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, Kudo M, Cancers, Cancers, 10(10), Sep. 2018 , Refereed
  DOI
• Cannulation method for intradiverticular papilla with long oral protrusion using biopsy forceps for axis alignment., Takenaka M, Minaga K, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 30(5), 700 - 701, Sep. 2018 , Refereed
  DOI
• Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection., Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ, Journal of hepatology, Journal of hepatology, Sep. 2018 , Refereed
  DOI
• Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 7(3), 215 - 224, Sep. 2018 , Refereed
  DOI
• Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial., Kudo M, Liver cancer, Liver cancer, 7(3), 225 - 234, Sep. 2018 , Refereed
  DOI
• A novel biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (Uneven method)., Takenaka M, Arisaka Y, Sakai A, Kobayashi T, Shiomi H, Masuda A, Kudo M, Endoscopy, Endoscopy, 50(8), E229 - E230, Aug. 2018 , Refereed
  DOI
• ENBD tube guided scope insertion technique for internal drainage in a case of difficult selective biliary duct guiding., Takenaka M, Minaga K, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(1), e1 - e2, Aug. 2018 , Refereed
  DOI
• A novel method of biliary cannulation for patients with Roux-en-Y anastomosis using a unique, uneven, double lumen cannula (Uneven method)., Takenaka M, Yamao K, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 30(6), 808 - 809, Aug. 2018 , Refereed
  DOI
• Neurilemmoma Mimicking a Multilocular Cystic Lesion of the Liver: A Case Report., Yoshida A, Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Matsumoto I, Takeyama Y, Chikugo T, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 57(23), 3377 - 3380, Aug. 2018 , Refereed
  DOI
• A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation., Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M, Journal of gastroenterology, Journal of gastroenterology, 54(2), 171 - 181, Aug. 2018 , Refereed
  DOI
• Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial., Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M, KEYNOTE, investigators, The Lancet. Oncology, The Lancet. Oncology, 19(7), 940 - 952, Jul. 2018 , Refereed
  DOI
• Clinical Efficacy and Safety of EUS-guided Gallbladder Drainage Replacement of Percutaneous Drainage: A Multicenter Retrospective Study., Minaga K, Yamashita Y, Ogura T, Takenaka M, Shimokawa Y, Hisa T, Itonaga M, Kato H, Nishikiori H, Okuda A, Matsumoto H, Uenoyama Y, Watanabe T, Chiba Y, Higuchi K, Kudo M, Kitano M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 31(2), 180 - 187, Jul. 2018 , Refereed
  DOI
• Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials., Yen CJ, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC, Journal of global oncology, Journal of global oncology, (4), 1 - 12, Jul. 2018 , Refereed
  DOI
• Immune checkpoint blockade for the treatment of human hepatocellular carcinoma., Nishida N, Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 48(8), 622 - 634, May 2018 , Refereed
  DOI
• Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma., Tanaka H, Kamata K, Takenaka M, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), May 2018 , Refereed
  DOI
• Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond., Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR, Cancer treatment reviews, Cancer treatment reviews, 68, 16 - 24, May 2018 , Refereed
  DOI
• Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis., Kamata K, Takenaka M, Minaga K, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Kudo M, Endoscopic ultrasound, Endoscopic ultrasound, 7(5), 349 - 350, May 2018 , Refereed
  DOI
• Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study., Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX, British journal of cancer, British journal of cancer, 119(1), 19 - 26, May 2018 , Refereed
  DOI
• Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review., Minaga K, Watanabe T, Kamata K, Asano N, Kudo M, World journal of gastroenterology, World journal of gastroenterology, 24(16), 1725 - 1733, Apr. 2018 , Refereed
  DOI
• Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms., Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, Nakai A, Tanaka H, Chiba Y, Watanabe T, Sakurai T, Nishida N, Chikugo T, Matsumoto I, Takeyama Y, Kitano M, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Apr. 2018 , Refereed
  DOI
• Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method., Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, Izumi N, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, Apr. 2018 , Refereed
  DOI
• Gastric Inverted Hyperplastic Polyp Mimicking a Papilla., Matsui S, Kashida H, Kudo M, The American journal of gastroenterology, The American journal of gastroenterology, 113(4), 462, Apr. 2018 , Refereed
  DOI
• Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial., Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, SILIUS study group, The lancet. Gastroenterology & hepatology, The lancet. Gastroenterology & hepatology, Apr. 2018 , Refereed
  DOI
• Reintervention for stent occlusion after endoscopic ultrasound-guided hepaticogastrostomy with novel use of a precut needle-knife., Minaga K, Takenaka M, Okamoto A, Omoto S, Miyata T, Imai H, Kudo M, Endoscopy, Endoscopy, 50(7), E153 - 154, Apr. 2018 , Refereed
  DOI
• Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 7(1), 1 - 19, Mar. 2018 , Refereed
  DOI
• Combination Cancer Immunotherapy in Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 7(1), 20 - 27, Mar. 2018 , Refereed
  DOI
• Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort., Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study, Group of Japan, Annals of surgery, Annals of surgery, Mar. 2018 , Refereed
  DOI
• Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting., Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study, Group of Japan, Liver international : official journal of the International Association for the Study of the Liver, Liver international : official journal of the International Association for the Study of the Liver, 38(3), 484 - 493, Mar. 2018 , Refereed
  DOI
• [Hepatitis C Virus-Induced Cryoglobulinemic Vasculitis]., Minami Y, Kudo M, Brain and nerve = Shinkei kenkyu no shinpo, Brain and nerve = Shinkei kenkyu no shinpo, 70(2), 133 - 137, Feb. 2018 , Refereed
  DOI
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial., Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL, Lancet (London, England), Lancet (London, England), 391(10126), 1163 - 1173, Feb. 2018 , Refereed
  DOI
• Autoimmune Pancreatitis Mouse Model., Kamata K, Watanabe T, Minaga K, Strober W, Kudo M, Current protocols in immunology, Current protocols in immunology, 120, 15.31.1 - 15.31.8, Feb. 2018 , Refereed
  DOI
• Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis., Minaga K, Takenaka M, Kamata K, Yoshikawa T, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakamoto H, Kitano M, Kudo M, Cancers, Cancers, 10(2), Feb. 2018 , Refereed
  DOI
• Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B., Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M, Antiviral therapy, Antiviral therapy, 23(6), 513 - 521, Feb. 2018 , Refereed
  DOI
• Dysbiosis-Associated Polyposis of the Colon-Cap Polyposis., Okamoto K, Watanabe T, Komeda Y, Okamoto A, Minaga K, Kamata K, Yamao K, Takenaka M, Hagiwara S, Sakurai T, Tanaka T, Sakamoto H, Fujimoto K, Nishida N, Kudo M, Frontiers in immunology, Frontiers in immunology, 9, 918, 2018 , Refereed
  DOI
• Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varices, Matsui S, Kashida H, Kudo M, Ann Gastroenterol, Ann Gastroenterol, 31, 636, 2018 , Refereed
• Management of hepatocellular carcinoma in Japan as a world-leading model, Masatoshi Kudo, Liver Cancer, Liver Cancer, 7, 134 - 147, 2018 , Refereed
• Cabozantinib as a second-line agent in advanced hepatocellular carcinoma, Masatoshi Kudo, Liver Cancer, Liver Cancer, 7, 123 - 133, 2018 , Refereed
• Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review., Minaga K, Watanabe T, Kamata K, Asano N, Kudo M, World J Gastroenterol, World J Gastroenterol, 2018 , Refereed
• How to perform Contrast-Enhanced Ultrasound (CEUS)., Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lyshchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S, Ultrasound international open, Ultrasound international open, 4(1), E2 - E15, Jan. 2018 , Refereed
  DOI
• Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in west Japan., Yamao K, Kitano M, Takenaka M, Minaga K, Sakurai T, Watanabe T, Kayahara T, Yoshikawa T, Yamashita Y, Asada M, Okabe Y, Hanada K, Chiba Y, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 88(1), 66 - 75.e2, Jan. 2018 , Refereed
  DOI
• Cabozantinib for advanced hepatocellular carcinoma, Masatoshi Kudo, Hepatobil Surg Nutr, Hepatobil Surg Nutr, 2018 , Refereed
  DOI
• Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy., Yoshida A, Hagiwara S, Watanabe T, Nishida N, Ida H, Sakurai T, Komeda Y, Yamao K, Takenaka M, Enoki E, Kimura M, Miyake M, Kawada A, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 57(17), 2505 - 2509, 2018 , Refereed
  DOI
• Induction of complete remission by azacitidine in a patient with myelodysplastic syndrome-associated inflammatory bowel disease., Kono M, Komeda Y, Sakurai T, Okamoto A, Minaga K, Kamata K, Hagiwara S, Inoue H, Enoki E, Matsumura I, Watanabe T, Kudo M, Journal of Crohn's & colitis, Journal of Crohn's & colitis, Dec. 2017 , Refereed
  DOI
• Endoscopic ultrasound-guided biliary drainage using a newly designed metal stent with a thin delivery system: a preclinical study in phantom and porcine models., Minaga K, Kitano M, Itonaga M, Imai H, Miyata T, Yamao K, Tamura T, Nuta J, Warigaya K, Kudo M, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 45(3), 391 - 397, Dec. 2017 , Refereed
  DOI
• Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study., Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ, Liver cancer, Liver cancer, 6(4), 313 - 324, Nov. 2017 , Refereed
  DOI
• Electronic hydraulic lithotripsy by antegrade digital cholangioscopy through endoscopic ultrasound-guided hepaticojejunostomy., Otsuka Y, Kamata K, Takenaka M, Minaga K, Tanaka H, Kudo M, Endoscopy, Endoscopy, Oct. 2017 , Refereed
  DOI
• Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice., Nishiyama H, Nagai T, Kudo M, Okazaki Y, Azuma Y, Watanabe T, Goto S, Ogata H, Sakurai T, Biochemical and biophysical research communications, Biochemical and biophysical research communications, 495(1), 273 - 279, Oct. 2017 , Refereed
  DOI
• Transrectal endoscopic ultrasound-guided paracentesis for diagnosis of malignant ascites in the pelvis., Minaga K, Takenaka M, Kamata K, Kudo M, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Oct. 2017 , Refereed
  DOI
• ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: advantage of ALBI grade for universal assessment of hepatic function., Hiraoka A, Michitaka K, Kumada, Kudo M, Liver Cancer, Liver Cancer, 6(4), 377 - 379, Oct. 2017 , Refereed
• Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function., Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M, The Liver Cancer Study, Group of Japan, Liver Cancer, Liver Cancer, 6(4), 325 - 336, Oct. 2017 , Refereed
• Lenvatinib in advanced hepatocellular carcinoma., Masatoshi Kudo, Liver Cancer, Liver Cancer, 6(4), 253 - 263, Oct. 2017 , Refereed
• Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study., Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y, The lancet. Gastroenterology & hepatology, The lancet. Gastroenterology & hepatology, 3(1), 37 - 46, Oct. 2017 , Refereed
  DOI
• Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General v, Yanagihara K, Watanabe A, Aoki N, Matsumoto T, Yoshida M, Sato J, Wakamura T, Sunakawa K, Kadota J, Kiyota H, Iwata S, Kaku M, Hanaki H, Ohsaki Y, Fujiuchi S, Takahashi M, Takeuchi K, Takeda H, Ikeda H, Miki M, Nakanowatari S, Takahashi H, Utagawa M, Nishiya H, Kawakami S, Morino E, Takasaki J, Mezaki K, Chonabayashi N, Tanaka C, Sugiura H, Goto H, Saraya T, Kurai D, Katono Y, Inose R, Niki Y, Takuma T, Kudo M, Ehara S, Sato Y, Tsukada H, Watabe N, Honma Y, Mikamo H, Yamagishi Y, Nakamura A, Ohashi M, Seki M, Hamaguchi S, Toyokawa M, Fujikawa Y, Mitsuno N, Ukimura A, Miyara T, Nakamura T, Mikasa K, Kasahara K, Ui K, Fukuda S, Nakamura A, Morimura M, Yamashita M, Takesue Y, Wada Y, Sugimoto K, Kusano N, Nose M, Mihara E, Kuwabara M, Doi M, Watanabe Y, Tokuyasu H, Hino S, Negayama K, Mukae H, Kawanami T, Ota T, Fujita M, Honda J, Hiramatsu K, Aoki Y, Fukuoka M, Magarifuchi H, Nagasawa Z, Kaku N, Fujita J, Higa F, Tateyama M, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 23(9), 587 - 597, Sep. 2017 , Refereed
  DOI
• Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis., Hagiwara S, Nishida N, Park AM, Komeda Y, Sakurai T, Watanabe T, Kudo M, Scientific reports, Scientific reports, 7(1), 10440, Sep. 2017 , Refereed
  DOI
• High glucose stimulates expression of aldosterone synthase (CYP11B2) and secretion of aldosterone in human adrenal cells., Shimada H, Kogure N, Noro E, Kudo M, Sugawara K, Sato I, Shimizu K, Kobayashi M, Suzuki D, Parvin R, Saito-Ito T, Uruno A, Saito-Hakoda A, Rainey WE, Ito S, Yokoyama A, Sugawara A, FEBS open bio, FEBS open bio, 7(9), 1410 - 1421, Sep. 2017 , Refereed
  DOI
• Endoscopic ultrasound-guided choledochoduodenostomy with novel use of contrast-enhanced harmonic imaging., Minaga K, Takenaka M, Kamata K, Miyata T, Yamao K, Imai H, Kudo M, Endoscopy, Endoscopy, 49(11), E281 - E282, Sep. 2017 , Refereed
  DOI
• Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey., Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study, Group of Japan, Annals of surgery, Annals of surgery, 269(4), 692 - 699, Sep. 2017 , Refereed
  DOI
• Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay., Morimoto R, Ono Y, Tezuka Y, Kudo M, Yamamoto S, Arai T, Gomez-Sanchez CE, Sasano H, Ito S, Satoh F, Hypertension (Dallas, Tex. : 1979), Hypertension (Dallas, Tex. : 1979), 70(2), 334 - 341, Aug. 2017 , Refereed
  DOI
• Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial., Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T, Miriplatin TACE, Study Group, Journal of gastroenterology, Journal of gastroenterology, Aug. 2017 , Refereed
  DOI
• Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma., Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, Kudo M, Cancer science, Cancer science, 108(10), 1996 - 2003, Aug. 2017 , Refereed
  DOI
• Utility of contrast-enhanced harmonic EUS for evaluating the effects of steroid therapy in a case of immunoglobulin G4-negative focal autoimmune pancreatitis., Kamata K, Takenaka M, Minaga K, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, Jul. 2017 , Refereed
  DOI
• Portal vein stenting for portal vein stenosis caused by bile duct cancer., Kamata K, Takenaka M, Tsurusaki M, Kudo M, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Jul. 2017 , Refereed
  DOI
• Fatal liver gas gangrene after biliary surgery., Miyata Y, Kashiwagi H, Koizumi K, Kawachi J, Kudo M, Teshima S, Isogai N, Miyake K, Shimoyama R, Fukai R, Ogino H, International journal of surgery case reports, International journal of surgery case reports, 39, 5 - 8, Jul. 2017 , Refereed
  DOI
• Achievement of long-term stent patency in endoscopic ultrasonography-guided right bile duct drainage after left hepatic lobectomy (with video), Minaga K, Takenaka M, Miyata T, Yamao K, Kitano M, Kudo M, Endosc Ultrasound, Endosc Ultrasound, in press, Jul. 2017 , Refereed
• 肝動脈化学塞栓療法(TACE)の適応の再考 (1)BCLC-Bの亜分類とTACEの適応, Tadaaki Arizumi, Masatoshi Kudo, The Liver Cancer Journal, The Liver Cancer Journal, 9(1), 26 - 29, Jun. 2017 , Refereed
• Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of fine-needle aspiration for pancreatic adenocarcinoma., Kamata K, Takenaka M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 87(1), 158 - 163, Jun. 2017 , Refereed
  DOI
• Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update., Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK, Hepatology international, Hepatology international, 11(4), 317 - 370, Jun. 2017 , Refereed
  DOI
• Stent migration during EUS-guided hepaticogastrostomy in a patient with massive ascites: Troubleshooting using additional EUS-guided antegrade stenting., Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, Kudo M, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 18(2), 120 - 121, Jun. 2017 , Refereed
  DOI
• Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions., Kamata K, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Kashida H, Chikugo T, Chiba Y, Nakai T, Takeyama Y, Lisotti A, Fusaroli P, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Jun. 2017 , Refereed
  DOI
• The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization., Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M, Liver cancer, Liver cancer, 6(3), 227 - 235, Jun. 2017 , Refereed
  DOI
• Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC., Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM, Journal of hepatology, Journal of hepatology, 66(6), 1166 - 1172, Jun. 2017 , Refereed
  DOI
• S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial., Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T, The lancet. Gastroenterology & hepatology, The lancet. Gastroenterology & hepatology, 2(6), 407 - 417, Jun. 2017 , Refereed
  DOI
• Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patients., Toguchi M, Tsurusaki M, Yada N, Sofue K, Hyodo T, Onoda M, Numoto I, Matsuki M, Imaoka I, Kudo M, Murakami T, Abdominal radiology (New York), Abdominal radiology (New York), 42(6), 1659 - 1666, Jun. 2017 , Refereed
  DOI
• Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib., Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K, International journal of oncology, International journal of oncology, 50(6), 2049 - 2058, Jun. 2017 , Refereed
  DOI
• A Case of Type II Enteropathy-Associated T-Cell Lymphoma in a Patient With Ulcerative Colitis., Komeda Y, Kashida H, Sakurai T, Kono M, Nagai T, Asakuma Y, Hagiwara S, Matsui S, Watanabe T, Chikugo T, Kudo M, The American journal of gastroenterology, The American journal of gastroenterology, 112(6), 833, Jun. 2017 , Refereed
  DOI
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study., Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX, European journal of cancer (Oxford, England : 1990), European journal of cancer (Oxford, England : 1990), 81, 17 - 25, Jun. 2017 , Refereed
  DOI
• Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications, Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Kawasaki H, Hiasa Y, Michitaka K, o, f, Real-Life Practice Experts for, HCC (RELPEC, Study Group, and HC, Group, Liver Cancer, Liver Cancer, 6(3), 204 - 215, Jun. 2017 , Refereed
  DOI
• Albumin-Bilirubin grade and hepatocellular carcinoma treatment algorithm, Masatoshi Kudo, Liver Cancer, Liver Cancer, 6(3), 185 - 188, Jun. 2017 , Refereed
  DOI
• A new era of systemic therapy for hepatocellular carcinoma with regorafenib and lenvatinib, Masatoshi Kudo, Liver Cancer, Liver Cancer, 6(3), 177 - 184, Jun. 2017 , Refereed
  DOI
• A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half Molecule., Imoto M, Yoshida K, Maeda Y, Nakae KI, Kudo M, Sakurabayashi I, Yamada T, Kamisako T, Clinical laboratory, Clinical laboratory, 63(5), 983 - 989, May 2017 , Refereed
• Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib., Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J, Sellers L, Kudo M, Pirisi M, Sharma R, Oncotarget, Oncotarget, 8(22), 36161 - 36170, May 2017 , Refereed
  DOI
• Chronic Fibro-Inflammatory Responses in Autoimmune Pancreatitis Depend on IFN-α and IL-33 Produced by Plasmacytoid Dendritic Cells., Watanabe T, Yamashita K, Arai Y, Minaga K, Kamata K, Nagai T, Komeda Y, Takenaka M, Hagiwara S, Ida H, Sakurai T, Nishida N, Strober W, Kudo M, Journal of immunology (Baltimore, Md. : 1950), Journal of immunology (Baltimore, Md. : 1950), 198(10), 3886 - 3896, May 2017 , Refereed
  DOI
• On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study., Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park JW, Sharma R, Alimentary pharmacology & therapeutics, Alimentary pharmacology & therapeutics, 45(8), 1146 - 1155, Apr. 2017 , Refereed
  DOI
• Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al., Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T, Annals of oncology : official journal of the European Society for Medical Oncology, Annals of oncology : official journal of the European Society for Medical Oncology, 28(4), 903 - 904, Apr. 2017 , Refereed
  DOI
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial., Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX, Journal of gastroenterology, Journal of gastroenterology, 52(4), 494 - 503, Apr. 2017 , Refereed
  DOI
• Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma., Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H, Journal of gastroenterology, Journal of gastroenterology, 52(4), 512 - 519, Apr. 2017 , Refereed
  DOI
• Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey., Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N, Liver Cancer Study, Group of Japan, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), Apr. 2017 , Refereed
  DOI
• Multimaterial Decomposition Algorithm for the Quantification of Liver Fat Content by Using Fast-Kilovolt-Peak Switching Dual-Energy CT: Clinical Evaluation., Hyodo T, Yada N, Hori M, Maenishi O, Lamb P, Sasaki K, Onoda M, Kudo M, Mochizuki T, Murakami T, Radiology, Radiology, 283(1), 108 - 118, Apr. 2017 , Refereed
  DOI
• The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3., Sakurai T, Higashitsuji H, Kashida H, Watanabe T, Komeda Y, Nagai T, Hagiwara S, Kitano M, Nishida N, Abe T, Kiyonari H, Itoh K, Fujita J, Kudo M, Oncotarget, Oncotarget, 8(15), 24762 - 24776, Apr. 2017 , Refereed
  DOI
• Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan., Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, Kudo M, Matsuda M, Motosugi U, Saitoh S, Yoshimitsu K, Crawford B, Kruger E, Ball G, Honda H, Clinical therapeutics, Clinical therapeutics, 39(4), 738 - 750.e4, Apr. 2017 , Refereed
  DOI
• Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention., Minaga K, Takenaka M, Kitano M, Chiba Y, Imai H, Yamao K, Kamata K, Miyata T, Omoto S, Sakurai T, Watanabe T, Nishida N, Kudo M, Surgical endoscopy, Surgical endoscopy, Apr. 2017 , Refereed
  DOI
• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial., El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I, Lancet (London, England), Lancet (London, England), Apr. 2017 , Refereed
  DOI
• Immunopathogenesis of pancreatitis., Watanabe T, Kudo M, Strober W, Mucosal immunology, Mucosal immunology, 10(2), 283 - 298, Mar. 2017 , Refereed
  DOI
• Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain cone-beam computed tomography., Minami Y, Takita M, Tsurusaki M, Yagyu Y, Ueshima K, Murakami T, Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 47(3), E113 - E119, Mar. 2017 , Refereed
  DOI
• Endoscopic ultrasonography-guided choledochoduodenostomy using a newly designed laser-cut metal stent: Feasibility study in a porcine model., Minaga K, Kitano M, Gon C, Yamao K, Imai H, Miyata T, Kamata K, Omoto S, Takenaka M, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 29(2), 211 - 217, Mar. 2017 , Refereed
  DOI
• Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer., Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K, Investigational new drugs, Investigational new drugs, Mar. 2017 , Refereed
  DOI
• A case of successful transluminal drainage of walled-off necrosis under contrast-enhanced harmonic endoscopic ultrasonography guidance., Minaga K, Takenaka M, Omoto S, Miyata T, Kamata K, Yamao K, Imai H, Watanabe T, Kitano M, Kudo M, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 45(1), 161 - 165, Mar. 2017 , Refereed
  DOI
• The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development, Pinato DJ, Yen C, Bettinger D, Ramaswami R, Arizumi T, Ward C, Pirisi M, Burlone ME, Thimme R, Kudo M, Sharma R, Aliment Pharm Ther, Aliment Pharm Ther, 45(5), 714 - 722, Mar. 2017 , Refereed
  DOI
• Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract., Kamata K, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Chikugo T, Chiba Y, Imamoto H, Yasuda T, Lisotti A, Fusaroli P, Kudo M, Journal of gastroenterology and hepatology, Journal of gastroenterology and hepatology, Feb. 2017 , Refereed
  DOI
• Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey., Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M, Liver Cancer Study, Group of Japan, Journal of gastroenterology, Journal of gastroenterology, Feb. 2017 , Refereed
  DOI
• The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma., Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI, J Hepatol, J Hepatol, 66(2), 338 - 346, Feb. 2017 , Refereed
  DOI
• MicroRNAs for the prediction of early response to sorafenib treatment in human hepatocellular carcinoma, Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T, Kudo M, Liver Cancer, Liver Cancer, 6(2), 113 - 125, Feb. 2017 , Refereed
  DOI
• Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives, Masatoshi Kudo, Liver Cancer, Liver Cancer, 6(2), 101 - 112, Feb. 2017 , Refereed
  DOI
• Characterization of Pancreatic Tumors with Quantitative Perfusion Analysis in Contrast-Enhanced Harmonic Endoscopic Ultrasonography., Omoto S, Takenaka M, Kitano M, Miyata T, Kamata K, Minaga K, Arizumi T, Yamao K, Imai H, Sakamoto H, Harwani Y, Sakurai T, Watanabe T, Nishida N, Takeyama Y, Chiba Y, Kudo M, Oncology, Oncology, 93 Suppl 1, 55 - 60, 2017 , Refereed
  DOI
• Risk Factors for Postoperative Bleeding in Endoscopic Submucosal Dissection of Colorectal Tumors., Okamoto K, Watanabe T, Komeda Y, Kono T, Takashima K, Okamoto A, Kono M, Yamada M, Arizumi T, Kamata K, Minaga K, Yamao K, Nagai T, Asakuma Y, Takenaka M, Sakurai T, Matsui S, Nishida N, Chikugo T, Kashida H, Kudo M, Oncology, Oncology, 93 Suppl 1, 35 - 42, 2017 , Refereed
  DOI
• Detection of High-Grade Pancreatic Intraepithelial Neoplasia without Morphological Changes of the Main Pancreatic Duct over a Long Period: Importance for Close Follow-Up for Confirmation., Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Sakurai T, Watanabe T, Nishida N, Matsumoto I, Takeyama Y, Chikugo T, Kudo M, Oncology, Oncology, 93 Suppl 1, 81 - 86, 2017 , Refereed
  DOI
• Computer-Aided Diagnosis Based on Convolutional Neural Network System for Colorectal Polyp Classification: Preliminary Experience., Komeda Y, Handa H, Watanabe T, Nomura T, Kitahashi M, Sakurai T, Okamoto A, Minami T, Kono M, Arizumi T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Kashida H, Kudo M, Oncology, Oncology, 93 Suppl 1, 30 - 34, 2017 , Refereed
  DOI
• Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)., Kudo M, Arizumi T, Oncology, Oncology, 93 Suppl 1, 127 - 134, 2017 , Refereed
  DOI
• Chronic Pancreatitis Finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of Intraductal Papillary Mucinous Neoplasms Is Associated with Invasive Intraductal Papillary Mucinous Carcinoma., Takenaka M, Masuda A, Shiomi H, Yagi Y, Zen Y, Sakai A, Kobayashi T, Arisaka Y, Okabe Y, Kutsumi H, Toyama H, Fukumoto T, Ku Y, Kudo M, Azuma T, Oncology, Oncology, 93 Suppl 1, 61 - 68, 2017 , Refereed
  DOI
• Clinical Analysis of Esophageal Stricture in Patients Treated with Intralesional Triamcinolone Injection after Endoscopic Submucosal Dissection for Superficial Esophageal Cancer., Okamoto K, Matsui S, Watanabe T, Asakuma Y, Komeda Y, Okamoto A, Rei I, Kono M, Yamada M, Nagai T, Arizumi T, Minaga K, Kamata K, Yamao K, Takenaka M, Sakurai T, Nishida N, Kashida H, Chikugo T, Kudo M, Oncology, Oncology, 93 Suppl 1, 9 - 14, 2017 , Refereed
  DOI
• New Paradigm in Gastrointestinal Cancer Treatment., Kudo M, Oncology, Oncology, 93 Suppl 1, 1 - 8, 2017 , Refereed
  DOI
• A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi Project., Sakamoto H, Harada S, Nishioka N, Maeda K, Kurihara T, Sakamoto T, Higuchi K, Kitano M, Takeyama Y, Kogire M, Kudo M, Oncology, Oncology, 93 Suppl 1, 89 - 97, 2017 , Refereed
  DOI
• Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases., Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K, Kudo M, Oncology, Oncology, 93 Suppl 1, 120 - 126, 2017 , Refereed
  DOI
• Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori., Adachi T, Matsui S, Watanabe T, Okamoto K, Okamoto A, Kono M, Yamada M, Nagai T, Komeda Y, Minaga K, Kamata K, Yamao K, Takenaka M, Asakuma Y, Sakurai T, Nishida N, Kashida H, Kudo M, Oncology, Oncology, 93 Suppl 1, 15 - 19, 2017 , Refereed
  DOI
• New Era of the Management of Liver Diseases and Liver Cancer: State-of-the-Art Progress in 2017., Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 35(6), 493 - 497, 2017 , Refereed
  DOI
• Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C., Imoto S, Kim SR, Amano K, Iio E, Yoon S, Hirohata S, Yano Y, Ishikawa T, Katsushima S, Komeda T, Fukunaga T, Chung H, Kokuryu H, Horie Y, Hatae T, Fujinami A, Kim SK, Kudo M, Tanaka Y, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 35(6), 531 - 540, 2017 , Refereed
  DOI
• Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Ca, Iwamoto T, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Ohashi H, Fujita N, Kudo M, Takehara T, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 35(6), 574 - 582, 2017 , Refereed
  DOI
• THE REGULATION OF AIRWAY SMOOTH MUSCLE CONTRACTION., Kudo M, Arerugi = [Allergy], Arerugi = [Allergy], 66(6), 798 - 803, 2017 , Refereed
  DOI
• Cyclocarya paliurus extract activates insulin signaling via Sirtuin1 in C2C12 myotubes and decreases blood glucose level in mice with impaired insulin secretion., Yoshitomi H, Tsuru R, Li L, Zhou J, Kudo M, Liu T, Gao M, PloS one, PloS one, 12(8), e0183988, 2017 , Refereed
  DOI
• Evidence and topics of chemotherapy for hepatocellular carcinoma., Ueshima K, Kudo M, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 114(9), 1621 - 1628, 2017 , Refereed
  DOI
• Management of developmental enamel defects in the primary dentition., Wada K, Kanazawa H, Kudo M, Kindaichi J, Miyashin M, Journal of oral science, Journal of oral science, 59(3), 457 - 460, 2017 , Refereed
  DOI
• Oncogenic signal and tumor microenvironment in hepatocellular carcinoma., Naoshi Nishida, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 160 - 164, 2017 , Refereed
  DOI
• Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 147 - 159, 2017 , Refereed
  DOI
• Systemic Therapy for Hepatocellular Carcinoma: 2017 Update, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 135 - 146, 2017 , Refereed
  DOI
• Transarterial Chemoembolization in Combination with Molecular Targeted Agent: Lessons from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2), Masatoshi Kudo, Tadaaki Arizumi, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• Validation of newly proposed time to TACE progression (TTTP) in intermediate stage hepatocellular carcinoma cases, Hirofumi Izumoto, Atsushi Hiraoka, Yoshihiro Ishimaru, Tadashi Murakami, Shogo Kitahata, Hidetaro Ueki, Toshihiko Aibiki, Tomonari Okudaira, Yuji Miyamoto, Hiroka Yamago, Ryuichiro Iwasaki, Hideomi Tomida, Kenichiro Mori, Masato Kishida, Eiji Tsubouchi, Hideki Miyata, Tomoyuki Ninomiya, Hideki Kawasaki, Masashi Hirooka, Bunzo Matsuura, Masanori Abe, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• A case of pancreatic carcinoma in situ diagnosed by repeated pancreatic juice cytology, Takeshi Miyata, Mamoru Takenaka, Shunsuke Omoto, Ken Kamata, Kosuke Minaga, Kentaro Yamao, Hajime Imai, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 98 - 101, 2017 , Refereed
  DOI
• A social program for the early detection of pancreatic cancer, the Kishiwada project: A multi-center study, Hiroki Sakamoto, Satoshi Harada, Nobu Nishioka, Kazuo Maeda, Takamasa Kurihara, Tateki Sakamoto, Kazuhide Higuchi, Masayuki Kitano, Yoshifumi Takeyama, Masafumi Kogire, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study., Chikara Ogawa, Masahiro Morita, Akina Omura, Teruyo Noda, Atsushi Kubo, Toshihiro Matsunaka, Hiroyuki Tamaki, Mitsushige Shibatoge, Akemi Tsutsui, Tomonori Senoh, Takuya Nagano, Kouichi Takaguchi, Joji Tani, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki, Akio Moriya, Masaharu Ando, Akihiro Deguchi, Yasutaka Kokudo, Yasunori Minami, Kazuomi Ueshima, Toshiharu Sakurai, Naoshi Nishida, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 113 - 119, 2017 , Refereed
  DOI
• EUS-guided pancreatic duct drainage for repeat pancreatitis in a patient with pancreatic cancer., Ken Kamata, Mamoru Takenaka, Kosuke Minaga, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 87 - 88, 2017 , Refereed
  DOI
• Detection of High-grade pancreatic intraepithelial neoplasia without morphological changes of the main pancreatic duct over long period: Importance for close follow-up for confirmation., Kentaro Yamao, Mamoru Takenaka, Atsushi Nakai, Shunske Omoto, Ken Kamata, Kosuke Minaga, Takeshi Miyata, Hajime Imai, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Ippei Matsumoto, Yosihumi Takeyama, Takaaki Chikugo, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• Primary hepatic adenosquamous carcinoma associated with primary sclerosing cholangitis., Kentaro Yamao, Mamoru Takenaka, Hajime Imai, Atsushi Nakai, Shunske Omoto, Ken Kamata, Kosuke Minaga, Takeshi Miyata, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Ippei Matsumoto, Yosihumi Takeyama, Takaaki Chikugo, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 76 - 80, 2017 , Refereed
  DOI
• Needle tract seeding: an overlooked rare complication of endoscopic ultrasound-guided fine-needle aspiration, Kosuke Minaga, Mamoru Takenaka, Akio Katanuma, Masayuki Kitano, Yukitaka Yamashita, Ken Kamata, Kentaro Yamao, Tomohiro Watanabe, Hiroyuki Maguchi, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 107 - 112, 2017 , Refereed
  DOI
• Association between the risk factors for pancreatic ductal adenocarcinoma and those for malignant intraductal papillary mucinous neoplasm, Ken Kamata, Mamoru Takenaka, Atsushi Nakai, Shunsuke Omoto, Takeshi Miyata, Kosuke Minaga, Tomohiro Matsuda, Kentaro Yamao, Hajime Imai, Yasutaka Chiba, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Takaaki Chikugo, Ippei Matsumoto, Yoshifumi Takeyama, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 102 - 106, 2017 , Refereed
  DOI
• Utility of endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting for malignant biliary obstruction after failed endoscopic retrograde cholangiopancreatography., Hajime Imai, Mamoru Takenaka, Shunsuke Omoto, Ken Kamata, Takeshi Miyata, Kosuke Minaga, Kentaro Yamao, Toshihiko Sakurai, Naoshi Nishida, Tomohiro Watanabe, Masayuki Kitano, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 69 - 75, 2017 , Refereed
  DOI
• Chronic Pancreatitis finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of IPMNs is Associated with Invasive IPMC, Mamoru Takenaka, Atsuhiro Masuda, Hideyuki Shiomi, Yosuke Yagi, Yoh Zen, Arata Sakai, Takashi Kobayashi, Yoshifumi Arisaka, Yoshihiro Okabe, Hiromu Kutsumi, Hirochika Toyama, Takumi Fukumoto, Yonson Ku, Masatoshi Kudo, Takeshi Azuma, Oncology, Oncology, Supple(in press), 2017 , Refereed
• Characterization of pancreatic tumors with quantitative perfusion analysis in contrast-enhanced harmonic EUS., Shunsuke Omoto, Mamoru Takenaka, Masayuki Kitano, Takeshi Miyata, Ken Kamata, Kosuke Minaga, Tadaaki Arizumi, Kentaro Yamao, Hajime Imai, Hiroki Sakamoto, Yogesh Harwani, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Yoshifumi Takeyama, Yasutaka Chiba, Masatoshi Kudo, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• The feasibility of 18-mm diameter colonic stents for obstructive colorectal cancers, Ogawa S, Ishii T, Minaga K, Nakatani Y, Hatamaru K, Akamatsu T, Seta T, Urai S, Uenoyama Y, Yamashita Y, Kudo M, Oncology, Oncology, Suppl(in press), 43 - 48, 2017 , Refereed
  DOI
• Magnifying narrow band imaging (NBI) for the diagnosis of localized colorectal lesions using the Japan NBI Expert Team (JNET) classification., Yoriaki Komeda, Hiroshi Kashida, Toshiharu Sakurai, Yutaka Asakuma, George Tribonias, Tomoyuki Nagai, Masashi Kono, Kosuke Minaga, Mamoru Takenaka, Tadaaki Arizumi, Satoru Hagiwara, Shigenaga Matsui, Tomohiro Watanabe, Naoshi Nishida, Takaaki Chikugo, Yasutaka Chiba, Masatoshi Kudo, Oncology, Oncology, Supple(in press), 49 - 54, 2017 , Refereed
  DOI
• Risk factors for post-operative bleeding in endoscopic submucosal dissection for colorectal tumors., Okamoto K, Watanabe T, Komeda Y, Kono T, Takashima K, Okamoto A, Kono M, Yamada MArizumi T, Kamata K, Minaga K, Yamao K, Nagai T, Asakuma Y, Takenaka M, Sakurai T, Matsui S, Nishida N, Chikugo T, Kashida H, Kudo M, Oncology, Oncology, in press, 2017 , Refereed
• Computer-aided diagnosis based on convolutional neural network system for colorectal polyp classification:, Komeda Y, Handa H, Watanabe T, Nomura T, Kitahashi M, Sakurai T, Okamoto A, Minami T, Kono M, Arizumi T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Kashida H, Kudo M, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• Prophylactic Suturing Closure is Recommended after Endoscopic Treatment of Colorectal Tumors in Patients with Antiplatelet/Anticoagulant Therapy., Sakurai T, Adachi T, Kono M, Arizumi T, Kamata K, Minaga K, Yamao K, Komeda Y, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Kudo M, Oncology, Oncology, Suppl(in press), 27 - 29, 2017 , Refereed
  DOI
• Clinical significance of Bmi1 expression in inflammatory bowel disease., Yamada M, Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Watanave T, Nishida N, Kashida H, Kudo M, Oncology, Oncology, Suppl(in press), 20 - 26, 2017 , Refereed
  DOI
• Comparative study of clarithromycin vs. metronidazole-based triple therapy as first-line eradication for Helicobacter pylori., Adachi T, Matsui S, Watanabe T, Okamoto K, Okamoto A, Kono M, Yamada M, Nagai T, Komeda Y, Minaga K, Kamata K, Yamao K, Takenaka M, Asakuma Y, Sakurai T, Nishida N, Kashida H, Kudo M, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• linical analysis of esophageal stricture in patients treated with intra-lesional triamcinolone injection post endoscopic submucosal dissection for superficial esophageal cancer., Okamoto K, Matsui S, Watanabe T, Asakuma Y, Komeda Y, Okamoto A, Ishikawa R, Kono M, Yamada M, Nagai T, Arizumi T, Minaga, K, Kamata K, Yamao K, Takenaka M, Sakurai T, Nishida N, Kashida H, Chikugo T, Kudo M, Oncology, Oncology, Suppl(in press), 2017 , Refereed
• Preface: New Paradigm in Gastrointestinal Cancer Treatment, Masatoshi Kudo, Oncology, Oncology, Supple(in press), 2017 , Refereed
• Role of immune checkpoint blockade in the treatment for human hepatocellular carcinoma., Nishida N, Kudo M, Digest Dis, Digest Dis, 35(6), 618 - 622, 2017 , Refereed
  DOI
• Sorafenib-regorafenib sequential therapy in advanced hepatocellular carcinoma: a single-institute experience., Ueshima K, Nishida N, Kudo M, Digest Dis, Digest Dis, 35(6), 611 - 617, 2017 , Refereed
  DOI
• Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable HCC – multicenter analysis., Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K, Digest Dis, Digest Dis, 35(6), 602 - 610, 2017 , Refereed
  DOI
• Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study., Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T, Kudo M, Digest Dis, Digest Dis, 35(6), 598 - 601, 2017 , Refereed
  DOI
• Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2., Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M, Digest Dis, Digest Dis, 35(6), 589 - 597, 2017 , Refereed
  DOI
• Impact of Tumor Factors on survival in Patients with Hepatocellular Carcinoma classified based on Kinki Criteria Stage B2., Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M, Digest Dis, Digest Dis, 35(6), 583 - 588, 2017 , Refereed
  DOI
• Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma., Iwamoto T, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Ohashi H, Fujita N, Kudo M, Takehara T, Digest Dis, Digest Dis, 35(6), 574 - 582, 2017 , Refereed
• Hepatocellular carcinoma after achievement of sustained viral response with daclatasvir and asunaprevir in patients with chronic hepatitis C virus infection., Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, Kudo M, Digest Dis, Digest Dis, 35(6), 565 - 573, 2017 , Refereed
  DOI
• Unique characteristics associated with sustained liver damage in chronic hepatitis C patients treated with direct acting antivirals., Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T, Minaga K, Kamata K, Komeda Y, Sakurai T, Takenaka M, Takita M, Yada N, Ida H, Minami Y, Ueshima K, Watanabe T, Kudo M, Digest Dis, Digest Dis, 35(6), 556 - 564, 2017 , Refereed
  DOI
• Hepatocarcinogenesis is associated with serum albumin levels after sustained virological responses with interferon based therapy in patients with hepatitis C., Umehara Y, Hagiwara S, Nishida N, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Chishina H, Ueshima K, Komeda Y, Arizumi T, Watanabe T, Kudo M, Digest Dis, Digest Dis, 35(6), 548 - 555, 2017 , Refereed
  DOI
• Comparison of Sofosbuvir plus Ribavirin treatment with pegylated interferon plus Ribavirin treatment for chronic hepatitis C genotype 2., Seo K, Kim SK, Kim SR, Ohtani A, Kobayashi M, Kato A, Morimoto E, Saijo Y, Kim KI, Imoto S, Kim CW, Yano Y, Kudo M, Hayashi Y, Digest Dis, Digest Dis, 35(6), 541 - 547, 2017 , Refereed
  DOI
• Serum IFN-λ3 levels correlate with serum HCV RNA levels in symptomatic patients with acute hepatitis C., Imoto S, Kim SR, Amano K, Iio E, Yoon S, Hirohata S, Yano Y, Ishikawa T, Katsushima S, Komeda T, Fukunaga T, Chung H, Kokuryu H, Horie Y, Hatae T, Fujinami A, Kim SK, Kudo M, Tanaka Y, Digest Dis, Digest Dis, 35(6), 531 - 540, 2017 , Refereed
• Ability of cytokeratin-18 fragments and FIB-4 index to diagnose overall and mild fibrosis nonalcoholic steatohepatitis in Japanese nonalcoholic fatty liver disease patients., Kobayashi N, Kumada T, Toyoda H, Tada T, Ito T, Kage M, Okanoue T, Kudo M, Digest Dis, Digest Dis, 35(6), 521 - 530, 2017 , Refereed
  DOI
• Diagnosis of fibrosis and activity by a combined use of strain and shear wave imaging in patients with liver disease., Yada N, Tamaki N, Koizumi Y, Hirooka M, Nakashima O, Hiasa Y, Izumi N, Kudo M, Digest Dis, Digest Dis, 35(6), 515 - 520, 2017 , Refereed
  DOI
• Clinicopathological study of autoimmune hepatitis cases that were difficult to differentiate from drug-induced liver injury., Tsutsui A, Harada K, Tsuneyama K, Senoh T, Nagano T, Takaguchi K, Ando M, Nakamura S, Mizobuchi K, Kudo M, Digest Dis, Digest Dis, 35(6), 506 - 514, 2017 , Refereed
  DOI
• Abdominal ultrasound findings of tumor-forming hepatic malignant lymphoma, Kitahata S, Hiraoka A, Kudo M, Murakami T, Ochi M, Izumoto H, Ueki H, Kaneto M, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Kishida M, Miyata H, Tsubouchi E, Hirooka M, Koizumi Y, Ninomiya T, Hiasa Y, Michitaka K, Digest Dis, Digest Dis, 35(6), 498 - 505, 2017 , Refereed
  DOI
• Impact of age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey., Kaibori M, Yoshii K, Yokota I, Hasegwa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, J Hepatol, J Hepatol, in press, 2017 , Refereed
• Nucleotide-binding oligomerization domain 1 andgastrointestinal disorders., Watanabe T, Asano N, Kudo M, Strober W, Proc Jpn Acad Ser B Phys Biol Sci, Proc Jpn Acad Ser B Phys Biol Sci, in press(8), 578 - 599, 2017 , Refereed
  DOI
• Identification of a HBx mutation that enhances human hepatocarcinogenesis through the activation of the JNK and Wnt pathways., Hagiwara S, Nishida N, Sakurai T, Park AM, Komeda Y, Kitano M, Kudo M, BMC Cancer, BMC Cancer, in press, 2017 , Refereed
• Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study., Nishikawa H, Enomoto H, Saito M, Aizawa N, Tsuda Y, Higuchi K, Okazaki K, Seki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M, Osaki Y, Nishiguchi S, Acta Gastro-Ent Belg, Acta Gastro-Ent Belg, in press, 2017 , Refereed
• Second IA of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) non-interventional study, Lencioni R, Kudo M, Venook A, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Marrero JA, Liver Int, Liver Int, in press, 2017 , Refereed
• New Era in the Treatment of Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2017, Masatoshi Kudo, Digest Dis, Digest Dis, 35(6), 493 - 497, 2017 , Refereed
• Endoscopic Treatment of Tracheoesophageal Fistula using the Over-The-Scope-Clip System., Matsui S, Kashida H, Asakuma Y, Kudo M, Ann Gastol, Ann Gastol, 30(30), 578 - 578, 2017 , Refereed
  DOI
• Stent migration into the abdominal cavity after EUS-guided hepaticogastrostomy., Minaga K, Kitano M, Yamashita Y, Nakatani Y, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 85(1), 263 - 264, Jan. 2017 , Refereed
  DOI
• IgG4-Related Disease and Innate Immunity., Watanabe T, Yamashita K, Kudo M, Current topics in microbiology and immunology, Current topics in microbiology and immunology, 401, 115 - 128, 2017 , Refereed
  DOI
• Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer., Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S, Watanabe T, Kitano M, Nishida N, Fujita J, Kudo M, Inflammatory bowel diseases, Inflammatory bowel diseases, 23(1), 57 - 65, Jan. 2017 , Refereed
  DOI
• Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials., Kudo M, Oncology, Oncology, 92 Suppl 1, 50 - 62, 2017 , Refereed
  DOI
• Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: long-term outcomes after removal of a self-expandable metal stent, Kamata K, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Kudo M, World J Gastroenterol, World J Gastroenterol, 23(4), 661 - 667, Jan. 2017 , Refereed
  DOI
• CD68-positive cells in hepatic angiomyolipoma, Tochio H, Tamaki E, Imai Y, Iwasaki N, Minowa K, Chung H, Suginoshita Y, Inokuma T, Kudo M, Oncology, Oncology, 92, 35 - 39, 2017 , Refereed
  DOI
• Immunological microenvironment of hepatocellular carcinoma and its clinical implication, Nishida N, Kudo M, nment of hepatocellular carcinoma and its clinical implication., nment of hepatocellular carcinoma and its clinical implication., 92, 40 - 49, 2017 , Refereed
  DOI
• Influence of liver inflammation on liver stiffness measurement in patients with autoimmune hepatitis evaluation by combinational elastography, Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M, Oncology, Oncology, 92, 10 - 15, 2017 , Refereed
  DOI
• A new horizon in liver disease, Masatoshi Kudo, Oncology, Oncology, 92, 1 - 2, 2017 , Refereed
  DOI
• Outcome of combination therapy with sofosbuvir and ledipasvir for chronic type C liver disease, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M, Oncology, Oncology, 92, 3 - 9, 2017 , Refereed
  DOI
• Malignant transformation of hepatocellular adenoma, Kwok WY, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Kono M, Ueshima K, Komeda Y, Arizumi T, Enoki E, Nakai T, Kumabe T, Nakashima O, Kondo F, Kudo M, Oncology, Oncology, 92, 16 - 28, 2017 , Refereed
  DOI
• Contrast-enhanced tissue harmonic imaging versus phase inversion harmonic sonographic imaging for the delineation of hepatocellular carcinomas, Kono M, Minami Y, Iwanishi M, Minami T, Chishina H, Arizumi T, Komeda Y, Sakurai T, Takita M, Yada N, Ida H, Hagiwara S, Ueshima K, Nishida N, Kudo M, Oncology, Oncology, 92, 29 - 34, 2017 , Refereed
  DOI
• Diagnosis of hepatocellular carcinoma with non-invasive imaging: a plea for worldwide adoption of standard and precise terminology for describing enhancement criteria, Piscaglia F, Kudo M, Han KH, Sirlin C, Ultraschall Med, Ultraschall Med, 38(1), 9 - 11, Jan. 2017 , Refereed
  DOI
• Stress response protein RBM3 promotes the development of colitis-associated cancer, Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S, Watanabe T, Kitano M, Nishida N, Fujita J, Kudo M, Inflamm Bowel Dis, Inflamm Bowel Dis, 23(1), 57 - 65, Jan. 2017 , Refereed
  DOI
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami, Masi G, Ross P, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, on behalf of, the, RESORCE Investigators, Lancet, Lancet, 389(10064), 56 - 66, Jan. 2017 , Refereed
  DOI
• Removal of diminutive colorectal polyps: a prospective randomized clinical trial between cold snare polypectomy and hot forceps biopsy, Komeda Y, Kashida H, Sakurai T, Tribonias G, Okamoto K, Kono M, Yamada M, Adachi T, Mine H, Nagai T, Asakuma Y, Hagiwara S, Matsui S, Watanabe T, Kitano M, Chikugo T, Chiba Y, Kudo M, World J Gastroenterol, World J Gastroenterol, 23(2), 328 - 335, Jan. 2017 , Refereed
  DOI
• Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study, Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R, J Hepatol, J Hepatol, 65(6), 1140 - 1147, Dec. 2016 , Refereed
  DOI
• Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON, Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N, J Gastroenterol, J Gastroenterol, 51(12), 1150 - 1160, Dec. 2016 , Refereed
  DOI
• Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update., Kudo M, Liver cancer, Liver cancer, 6(1), 1 - 12, Nov. 2016 , Refereed
  DOI
• Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis, Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T, Oncotarget, Oncotarget, 7(46), 75482 - 75491, Nov. 2016 , Refereed
  DOI
• Hepatocellular carcinoma: therapeutic guidelines and medical treatment, Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L, Liver Cancer, Liver Cancer, 6(1), 16 - 26, Nov. 2016 , Refereed
  DOI
• Factors predicting through-the-scope gastroduodenal stenting outcomes in patients with gastric outlet obstruction: a large multicenter retrospective study in West Japan, Yamao K, Kitano M, Kayahara T, Ishida E, Yamamoto H, Minaga K, Yamashita Y, Nakajima J, Asada M, Okabe Y, Osaki Y, Chiba Y, Imai H, Kudo M, Gastrointest Endosc, Gastrointest Endosc, 84(5), 757 - 763, Nov. 2016 , Refereed
  DOI
• Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion, Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N, J Hepatol, J Hepatol, 65(5), 938 - 943, Nov. 2016 , Refereed
  DOI
• Bile duct adenoma in patient with chronic hepatitis C: As a benign neoplasm by pathological and imaging studies, Kim SK, Kim SR, Imoto S, Kim CW, Matsuoka T, Nakashima O, Sasaki M, Kumabe T, Kudo M, Fukusato T, Kondo F, Pathol Int, Pathol Int, 66(11), 640 - 642, Nov. 2016 , Refereed
  DOI
• Needle-tract seeding on the proximal gastric wall after EUS-guided fine-needle aspiration of a pancreatic mass, Minaga K, Kitano M, Enoki E, Kashida H, Kudo M, Am J Gastroenterol, Am J Gastroenterol, 111(11), 1515, Nov. 2016 , Refereed
  DOI
• Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: Randomized phase II trial, Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T, Ann Oncol, Ann Oncol, 27(11), 2090 - 2096, Nov. 2016 , Refereed
  DOI
• Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma, Masatoshi Kudo, Liver Cancer, Liver Cancer, 5(4), 235 - 244, Oct. 2016 , Refereed
  DOI
• Feasibility of extracted-overlay fusion imaging for intraoperative treatment evaluation of radiofrequency ablation for hepatocellular carcinoma, Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Iwamoto T, Okabe J, Takamura M, Fujita N, Hori M, Takehara T, Kudo M, Murakami T, Liver Cancer, Liver Cancer, 5(4), 269 - 279, Oct. 2016 , Refereed
  DOI
• Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis, Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R, Med Oncol, Med Oncol, 33(10), 114 - 121, Oct. 2016 , Refereed
  DOI
• Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis., Watanabe T, Sadakane Y, Yagama N, Sakurai T, Ezoe H, Kudo M, Chiba T, Strober W, Mucosal immunology, Mucosal immunology, 9(5), 1234 - 1249, Sep. 2016 , Refereed
  DOI
• Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease., Nishida N, Yada N, Hagiwara S, Sakurai T, Kitano M, Kudo M, Journal of gastroenterology and hepatology, Journal of gastroenterology and hepatology, 31(9), 1646 - 1653, Sep. 2016 , Refereed
  DOI
• Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score., Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I, JAMA oncology, JAMA oncology, Sep. 2016 , Refereed
  DOI
• Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma, Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT, Hepatology, Hepatology, 64(3), 774 - 784, Sep. 2016 , Refereed
  DOI
• Evaluation of anti-migration properties of biliary covered self-expandable metal stents, Minaga K, Kitano M, Imai H, Harwani Y, Yamao K, Kamata K, Miyata T, Omoto S, Kadosaka K, Sakurai T, Nishida N, Kudo M, World J Gastroenterol, World J Gastroenterol, 22(30), 6917 - 6924, Aug. 2016 , Refereed
  DOI
• Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study, Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladron de, Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL, Liver Int, Liver Int, 36(8), 1196 - 1205, Aug. 2016 , Refereed
  DOI
• Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma, Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyi S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ, J Hepatol, J Hepatol, 65(2), 289 - 295, Aug. 2016 , Refereed
  DOI
• Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response., Kudo M, Liver cancer, Liver cancer, 5(3), 155 - 161, Jul. 2016 , Refereed
  DOI
• Reply., Hagiwara S, Nishida N, Kudo M, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), 64(1), 306, Jul. 2016 , Refereed
  DOI
• Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer., Minaga K, Kitano M, Sakamoto H, Miyata T, Imai H, Yamao K, Kamata K, Omoto S, Kadosaka K, Sakurai T, Nishida N, Chiba Y, Kudo M, Therapeutic advances in gastroenterology, Therapeutic advances in gastroenterology, 9(4), 483 - 494, Jul. 2016 , Refereed
  DOI
• Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis., Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, Liver Cancer Study, Group of Japan, Liver cancer, Liver cancer, 5(3), 175 - 189, Jul. 2016 , Refereed
  DOI
• Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study, Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah P, Smirne C, Tait P, Pai M, Grossi G, Kim YW, Pirisi M, Kudo M, Sharma R, Oncotarget, Oncotarget, 7(28), 44705 - 44718, Jul. 2016 , Refereed
  DOI
• Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan, Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver, Cancer Study, Group of Japan, Liver Cancer, Liver Cancer, 5(3), 190 - 197, Jul. 2016 , Refereed
  DOI
• EUS-guided gallbladder drainage for rescue treatment of malignant distal biliary obstruction after unsuccessful ERCP, Imai H, Kitano M, Omoto S, Kadosaka K, Kamata K, Miyata T, Yamao K, Sakamoto H, Harwani Y, Kudo M, Gastrointest Endosc, Gastrointest Endosc, 84(1), 147 - 151, Jul. 2016 , Refereed
  DOI
• New endoscopic ultrasonography techniques for pancreaticobiliary diseases, Kamata K, Kitano M, Omoto S, Kadosaka K, Miyata T, Minaga K, Yamao K, Imai H, Kudo M, Ultrasonography, Ultrasonography, 35(3), 169 - 179, Jul. 2016 , Refereed
  DOI
• Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial, Kamata K, Kitano M, Yasukawa S, Kudo M, Chiba Y, Ogura T, Higuchi K, Fukutake N, Ashida R, Yamasaki T, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Yanagisawa A, Endoscopy, Endoscopy, 48(7), 1 - 7, Jul. 2016 , Refereed
  DOI
• Response, Kitano M, Imai H, Kamata K, Kudo M, Gastrointest Endosc, Gastrointest Endosc, 83(6), 1303, Jun. 2016 , Refereed
  DOI
• Modified single transluminal gateway transcystic multiple drainage technique for a huge infected walled-off pancreatic necrosis: A case report, Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Yoshikawa T, Kudo M, walled-off pancreatic necrosis: A case report., walled-off pancreatic necrosis: A case report., 22(21), 5132 - 5136, Jun. 2016 , Refereed
  DOI
• Reply., Hagiwara S, Nishida N, Kudo M, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), 63(5), 1744 - 1745, May 2016 , Refereed
  DOI
• TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON., Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de, Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R, Radiology, Radiology, 279(2), 630 - 640, May 2016 , Refereed
  DOI
• Epigenetic regulation and development of hepatocellular carcinoma., Nishida N, Kudo M, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 113(5), 775 - 784, May 2016 , Refereed
  DOI
• Acute spinal cord infarction after EUS-guided celiac plexus neurolysis, Minaga K, Kitano M, Imai H, Miyata T, Kudo M, Gastrointest Endosc, Gastrointest Endosc, 83(5), 1039 - 1040, May 2016 , Refereed
  DOI
• Gastric Perineurioma., Matsui S, Kashida H, Kudo M, The American journal of gastroenterology, The American journal of gastroenterology, 111(4), 453, Apr. 2016 , Refereed
  DOI
• Urgent endoscopic ultrasound-guided choledochoduodenostomy for acute obstructive suppurative cholangitis-induced sepsis, Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Omoto S, Kadosaka K, Yoshikawa T, Kudo M, World J Gastroenterol, World J Gastroenterol, 22(16), 4264 - 4269, Apr. 2016 , Refereed
  DOI
• Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B, Masatoshi Kudo, Liver Cancer, Liver Cancer, 5(2), 91 - 96, Apr. 2016 , Refereed
  DOI
• Report of the 19th follow-up survey of primary liver cancer in Japan, Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y, the Liver Cancer Study Group of Japan, Hepatol Res, Hepatol Res, 46(5), 372 - 390, Mar. 2016 , Refereed
  DOI
• Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma, Miyata T, Kitano M, Omoto S, Kadosaka K, Kamata K, Imai H, Sakamoto H, Nishida N, Harwani Y, Murakami T, Takeyamas Y, Chiba Y, Kudo M, World J Gastroenterol, World J Gastroenterol, 22(12), 3381 - 3391, Mar. 2016 , Refereed
  DOI
• Breakthrough Imaging in Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 5(1), 47 - 54, Feb. 2016 , Refereed
  DOI
• Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 5(1), 1 - 7, Feb. 2016 , Refereed
  DOI
• Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study., Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, Tanaka H, Iijima H, Ochi H, Hirooka M, Numata K, Kudo M, Journal of gastroenterology, Journal of gastroenterology, 51(2), 144 - 152, Feb. 2016 , Refereed
  DOI
• Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan., Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, Liver Cancer Study, Group of Japan, Cancer, Cancer, 122(1), 61 - 70, Jan. 2016 , Refereed
  DOI
• Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts., Kamata K, Kitano M, Omoto S, Kadosaka K, Miyata T, Yamao K, Imai H, Sakamoto H, Harwani Y, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, Kudo M, Endoscopy, Endoscopy, 48(1), 35 - 41, Jan. 2016 , Refereed
  DOI
• Inclusion of Journal of Medical Ultrasonics in MEDLINE., Kudo M, Kanai H, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 43(1), 163, Jan. 2016 , Refereed
  DOI
• Hepaticogastrostomy guided by real-time contrast-enhanced harmonic endoscopic ultrasonography: a novel technique., Minaga K, Kitano M, Yoshikawa T, Omoto S, Kamata K, Yamao K, Kudo M, Endoscopy, Endoscopy, 48 Suppl 1, E228 - 9, 2016 , Refereed
  DOI
• Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2., Nishida N, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 34(6), 632 - 639, 2016 , Refereed
  DOI
• Cases with Refractory Ascites and a Delayed Response to Tolvaptan., Hagiwara S, Nishida N, Chishina H, Ida H, Sakurai T, Komeda Y, Kitano M, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 55(22), 3273 - 3277, 2016 , Refereed
  DOI
• Through-the-mesh technique after endoscopic ultrasonography-guided hepaticogastrostomy: a novel re-intervention method, Minaga K, Takenaka M, Miyata T, Ueda Y, Kitano M, Kudo M, Endoscopy, Endoscopy, 48(S 01), 369 - 370, 2016 , Refereed
  DOI
• Impact of tight junction protein ZO-1 and TWIST expression on post-operative survival of patients with hepatocellular carcinoma, Nagai T, Arao T, Nishio K, Matsumoto K, Hagiwara S, Sakurai T, Minami Y, Ida H, Ueshima K, Nishida N, Sakai K, Saijo N, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Haji S, Kudo M, Digest Dis, Digest Dis, 34(6), 702 - 707, 2016 , Refereed
  DOI
• Comparison of two-dimensional shear wave elastography and real-time tissue elastography for assessing liver fibrosis in chronic hepatitis B, Wu T, Wang P, Zhang T, Zheng J, Li JZ, Zeng J, Kudo M, Zheng R, Digest Dis, Digest Dis, 34(6), 640 - 649, 2016 , Refereed
  DOI
• Validation of Kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma, Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ida H, Sakurai T, Kitano M, Nishida N, Kudo M, Digest Dis, Digest Dis, 34(6), 671 - 678, 2016 , Refereed
  DOI
• Comparison of contrast-enhanced ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-enhanced MRI for the diagnosis of macroscopic type of hepatocellular carcinoma, Iwamoto T, Imai Y, Kogita S, Igura T, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Seki Y, Ohashi H, Fujita N, Kudo M, Takehara T, Digest Dis, Digest Dis, 34(6), 679 - 686, 2016 , Refereed
  DOI
• Radiofrequency ablation guided by contrast-enhanced sonography versus B-mode sonography for hepatocellular carcinoma after transcatheter arterial chemoembolization, Kawasaki T, Hata K, Kinoshita D, Takayama M, Okuda H, Mizuno S, Kudo M, Digest Dis, Digest Dis, 34(6), 692 - 695, 2016 , Refereed
  DOI
• Efficacy and safety of sofosbuvir plus ribavirin treatment for patients with chronic hepatitis C genotype 2, Sugimoto K, Kim SK, Kim SR, Kobayashi M, Kato A, Morimoto E, Imoto S, Kim CW, Tanaka Y, Kudo M, Yano Y, Hayashi Y, Digest Dis, Digest Dis, 34(6), 627 - 631, 2016 , Refereed
  DOI
• Prospective risk analysis of hepatocellular carcinoma in patients with chronic hepatitis C by ultrasound strain elastography, Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M, Digest Dis, Digest Dis, 34(6), 650 - 653, 2016 , Refereed
  DOI
• Coffee intake and liver enzyme association in Korean immigrants and Japanese: a comprehensive cross-sectional study, Kim SK, Shin MH, Sugimoto K, Kim SR, Imoto S, Kim KI, Taniguchi M, Oh HK, Yano Y, Hayashi T, Kudo M, Digest Dis, Digest Dis, 34(6), 665 - 670, 2016 , Refereed
  DOI
• Recent trends in the management of hepatocellular carcinoma with special emphasis on treatment with regorafenib and immune checkpoint inhibitors, Masatoshi Kudo, Digest Dis, Digest Dis, 34(6), 714 - 730, 2016 , Refereed
  DOI
• Prediction of embolization area after conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using SYNAPSE VINCENT, Ogawa C, Minami Y, Morita M, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibatouge M, Kudo M, Digest Dis, Digest Dis, 34(6), 696 - 701, 2016 , Refereed
  DOI
• US-US fusion imaging in radiofrequency ablation for liver metastases, Minami Y, Minami T, Chishina H, Kono M, Arizumi T, Takita M, Yada N, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M, Digest Dis, Digest Dis, 34(6), 687 - 691, 2016 , Refereed
  DOI
• Clinical significance of epigenetic alterations in human hepatocellular carcinoma and its association with genetic mutations, Nishida N, Kudo M, Digest Dis, Digest Dis, 34(6), 708 - 713, 2016 , Refereed
  DOI
• Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis, Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M, Digest Dis, Digest Dis, 34(6), 659 - 664, 2016 , Refereed
  DOI
• Monoethanolamine oleate sclerotherapy for polycystic liver disease, Takita M, Iwanishi M, Minami T, Kono M, Chishina K, Arizumi T, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Nishida N, Kudo M, Digest Dis, Digest Dis, 34(6), 654 - 658, 2016 , Refereed
  DOI
• Outcome of asunaprevir/daclatasvir combination therapy for chronic liver disease type C, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M, Digest Dis, Digest Dis, 34(6), 620 - 626, 2016 , Refereed
  DOI
• Chronic Liver diseases and liver cancer: state-of-the art progress in 2016, Masatoshi Kudo, Digest Dis, Digest Dis, 34(6), 617 - 619, 2016 , Refereed
  DOI
• Response evaluation criteria in cancer of the liver (RECICL)(2015 revised version), Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N, Liver Cancer Study, Group of Japan, Hepatol Res, Hepatol Res, 46(1), 3 - 9, Jan. 2016 , Refereed
  DOI
• Immune Checkpoint Blockade in Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 4(4), 201 - 207, Dec. 2015 , Refereed
  DOI
• Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma., Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M, Annals of oncology : official journal of the European Society for Medical Oncology, Annals of oncology : official journal of the European Society for Medical Oncology, 26(12), 2457 - 2463, Dec. 2015 , Refereed
  DOI
• Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma., Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M, Liver cancer, Liver cancer, 4(4), 253 - 262, Dec. 2015 , Refereed
  DOI
• Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil., Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S, Liver cancer, Liver cancer, 4(4), 263 - 273, Dec. 2015 , Refereed
  DOI
• Multicenter cooperative case survey of hepatitis B Virus reactivation by chemotherapeutic agents, Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M, Hepatol Res, Hepatol Res, 45(12), 1220 - 1227, Dec. 2015 , Refereed
  DOI
• Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria., Hagiwara S, Nishida N, Park AM, Sakurai T, Kawada A, Kudo M, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), 62(5), 1638 - 1639, Nov. 2015 , Refereed
  DOI
• Plasmacytoid Dendritic Cell Activation and IFN-α Production Are Prominent Features of Murine Autoimmune Pancreatitis and Human IgG4-Related Autoimmune Pancreatitis., Arai Y, Yamashita K, Kuriyama K, Shiokawa M, Kodama Y, Sakurai T, Mizugishi K, Uchida K, Kadowaki N, Takaori-Kondo A, Kudo M, Okazaki K, Strober W, Chiba T, Watanabe T, Journal of immunology (Baltimore, Md. : 1950), Journal of immunology (Baltimore, Md. : 1950), 195(7), 3033 - 3044, Oct. 2015 , Refereed
  DOI
• Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial., Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM, STORM investigators, The Lancet. Oncology, The Lancet. Oncology, 16(13), 1344 - 1354, Oct. 2015 , Refereed
  DOI
• Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)., Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 33(6), 751 - 758, Oct. 2015 , Refereed
  DOI
• Antiviral therapy for chronic hepatitis B: combination of nucleoside analogs and interferon, Hagiwara S, Nishida N, Kudo M, World J Hepatol, World J Hepatol, 7(23), 2427 - 2431, Oct. 2015 , Refereed
  DOI
• Challenges of clinical research on hepatocellular carcinoma, Kudo M, Kitano M, Sakurai T, Nishida N, Digest Dis, Digest Dis, 33(6), 780 - 790, Oct. 2015 , Refereed
  DOI
• Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma, Nishida N, Kitano M, Sakurai T, Kudo M, Digest Dis, Digest Dis, 33(6), 771 - 779, Oct. 2015 , Refereed
  DOI
• General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan, Kudo M, Kitano M, Sakurai T, Nishida N, Digest Dis, Digest Dis, 33(6), 765 - 770, Oct. 2015 , Refereed
  DOI
• Cone-beam CT angiography for hepatocellular carcinoma: current status, Minami Y, Murakami T, Kitano M, Sakurai T, Nishida N, Kudo M, Digest Dis, Digest Dis, 33(6), 759 - 764, Oct. 2015 , Refereed
  DOI
• Hepatic DNA methylation is affected by hepatocellular carcinoma risk in patients with and without hepatitis virus, Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M, Digest Dis, Digest Dis, 33(6), 745 - 750, Oct. 2015 , Refereed
  DOI
• Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis, Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M, Digest Dis, Digest Dis, 33(6), 728 - 734, Oct. 2015 , Refereed
  DOI
• Characteristics of hypovascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2cm - focus on tumor size, markers and imaging detectability, Sugimoto K, Kim SR, Imoto S, Tohyama M, Kim SK, Matsuoka T, Yano Y, Kudo M, Hayashi Y, Digest Dis, Digest Dis, 33(6), 721 - 727, Oct. 2015 , Refereed
  DOI
• Usefulness of cytokeratin-18M65 in diagnosing non-alcoholic steatohepatitis in Japanese population, Hasegawa Y, Kim SR, Hatae T, Ohta M, Fujinami A, Sugimoto K, Kim KI, Imoto S, Tohyama M, Kim SK, Ikura Y, Kudo M, Digest Dis, Digest Dis, 33(6), 715 - 720, Oct. 2015 , Refereed
  DOI
• Early viral response predicts the efficacy of antiviral triple therapy with simeprevir, peg-interferon, and ribavirin in patients infected with hepatitis C virus genotype 1, Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M, Digest Dis, Digest Dis, 33(6), 708 - 714, Oct. 2015 , Refereed
  DOI
• Chronic Liver Diseases and Liver Cancer: An Update in 2015, Masatoshi Kudo, Digest Dis, Digest Dis, 33(6), 705 - 707, Oct. 2015 , Refereed
  DOI
• Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study, Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M, he investigators’study group, J Hepatol, J Hepatol, 63(4), 896 - 904, Oct. 2015 , Refereed
  DOI
• Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?, Kudo M, Liver cancer, Liver cancer, 4(3), I - VII, Sep. 2015 , Refereed
  DOI
• Locoregional Therapy for Hepatocellular Carcinoma., Kudo M, Liver cancer, Liver cancer, 4(3), 163 - 164, Sep. 2015 , Refereed
  DOI
• Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study, Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M, Liver Int, Liver Int, 35(9), 2155 - 2166, Sep. 2015 , Refereed
  DOI
• The role of hepatic resection in the treatment of hepatocellular cancer, Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts L, Sherman M, Hepatology, Hepatology, 62(2), 440 - 451, Aug. 2015 , Refereed
  DOI
• Primary leiomyosarcoma of the colon, Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, Kudo M, Clin J Gastroenterol, Clin J Gastroenterol, 8(4), 217 - 222, Aug. 2015 , Refereed
  DOI
• Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial., Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M, REACH Trial Investigators, The Lancet. Oncology, The Lancet. Oncology, 16(7), 859 - 870, Jul. 2015 , Refereed
  DOI
• [Gastric ulcer, duodenal ulcer]., Matsui S, Kashida H, Asakuma Y, Sakurai T, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 73(7), 1116 - 1122, Jul. 2015 , Refereed
• Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification., Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, Kudo M, Pirisi M, Sharma R, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 13(6), 1204 - 8.e2, Jun. 2015 , Refereed
  DOI
• Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized placebo-controlled trial, Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H, Peretinoin Study Group, J Gastroenterol, J Gastroenterol, 50(6), 667 - 674, Jun. 2015 , Refereed
  DOI
• Foreword to the WFUMB guidelines and recommendations on the clinical use of ultrasound elastography., Kudo M, Ultrasound in medicine & biology, Ultrasound in medicine & biology, 41(5), 1125, May 2015 , Refereed
  DOI
• Evaluation of the Response to Chemotherapy in Advanced Gastric Cancer by Contrast-Enhanced Harmonic EUS., Matsui S, Kudo M, Kitano M, Asakuma Y, Hepato-gastroenterology, Hepato-gastroenterology, 62(139), 595 - 598, May 2015 , Refereed
• WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2; Breast, Barr R, Nakashima K, Amy D, Cosgrove D, Farrokh A, Schafer F, Bamber J, Castera L, Choi B, Chou Y, Dietrich C, Ding H, Ferraioli G, Filice C, Friedrich-Rust M, Hall T, Nightingale K, Palmeri M, Shiina T, Suzuki S, Sporea I, Wilson S, Kudo M, Ultrasound Med Biol, Ultrasound Med Biol, 41(5), 1148 - 1160, May 2015 , Refereed
  DOI
• WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part3; Liver, Ferraioli G, Filice C, Castera L, Choi B, Sporea I, Wilson S, Cosgrove D, Dietrich C, Amy D, Bamber J, Barr R, Chou Y, Ding H, Farrokh A, Friedrich-Rust M, Hall T, Nakashima K, Nightingale K, Palmeri M, Schafer F, Shiina T, Suzuki S, Kudo M, Ultrasound Med Biol, Ultrasound Med Biol, 41(5), 1161 - 1179, May 2015 , Refereed
  DOI
• WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1; basic principles and terminology, Shiina T, Nightingale K, Palmeri M, Hall T, Bamber J, Barr R, Castera L, Choi B, Chou Y, Cosgrove D, Dietrich C, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M, Ultrasound Med Biol, Ultrasound Med Biol, 41(5), 1126 - 1147, May 2015 , Refereed
  DOI
• Cold-inducible RNA-binding protein promotes the development of liver cancer., Sakurai T, Yada N, Watanabe T, Arizumi T, Hagiwara S, Ueshima K, Nishida N, Fujita J, Kudo M, Cancer science, Cancer science, 106(4), 352 - 358, Apr. 2015 , Refereed
  DOI
• Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases., Kitano M, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 27 Suppl 1, 60 - 67, Apr. 2015 , Refereed
  DOI
• Heat shock protein A4 controls cell migration and gastric ulcer healing, Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, Kudo M, Digest Dis Sci, Digest Dis Sci, 60(4), 850 - 857, Apr. 2015 , Refereed
  DOI
• Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy, Masatoshi Kudo, Hepatol Int, Hepatol Int, 9(2), 155 - 156, Apr. 2015 , Refereed
  DOI
• Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe., Liver cancer, Liver cancer, 4(2), 85 - 95, Mar. 2015 , Refereed
  DOI
• A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients., Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N, Liver Cancer Study, Group of Japan, Annals of surgery, Annals of surgery, 261(3), 513 - 520, Mar. 2015 , Refereed
  DOI
• [US]., Kitano M, Imai H, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 3, 50 - 54, Mar. 2015 , Refereed
• [US]., Kitano M, Kamata K, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 3, 491 - 494, Mar. 2015 , Refereed
• Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan., Kudo M, Liver cancer, Liver cancer, 4(1), 39 - 50, Mar. 2015 , Refereed
  DOI
• Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI., Minami Y, Kudo M, Liver cancer, Liver cancer, 4(2), 106 - 114, Mar. 2015 , Refereed
  DOI
• Malignant transformation of hepatocellular adenoma: How frequently does it happen?, Masatoshi Kudo, Liver Cancer, Liver Cancer, 1(1), 1 - 5, Mar. 2015 , Refereed
  DOI
• Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver., Okada M, Murakami T, Yada N, Numata K, Onoda M, Hyodo T, Inoue T, Ishii K, Kudo M, Journal of magnetic resonance imaging : JMRI, Journal of magnetic resonance imaging : JMRI, 41(2), 329 - 338, Feb. 2015 , Refereed
  DOI
• Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study., Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H, Peretinoin Study Group, Journal of gastroenterology, Journal of gastroenterology, 50(2), 191 - 202, Feb. 2015 , Refereed
  DOI
• Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection, Okumura N, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Kawasaki M, Tomita T, Umehara Y, Taniike S, Kono M, Kudo M, Gastroenterol Rep, Gastroenterol Rep, 3(1), 69 - 74, Feb. 2015 , Refereed
  DOI
• Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer., Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K, Cancer letters, Cancer letters, 356(2 Pt B), 819 - 827, Jan. 2015 , Refereed
  DOI
• Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients., Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M, Journal of immunology research, Journal of immunology research, 2015, 473909, 2015 , Refereed
  DOI
• Evidence and Consensus on the Management of Hepatocellular Carcinoma: Update 2015., Kudo M, Oncology, Oncology, 89 Suppl 2, 1 - 3, 2015 , Refereed
  DOI
• Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration, Yamao K, Kitano M, Kudo M, Maenishi O, Endoscopy, Endoscopy, 47, 596 - 597, 2015 , Refereed
  DOI
• Recent advances in the management of chronic hepatitis B including suppression of hepatocellular carcinoma by entecavir and interferon, Kim SK, Kim SR, Imoto S, Tohyama M, Otono Y, Tamura T, Kim KI, Kobayashi M, Ohtani A, Sugimoto K, Mizuguchi A, Hiramatsu Y, Kudo M, Oncology, Oncology, 89, 60 - 69, 2015 , Refereed
  DOI
• A newly developed shear wave elastography modality: with a unique reliability index, Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ueshima K, Ida H, Nishida N, Kudo M, Oncology, Oncology, 89, 53 - 59, 2015 , Refereed
  DOI
• Validation of a modified substaging system (Kinki Criteria) for patients with intermediate-stage hepatocellular carcinoma, Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, Kudo M, Oncology, Oncology, 89, 47 - 52, 2015 , Refereed
  DOI
• Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma, Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y, Oncology, Oncology, 89, 42 - 46, 2015 , Refereed
  DOI
• Hyperenhanced rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: a histological indication of the presence of Kupffer cells, Tochio H, Sugahara M, Imai Y, Tei H, Suginoshita Y, Iwasaki N, Sasaki I, Hamada M, Minowa K, Inokuma T, Kudo M, Oncology, Oncology, 89, 33 - 41, 2015 , Refereed
  DOI
• Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience, Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Tsurusaki M, Yagyu Y, Ueshima K, Nishida N, Murakami T, Kudo M, Oncology, Oncology, 89, 27 - 32, 2015 , Refereed
  DOI
• Percutaneous radiofrequency ablation for Intermediate-stage hepatocellular carcinoma, Kariyama K, Wakuta A, Nishimura M, Kishida M, Oonishi A, Ohyama A, Nouso K, Kudo M, Oncology, Oncology, 89, 19 - 26, 2015 , Refereed
  DOI
• Initial experience performing percutaneous ultrasound examination with real-time virtual sonography with color display, Ogawa C, Minami Y, Noda T, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Kudo M, Oncology, Oncology, 89, 11 - 18, 2015 , Refereed
  DOI
• Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma, Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M, Oncology, Oncology, 89, 4 - 10, 2015 , Refereed
  DOI
• Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines), Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M, Hepatol Res, Hepatol Res, 45(2), 123 - 127, Jan. 2015 , Refereed
  DOI
• A bridge between multi-omics data and the management of hepatocellular carcinoma, Nishida N, Kudo M, Ann Transl Med, Ann Transl Med, 3(1), 1, Jan. 2015 , Refereed
  DOI
• Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, Nowiem SE, J Clin Oncol, J Clin Oncol, 33(2), 172 - 179, Jan. 2015 , Refereed
  DOI
• Involvement of heat shock protein A4/Apg-2 in refractory inflammatory bowel disease, Adachi T, Sakurai T, Kashida H, Mine H, Hagiwara S, Matsui S, Yoshida K, Nishida N, Watanabe T, Itoh K, Fujita J, Kudo M, Inflamm Bowel Dis, Inflamm Bowel Dis, 21(1), 31 - 39, Jan. 2015 , Refereed
  DOI
• Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study., Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R, Alimentary pharmacology & therapeutics, Alimentary pharmacology & therapeutics, 40(11-12), 1270 - 1281, Dec. 2014 , Refereed
  DOI
• Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma, Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M, J Gastroenterol, J Gastroenterol, 49(12), 1578 - 1587, Dec. 2014 , Refereed
  DOI
• Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial., Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), 60(5), 1697 - 1707, Nov. 2014 , Refereed
  DOI
• NOD2 Down-regulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6, Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, Kudo M, Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W, Mucosal Immunol, Mucosal Immunol, 7(6), 1312 - 1325, Nov. 2014 , Refereed
  DOI
• Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer, Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J, Kudo M, Cancer Res, Cancer Res, 74(21), 6119 - 6128, Nov. 2014 , Refereed
  DOI
• JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan., Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K, Liver Cancer Study, Group of Japan, Liver cancer, Liver cancer, 3(3-4), 458 - 468, Oct. 2014 , Refereed
  DOI
• Current treatment status of polycystic liver disease in Japan., Ogawa K, Fukunaga K, Takeuchi T, Kawagishi N, Ubara Y, Kudo M, Ohkohchi N, Hepatol Res, Hepatol Res, 44(11), 1110 - 1118, Oct. 2014 , Refereed
  DOI
• Alteration of epigenetic profile in human hepatocellular carcinoma and its clinical implications, Nishida N, Kudo M, Liver Cancer, Liver Cancer, 3(3-4), 417 - 427, Oct. 2014 , Refereed
  DOI
• Biomarkers and personalized sorafenib therapy, Masatoshi Kudo, Liver Cancer, Liver Cancer, 3(3-4), 399 - 404, Oct. 2014 , Refereed
  DOI
• Endoscopic ultrasonography-guided gallbladder drainage procedures: is the glass half-full or half-empty?, Kitano M, Kamata K, Kudo M, Digest Endosc, Digest Endosc, 26(5), 636 - 637, Sep. 2014 , Refereed
  DOI
• Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count., Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Siato M, Iijima H, Iimuro Y, Fujimoto J, Yamamoto S, Hirota S, Kudo M, Arii S, Nishiguchi S, Hepato Res, Hepato Res, 44(8), 829 - 836, Aug. 2014 , Refereed
  DOI
• Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial, Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Radosavljevic MPR, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT, J Am Med Assoc (JAMA), J Am Med Assoc (JAMA), 312(1), 57 - 67, Jul. 2014 , Refereed
  DOI
• Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma., Kudo M, Arizumi T, Ueshima K, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), 59(6), 2424 - 2425, Jun. 2014 , Refereed
  DOI
• Serum amyloid A and C-reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis, Kim SR, Kondo F, Otono Y, Imoto S, Ando K, Hirakawa M, Fukuda K, Sakaki M, Kim SK, Komaki T, Tsuchida S, Kobayashi S, Matsuoka T, Kudo M, Hepatol Res, Hepatol Res, 44(5), 584 - 590, May 2014 , Refereed
  DOI
• GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, FuruseJ, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ, Int J Clin Pract, Int J Clin Pract, 68(5), 609 - 617, May 2014 , Refereed
  DOI
• Recent advances in bioinformatics reveal the molecular heterogeneity of hepatocellular carcinoma., Liver cancer, Liver cancer, 3(2), 68 - 70, May 2014 , Refereed
  DOI
• Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic Masses, Ashida R, Yasukawa S, Yanagisawa A, Kamata K, Kudo M, Ogura T, Higuchi K, Fukutake N, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Kitano M, Gastrointest Endosc, Gastrointest Endosc, 79, AB111, May 2014 , Refereed
• Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer, Togashi Y, Sakamoto H, Hayashi H, Terashima M, Velasco Ma, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Kudo M, Nishio K, Mol Cancer, Mol Cancer, 13, 126 - 136, May 2014 , Refereed
  DOI
• Therapeutic Response Assessment of RFA for HCC: Contrast-enhanced US, CT and MRI, Minami Y, Nishida N, Kudo M, World J Gastroenterol, World J Gastroenterol, 20(15), 4160 - 4166, Apr. 2014 , Refereed
  DOI
• Reply to Kadayifci and brugge, Kitano K, Kamata K, Kudo M, Endoscopy, Endoscopy, 46(4), 358 - 358, Apr. 2014 , Refereed
  DOI
• Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy, Kawanaka M, Nishio K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G, Liver Cancer, Liver Cancer, 3(1), 41 - 52, Mar. 2014 , Refereed
  DOI
• Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Three-Dimensional Cone-Beam CT Angiography, Minami Y, Yagyu Y, Murakami T, Kudo M, Liver Cancer, Liver Cancer, 3(1), 53 - 61, Mar. 2014 , Refereed
  DOI
• Relevance of the core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a± ribavirin for chronic hepatitis C of genotype 1b: A multicenter randomized trial, ReGIT-J study, Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M, J Gastroenterol, J Gastroenterol, 49(3), 492 - 501, Mar. 2014 , Refereed
  DOI
• Prediction of hepatocellular carcinoma incidence risk by ultrasound elastography., Kudo M, Liver cancer, Liver cancer, 3(1), 1 - 5, Mar. 2014 , Refereed
  DOI
• Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey., Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M, Liver Cancer Study, Group of Japan, Annals of surgery, Annals of surgery, 259(3), 532 - 542, Mar. 2014 , Refereed
  DOI
• Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel, Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW, Liver Int, Liver Int, 34(2), 174 - 183, Feb. 2014 , Refereed
  DOI
• Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact., Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M for, the Liver Cancer Study, Group of Japan, Ann Surg, Ann Surg, 259(2), 336 - 345, Feb. 2014 , Refereed
  DOI
• Prognostic imapct of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1,160 cases from a nationwide survey, Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M, for the Liver, Cancer Study, Group of Japan, Ann Surg, Ann Surg, 259, 532 - 542, 2014 , Refereed
  DOI
• Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms., Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y, Endoscopy, Endoscopy, 46(1), 22 - 29, Jan. 2014 , Refereed
  DOI
• The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US, Hatanaka K, Minami Y, Kudo M, Inoue T, Chung H, Haji S, J Clin Ultrasound, J Clin Ultrasound, 42(1), 1 - 8, Jan. 2014 , Refereed
  DOI
• Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey., Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Liver Cancer Study, Group of Japan, Annals of surgery, Annals of surgery, 259(1), 166 - 170, Jan. 2014 , Refereed
  DOI
• Breakthroughs in the management of hepatocellular carcinoma: celebrating 50 years of the liver cancer study group of Japan., Kudo M, Oncology, Oncology, 87 Suppl 1, 1 - 6, 2014 , Refereed
  DOI
• Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update., Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Liver Cancer Study, Group of Japan, Oncology, Oncology, 87 Suppl 1, 7 - 21, 2014 , Refereed
  DOI
• Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update., Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Liver Cancer Study, Group of Japan, Oncology, Oncology, 87 Suppl 1, 22 - 31, 2014 , Refereed
  DOI
• Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ., Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M, Oncology, Oncology, 87 Suppl 1, 32 - 36, 2014 , Refereed
  DOI
• Pathological diagnosis of benign hepatocellular nodular lesions based on the new World Health Organization classification., Kondo F, Fukusato T, Kudo M, Oncology, Oncology, 87 Suppl 1, 37 - 49, 2014 , Refereed
  DOI
• Virtual sonography for novice sonographers: usefulness of SYNAPSE VINCENT® with pre-check imaging of tumor location., Ogawa C, Minami Y, Morioka Y, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibatouge M, Kudo M, Oncology, Oncology, 87 Suppl 1, 50 - 54, 2014 , Refereed
  DOI
• Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging., Minami T, Minami Y, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Inoue T, Hagiwara S, Ueshima K, Nishida N, Kudo M, Oncology, Oncology, 87 Suppl 1, 55 - 62, 2014 , Refereed
  DOI
• Noninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree., Yada N, Kudo M, Kawada N, Sato S, Osaki Y, Ishikawa A, Miyoshi H, Sakamoto M, Kage M, Nakashima O, Tonomura A, Oncology, Oncology, 87 Suppl 1, 63 - 72, 2014 , Refereed
  DOI
• Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma., Ikeda K, Osaki Y, Nakanishi H, Nasu A, Kawamura Y, Jyoko K, Sano T, Sunagozaka H, Uchino K, Minami Y, Saito Y, Nagai K, Inokuchi R, Kokubu S, Kudo M, Oncology, Oncology, 87 Suppl 1, 73 - 77, 2014 , Refereed
  DOI
• Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona Clinic Liver Cancer stage B)., Yamakado K, Kudo M, Oncology, Oncology, 87 Suppl 1, 78 - 81, 2014 , Refereed
  DOI
• Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis., Nouso K, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H, Oishi N, Kuwaki K, Kusanaga M, Sakaguchi T, Morise Z, Kitai S, Kudo M, Oncology, Oncology, 87 Suppl 1, 99 - 103, 2014 , Refereed
  DOI
• Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan., Tanaka K, Shimada M, Kudo M, Oncology, Oncology, 87 Suppl 1, 104 - 109, 2014 , Refereed
  DOI
• Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus., Takita M, Hagiwara S, Kudo M, Kouno M, Chishina H, Arizumi T, Kitai S, Yada N, Inoue T, Minami Y, Ueshima K, Oncology, Oncology, 87 Suppl 1, 110 - 117, 2014 , Refereed
  DOI
• Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C., Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Inoue T, Hagiwara S, Ueshima K, Nishida N, Kudo M, Oncology, Oncology, 87 Suppl 1, 118 - 123, 2014 , Refereed
  DOI
• Stabilization technique for real-time high-resolution vascular ultrasound using frequency domain interferometry, Taki H, Taki K, Yamakawa M, Shiina T, Kudo M, Sato T, Conf Proc IEEE Eng Med Biol Soc, Conf Proc IEEE Eng Med Biol Soc, 2014, 5085 - 5088, 2014 , Refereed
  DOI
• Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study, Wu T, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ, Digest Dis, Digest Dis, 32(6), 791 - 799, 2014 , Refereed
  DOI
• Clinical features of vascular disorders associated with chronic hepatitis virus infection, Nishida N, Kudo M, Digest Dis, Digest Dis, 32(6), 786 - 790, 2014 , Refereed
  DOI
• Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking, Nishida N, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Kudo M, Digest Dis, Digest Dis, 32(6), 740 - 746, 2014 , Refereed
  DOI
• Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma, Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M, Digest Dis, Digest Dis, 32(6), 733 - 739, 2014 , Refereed
  DOI
• Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score, and BCLC system) in 4,649 cases from a Japanese nationwide survey, Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T, for the Liver, Cancer Study, Group of Japan, Digest Dis, Digest Dis, 32(6), 717 - 724, 2014 , Refereed
  DOI
• Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib, Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M, Digest Dis, Digest Dis, 32(6), 705 - 710, 2014 , Refereed
  DOI
• Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence, Minami Y, Kudo M, Diegst Dis, Diegst Dis, 32(6), 690 - 695, 2014 , Refereed
  DOI
• Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: Results and risk factors for local recurrence, Kono M, Inoue T, Kudo M, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Ueshima K, Nishida N, Murakami T, Digest Dis, Digest Dis, 32(6), 670 - 677, 2014 , Refereed
  DOI
• Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma, Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Kudo M, Digest Dis, Digest Dis, 32(6), 658 - 663, 2014 , Refereed
  DOI
• Emerging strategies for the management of hepatocellular carcinoma, Masatoshi Kudo, Digest Dis, Digest Dis, 32(6), 655 - 657, 2014 , Refereed
  DOI
• Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphasic fast CT imaging technique., Kagawa Y, Okada M, Yagyu Y, Kumano S, Kanematsu M, Kudo M, Murakami T, Acta radiologica (Stockholm, Sweden : 1987), Acta radiologica (Stockholm, Sweden : 1987), 54(8), 843 - 850, Oct. 2013 , Refereed
  DOI
• Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study., Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3517 - 3524, Oct. 2013 , Refereed
  DOI
• Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study., Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3509 - 3516, Oct. 2013 , Refereed
  DOI
• JSUM ultrasound elastography practice guidelines: liver., Kudo M, Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y, Kumada T, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 40(4), 325 - 357, Oct. 2013 , Refereed
  DOI
• A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation., Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, Kudo M, Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y, European journal of cancer (Oxford, England : 1990), European journal of cancer (Oxford, England : 1990), 49(13), 2832 - 2840, Sep. 2013 , Refereed
  DOI
• Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?, Kudo M, Liver cancer, Liver cancer, 2(3-4), 151 - 152, Aug. 2013 , Refereed
  DOI
• [Recurrent hepatocellular carcinoma]., Ueshima K, Kudo M, Gan to kagaku ryoho. Cancer & chemotherapy, Gan to kagaku ryoho. Cancer & chemotherapy, 40(8), 995 - 997, Aug. 2013 , Refereed
• Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma., Sakurai T, Kudo M, Liver cancer, Liver cancer, 2(3-4), 365 - 366, Aug. 2013 , Refereed
  DOI
• Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesions, Das K, Kudo M, Kitano M, Sakamoto H, Komaki T, Takagi T, Yamao K, J Med Ultrason, J Med Ultrason, 40(3), 211 - 218, Jul. 2013 , Refereed
  DOI
• Senile systemic amyloidosis localized to the stomach., Matsui S, Kashida H, Kudo M, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 25(4), 468 - 469, Jul. 2013 , Refereed
  DOI
• Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B., Hagiwara S, Kudo M, Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada N, Nishida N, Journal of medical virology, Journal of medical virology, 85(6), 987 - 995, Jun. 2013 , Refereed
  DOI
• [Recent advances in EUS-guided biliary drainage]., Kitano M, Kudo M, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 110(4), 557 - 567, Apr. 2013 , Refereed
  DOI
• Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS., Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX, Ultraschall in der Medizin (Stuttgart, Germany : 1980), Ultraschall in der Medizin (Stuttgart, Germany : 1980), 34(1), 11 - 29, Feb. 2013 , Refereed
  DOI
• Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS., Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX, World Federation for Ultrasound in Medicine, European Federation of, Societies for, Ultrasound, Ultrasound in medicine & biology, Ultrasound in medicine & biology, 39(2), 187 - 210, Feb. 2013 , Refereed
  DOI
• Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma., Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T, Radiology, Radiology, 266(2), 480 - 490, Feb. 2013 , Refereed
  DOI
• Real-time high-resolution vascular ultrasound using frequency domain interferometry with the ROI-division process., Taki H, Sakamoto T, Taki K, Yamakawa M, Shiina T, Kudo M, Sato T, Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference, Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference, 2013, 1398 - 1401, 2013 , Refereed
  DOI
• p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species., Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, Karin M, Cancer research, Cancer research, 73(1), 215 - 224, Jan. 2013 , Refereed
  DOI
• Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma., Nishida N, Kudo M, Nishimura T, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A, PloS one, PloS one, 8(9), e72312, 2013 , Refereed
  DOI
• Chronic liver diseases and hepatocellular carcinoma: an update for 2013., Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 31(5-6), 405 - 407, 2013 , Refereed
  DOI
• Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy., Sugimoto K, Kim SR, El-Shamy A, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 31(5-6), 434 - 439, 2013 , Refereed
  DOI
• Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors., Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 31(5-6), 472 - 479, 2013 , Refereed
  DOI
• Radiofrequency ablation for hepatic malignancies: is needle tract cauterization necessary for preventing iatrogenic bleeding?, Minami Y, Hayaishi S, Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 31(5-6), 480 - 484, 2013 , Refereed
  DOI
• Usefulness of the extracted-overlay function in CT/MR-ultrasonography fusion imaging for radiofrequency ablation of hepatocellular carcinoma., Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Hori M, Kudo M, Murakami T, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 31(5-6), 485 - 489, 2013 , Refereed
  DOI
• Targeted therapy for liver cancer: updated review in 2012., Kudo M, Current cancer drug targets, Current cancer drug targets, 12(9), 1062 - 1072, Nov. 2012 , Refereed
• Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance., Kudo M, Liver cancer, Liver cancer, 1(3-4), 141 - 143, Nov. 2012 , Refereed
  DOI
• Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma., Kudo M, World journal of gastroenterology, World journal of gastroenterology, 18(42), 6005 - 6017, Nov. 2012 , Refereed
  DOI
• [Molecular targeted agent for hepatocellular carcinoma]., Ueshima K, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 457 - 462, Nov. 2012 , Refereed
• A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma., Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K, Investigational new drugs, Investigational new drugs, 30(5), 2015 - 2025, Oct. 2012 , Refereed
  DOI
• Transcatheter endoscopy for pancreaticobiliary duct diseases (with videos)., Sakamoto H, Kitano M, Kamata K, Miyata T, Kadosaka K, Imai H, Takeyama Y, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 76(4), 892 - 899, Oct. 2012 , Refereed
  DOI
• Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT., Inoue T, Kudo M, Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, Chung H, Sakurai T, Ueshima K, Sakamoto M, Maenishi O, Hyodo T, Okada M, Kumano S, Murakami T, Journal of gastroenterology, Journal of gastroenterology, 47(9), 1036 - 1047, Sep. 2012 , Refereed
  DOI
• Treatment of advanced hepatocellular carcinoma, KUDO Masatoshi, Nihon Shokakibyo Gakkai Zasshi, Nihon Shokakibyo Gakkai Zasshi, 109(8), 1327 - 1334, Aug. 05 2012
  DOI
• Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system., Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O, Clinical drug investigation, Clinical drug investigation, 32 Suppl 2, 37 - 51, Aug. 2012 , Refereed
  DOI
• Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging., Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, Kudo M, Murakami T, European journal of radiology, European journal of radiology, 81(7), 1460 - 1464, Jul. 2012 , Refereed
  DOI
• Long duration of stable disease may improve overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib, ARIZUMI Tadaaki, UESHIMA Kazuomi, HAYAISHI Sousuke, TAKITA Masahiro, KITAI Satoshi, INOUE Tatsuo, YADA Norihisa, HAGIWARA Satoru, MINAMI Yasunori, SAKURAI Toshiharu, NISHIDA Naoshi, KUDO Masatoshi, Kanzo, Kanzo, 53(6), 348 - 350, Jun. 25 2012
  Summary:【PURPOSE】 Sorafenib is a molecularly-targeted drug, which have been proven survival benefit for advanced hepatocellular carcinoma (HCC). Because of the unique side effects of sorafenib such as hand-foot skin reaction (HFSR), the administration of sorafenib is often discontinued. We compared the efficacy of overall survival (OS) in the view of the duration of stable disease (SD). 【METHODS】 112 patients with advanced HCC have been treated with sorafenib in our hospital. They were evaluated the antitumor response according to the modified Response Evaluation Criteria in Solid Tumor. We compared the relationship between the duration of SD and OS. 【RESULTS】 Complete response (CR) was observed in 2 patients, partial response (PR) in 16 patients, SD in 36 patients and progression disease (PD) in 27 patients, respectively. CR+PR patients (CR+PR group) had Child-Pugh A/B=18/0, BCLC stage A/B/C=3/6/9 and HBV/HCV/NBNC=6/8/4. SD patients (SD group) had Child-Pugh A/B=30/6, BCLC stage A/B/C=16/6/14 and HBV/HCV/NBNC=5/20/11. In the SD group the median duration of SD was 3.3 months. The SD group was divided into two groups; less than three months defined as Short SD and more than three months defined as Long SD. We compared the relationship of overall survival between the group of PR, Long SD, and Short SD. In the Short SD group, the median OS was 6.2 months (95%C.I. 4.7-7.3). In the Long SD group, the median OS was 17.6 months (95%C.I. 10.4-23.6). In the CR+PR Group, the median OS was 19.1 months (95%C.I. 14.2-23.8). There was not statistically significant difference between the OS of CR+PR group and the OS of Long SD group, however, there was statistically significant difference between the OS of Long SD group and the OS of Short SD group. 【CONCLUSION】 In the treatment of sorafenib for advanced HCC, long duration of SD improves the OS as same as CR+PR. Controlling the unique side effects of sorafenib such as HFSR is important to obtain the longer treatment duration.
  DOI
• Comparison of tumor response in patients treated with sorafenib for hepatocellular carcinoma, ARIZUMI Tadaaki, UESHIMA Kazuomi, TAKEDA Haruhiko, OSAKI Yukio, HAGIWARA Satoru, INOUE Tatsuo, KITAI Satoshi, YADA Norihisa, SAKURAI Toshiharu, NISHIDA Naoshi, KUDO Masatoshi, Kanzo, Kanzo, 53(6), 344 - 347, Jun. 25 2012
  Summary:Response Evaluation Criteria In Solid Tumor version 1.1 (RECIST1.1), modified RECIST (mRECIST) and Response Evaluation Criteria In Cancer of the Liver (RECICL) are frequently used as a response evaluation criteria for hepatocellular carcinoma. The overall survival (OS) of the patients treated with sorafenib was evaluated among these criteria respectively. In patients treated with sorafenib over 30 days, OS was stratified by RECICL and mRECIST, but not stratified by RECIST1.1. There was a statistically significant difference in RECICL (p=0.0133). In patients treated with sorafenib over 60 days, OS was also stratified by RECICL and mRECIST, but not stratified by RECIST1.1. There was also a statistically significant difference in the RECICL (p=0.0173). In patients with advanced hepatocellular carcinoma treated with sorafenib, evaluation of the tumor necrosis is considered very important and bidimensional measurement is necessary to measure viable area more precisely. RECICL which evaluates the tumor necrosis and includes bidimensional measurement may be considered the most useful criteria to predict the prognosis in the evaluation of treatment with sorafenib.
  DOI
• Welcome to the first issue of liver cancer., Kudo M, Liver cancer, Liver cancer, 1(1), 1, Jun. 2012 , Refereed
  DOI
• p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expression., Park AM, Kudo M, Hagiwara S, Tabuchi M, Watanabe T, Munakata H, Sakurai T, Free radical biology & medicine, Free radical biology & medicine, 52(11-12), 2284 - 2291, Jun. 2012 , Refereed
  DOI
• Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update., Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 42(6), 523 - 542, Jun. 2012 , Refereed
  DOI
• Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?, Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, Kudo M, Murakami T, Hepatobiliary & pancreatic diseases international : HBPD INT, Hepatobiliary & pancreatic diseases international : HBPD INT, 11(3), 307 - 313, Jun. 2012 , Refereed
  DOI
• Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma., Hagiwara S, Kudo M, Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 42(4), 394 - 400, Apr. 2012 , Refereed
  DOI
• Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis., Watanabe T, Yamashita K, Fujikawa S, Sakurai T, Kudo M, Shiokawa M, Kodama Y, Uchida K, Okazaki K, Chiba T, Arthritis and rheumatism, Arthritis and rheumatism, 64(3), 914 - 924, Mar. 2012 , Refereed
  DOI
• A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir, INUZUKA Tadashi, OSAKI Yukio, MATSUDA Fumihiro, SAKAMOTO Azusa, HATAMARU Keiichi, HENMI Shinichiro, ISHIKAWA Tetsuro, SAITO Sumio, NISHIKAWA Hiroki, KITA Ryuichi, OKABE Yoshihiro, KIMURA Toru, WAKASA Tomoko, HAGIWARA Satoru, KUDO Masatoshi, Kanzo, Kanzo, 53(1), 42 - 47, Jan. 25 2012
  Summary:A 65-year-old Japanese male with chronic hepatitis B (CH-B) diagnosed in December 2008 was referred to our department in July 2009. He started combination therapy with peginterferon alfa-2b (80 μg/week) and entecavir (0.5 mg/day) for 48 weeks from December 2009. At the initiation of therapy, his significant laboratory test results were as follows: alanine aminotransferase (ALT) 55 IU/l, aspartate aminotransferase (AST) 37 IU/l, hepatitis B surface antigen (HBsAg) positive, hepatitis B e antigen (HBeAg) positive, hepatitis B virus (HBV) DNA levels 7.9 Log copies/ml. HBV DNA, HBsAg and HBeAg levels decreased progressively with therapy. After 36 weeks, HBV DNA, AST and ALT levels flared up, but after 44 weeks, HBV DNA levels decreased below 2.1 Log copies/ml and HBeAg seroconversion and HBsAg seroclearance were achieved. After 72 weeks he maintained HBsAg seroclearance and achieved a sustained viral response. Cases of spontaneous HBsAg seroclearance have been reported previously, but HBsAg seroclearance caused by combination therapy with peginterferon alfa-2b and entecavir has not been reported. Pre- and post-treatment cccDNA load in liver tissue, hepatitis B virus core-related antigen (HBcrAg) concentration in serum and expression of hepatitis B core antigen (HBcAg) in hepatocyte were compared, and it was found that all were drastically decreased. The present study suggests that these reduction appeared to contribute to the successful outcome of this therapy.
  DOI
• Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases., Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, Kudo M, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 39(1), 15 - 19, Jan. 2012 , Refereed
  DOI
• Hepatic nodules associated with an inferior mesentric arteriovenous malformation., Takahashi K, Kashida H, Kudo M, Internal medicine (Tokyo, Japan), Internal medicine (Tokyo, Japan), 51(19), 2753 - 2755, 2012 , Refereed
  DOI
• Viral hepatitis and hepatocellular carcinoma: update in 2012., Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 30(6), 539 - 540, 2012 , Refereed
  DOI
• Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy., Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Enomoto N, Inao M, Tanaka A, Kaito M, Imazeki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, Kudo M, RETRY Study Group, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 30(6), 554 - 560, 2012 , Refereed
  DOI
• Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2a., Hagiwara S, Sakurai T, Takita M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Nagai T, Hayaishi S, Arizumi T, Nishida N, Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 30(6), 561 - 567, 2012 , Refereed
  DOI
• Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage., Minami Y, Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 30(6), 592 - 597, 2012 , Refereed
  DOI
• [Effects of interferon treatment on recurrence and survival after curative treatment of hepatitis C virus-related hepatocellular carcinoma]., Ueda T, Chung H, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 4, 319 - 324, May 2011 , Refereed
• [Efficacy of adjuvant treatment after curative treatment in patients with HBV related hepatocellular carcinoma]., Hagiwara S, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 4, 546 - 550, May 2011 , Refereed
• Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo., Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K, Clinical cancer research : an official journal of the American Association for Cancer Research, Clinical cancer research : an official journal of the American Association for Cancer Research, 17(6), 1373 - 1381, Mar. 2011 , Refereed
  DOI
• Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos)., Sakamoto H, Kitano M, Matsui S, Kamata K, Komaki T, Imai H, Dote K, Kudo M, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 73(2), 227 - 237, Feb. 2011 , Refereed
  DOI
• Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma., Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T, The American journal of gastroenterology, The American journal of gastroenterology, 106(2), 368 - 370, Feb. 2011 , Refereed
  DOI
• Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009., Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 41(1), 1 - 21, Jan. 2011 , Refereed
  DOI
• The prognosis of patients with pancreatic cancer is extremely poor. Preface., Kudo M, Yamao K, Shimosegawa T, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 11 Suppl 2, 1 - 2, 2011 , Refereed
  DOI
• Endoscopic ultrasonography and contrast-enhanced endoscopic ultrasonography., Kitano M, Kudo M, Sakamoto H, Komaki T, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 11 Suppl 2, 28 - 33, 2011 , Refereed
  DOI
• Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma., Kudo M, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 29(3), 289 - 302, 2011 , Refereed
  DOI
• Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma., Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 29(3), 321 - 325, 2011 , Refereed
  DOI
• Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis., Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 29(3), 326 - 332, 2011 , Refereed
  DOI
• Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version., Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert, Panel of Japan, Society of, Hepatology, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 29(3), 339 - 364, 2011 , Refereed
  DOI
• Adjuvant therapy after curative treatment for hepatocellular carcinoma., Kudo M, Oncology, Oncology, 81 Suppl 1, 50 - 55, 2011 , Refereed
  DOI
• Diagnostic imaging of hepatocellular carcinoma: recent progress., Kudo M, Oncology, Oncology, 81 Suppl 1, 73 - 85, 2011 , Refereed
  DOI
• Relationship between urinary sodium excretion and pioglitazone-induced edema., Nakamura A, Osonoi T, Terauchi Y, Journal of diabetes investigation, Journal of diabetes investigation, 1(5), 208 - 211, Oct. 2010 , Refereed
  DOI
• Searching for biological markers of molecular targeting treatment of liver cancer., Arao T, Kudo M, Nishio K, Gan to kagaku ryoho. Cancer & chemotherapy, Gan to kagaku ryoho. Cancer & chemotherapy, 37(10), 1879 - 1882, Oct. 2010 , Refereed
• Hepatitis C virus core protein induces homotolerance and cross-tolerance to Toll-like receptor ligands by activation of Toll-like receptor 2., Chung H, Watanabe T, Kudo M, Chiba T, The Journal of infectious diseases, The Journal of infectious diseases, 202(6), 853 - 861, Sep. 2010 , Refereed
  DOI
• Diagnosis of subepithelial tumors in the upper gastrointestinal tract by endoscopic ultrasonography., Sakamoto H, Kitano M, Kudo M, World journal of radiology, World journal of radiology, 2(8), 289 - 297, Aug. 2010 , Refereed
  DOI
• Management of hepatocellular carcinoma: from prevention to molecular targeted therapy., Kudo M, Oncology, Oncology, 78 Suppl 1, 1 - 6, Jul. 2010 , Refereed
  DOI
• Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases., Inoue T, Minami Y, Chung H, Hayaishi S, Ueda T, Tatsumi C, Takita M, Kitai S, Hatanaka K, Ishikawa E, Yada N, Hagiwara S, Ueshima K, Kudo M, Oncology, Oncology, 78 Suppl 1, 94 - 101, Jul. 2010 , Refereed
  DOI
• Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan., Kudo M, Ueshima K, Oncology, Oncology, 78 Suppl 1, 154 - 166, Jul. 2010 , Refereed
  DOI
• Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)., Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M, Liver Cancer Study, Group of Jap, fo, Response Evaluation Criteria in, Cancer of the Liver, Liver Cancer Study, Group of Ja, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 40(7), 686 - 692, Jul. 2010 , Refereed
  DOI
• Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis., Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M, Liver Cancer Study, Group of Japan, AJR. American journal of roentgenology, AJR. American journal of roentgenology, 194(3), 830 - 837, Mar. 2010 , Refereed
  DOI
• Identification and characterization of IgG4-associated autoimmune hepatitis., Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T, Liver international : official journal of the International Association for the Study of the Liver, Liver international : official journal of the International Association for the Study of the Liver, 30(2), 222 - 231, Feb. 2010 , Refereed
  DOI
• Endoscopic ultrasound (EUS)-guided transluminal endoscopic removal of gallstones., Kamata K, Kitano M, Kudo M, Imai H, Sakamoto H, Komaki T, Endoscopy, Endoscopy, 42 Suppl 2, E331 - 2, 2010 , Refereed
  DOI
• Endoscopic findings of intestinal Behçet's disease complicated with toxic megacolon., Umehara Y, Kudo M, Kawasaki M, Endoscopy, Endoscopy, 42 Suppl 2, E173 - 4, 2010 , Refereed
  DOI
• Changing trends in hepatitis C infection over the past 50 years in Japan., Chung H, Ueda T, Kudo M, Intervirology, Intervirology, 53(1), 39 - 43, 2010 , Refereed
  DOI
• Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics., Kim SR, Imoto S, Kudo M, Mita K, Taniguchi M, Kim KI, Sasase N, Shoji I, Nagano-Fujii M, El-Shamy A, Hotta H, Nagai T, Nagata Y, Hayashi Y, Intervirology, Intervirology, 53(1), 44 - 48, 2010 , Refereed
  DOI
• Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b., Sasase N, Kim SR, Kudo M, Kim KI, Taniguchi M, Imoto S, Mita K, Hayashi Y, Shoji I, El-Shamy A, Hotta H, Intervirology, Intervirology, 53(1), 49 - 54, 2010 , Refereed
  DOI
• PEG-IFNalpha/RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate., Yada N, Kudo M, Chung H, Hayaishi S, Takita M, Ueda T, Tatsumi C, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Ueshima K, Intervirology, Intervirology, 53(1), 60 - 65, 2010 , Refereed
  DOI
• Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial., Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S, Sato T, Journal of hepatology, Journal of hepatology, 51(6), 1030 - 1036, Dec. 2009 , Refereed
  DOI
• Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma., Minami Y, Kudo M, World journal of radiology, World journal of radiology, 1(1), 86 - 91, Dec. 2009 , Refereed
  DOI
• Small invasive ductal carcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasm., Sakamoto H, Kitano M, Komaki T, Imai H, Kamata K, Kimura M, Takeyama Y, Kudo M, World journal of gastroenterology, World journal of gastroenterology, 15(43), 5489 - 5492, Nov. 2009 , Refereed
  DOI
• [Radio frequency ablation for metastatic liver cancer]., Inoue T, Kudo M, Gan to kagaku ryoho. Cancer & chemotherapy, Gan to kagaku ryoho. Cancer & chemotherapy, 36(8), 1253 - 1255, Aug. 2009 , Refereed
• Utility of Gd-EOB-DTPA-Enhanced MRI in Diagnosing Small Hepatocellular Carcinoma., Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Fukuda K, Nishikawa R, Koma YI, Matsuoka T, Kudo M, Hayashi Y, Case reports in gastroenterology, Case reports in gastroenterology, 3(2), 187 - 192, Jul. 2009 , Refereed
  DOI
• Value of liver parenchymal phase contrast-enhanced sonography to diagnose premalignant and borderline lesions and overt hepatocellular carcinoma., Inoue T, Kudo M, Maenishi O, Komuta M, Nakashima O, Kojiro M, Maekawa K, AJR. American journal of roentgenology, AJR. American journal of roentgenology, 192(3), 698 - 705, Mar. 2009 , Refereed
  DOI
• Evaluation of therapeutic response to gemcitabine in pancreatic cancer., Suetomi Y, Kitano M, Kudo M, Sakamoto H, Maekawa K, Hepato-gastroenterology, Hepato-gastroenterology, 55(86-87), 1785 - 1788, Sep. 2008 , Refereed
• [Prevention of recurrence of liver cancer]., Kudo M, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 97(7), 1681 - 1689, Jul. 2008 , Refereed
• Molecular mechanisms of portal vein tolerance., Watanabe T, Kudo M, Chiba T, Wakatsuki Y, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 38(5), 441 - 449, May 2008 , Refereed
  DOI
• The clinical characteristics, endoscopic treatment, and prognosis for patients presenting with duodenal varices., Matsui S, Kudo M, Ichikawa T, Okada M, Miyabe Y, Hepato-gastroenterology, Hepato-gastroenterology, 55(84), 959 - 962, May 2008 , Refereed
• Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey., Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, Ikai I, Kudo M, Kojiro M, Makuuchi M, Monden M, Matsuyama Y, Nakanuma Y, Takayasu K, Liver Cancer Study, Group of Japan, Surgery, Surgery, 143(4), 469 - 475, Apr. 2008 , Refereed
  DOI
• Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma., Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, Fuki S, Sasase N, Matsuoka T, Kudo M, Hayashi Y, World journal of gastroenterology, World journal of gastroenterology, 14(13), 1997 - 2002, Apr. 2008 , Refereed
  DOI
• Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score., Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T, Journal of gastroenterology and hepatology, Journal of gastroenterology and hepatology, 23(3), 445 - 452, Mar. 2008 , Refereed
  DOI
• Foreign body granuloma mimicking disseminated tumour recurrence after radiofrequency ablation for hepatocellular carcinoma., Takahashi S, Chung H, Kitai S, Inoue T, Minami Y, Ueshima K, Kudo M, Liver international : official journal of the International Association for the Study of the Liver, Liver international : official journal of the International Association for the Study of the Liver, 28(3), 414 - 415, Mar. 2008 , Refereed
  DOI
• Effects of decorin on the expression of alpha-smooth muscle actin in a human myofibroblast cell line., Nakatani T, Honda E, Hayakawa S, Sato M, Satoh K, Kudo M, Munakata H, Molecular and cellular biochemistry, Molecular and cellular biochemistry, 308(1-2), 201 - 207, Jan. 2008 , Refereed
  DOI
• Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study., Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, Itani T, Kasugai H, Kanematsu M, Ito K, Usuki N, Shimamatsu K, Kage M, Kojiro M, Intervirology, Intervirology, 51 Suppl 1, 17 - 26, 2008 , Refereed
  DOI
• Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography., Tatsumi C, Kudo M, Ueshima K, Kitai S, Takahashi S, Inoue T, Minami Y, Chung H, Maekawa K, Fujimoto K, Akiko T, Takeshi M, Intervirology, Intervirology, 51 Suppl 1, 27 - 33, 2008 , Refereed
  DOI
• Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b., Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Mita K, Hotta H, Shouji I, El-Shamy A, Kawada N, Kudo M, Hayashi Y, Intervirology, Intervirology, 51 Suppl 1, 70 - 75, 2008 , Refereed
  DOI
• Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy., Kudo M, Oncology, Oncology, 75 Suppl 1, 1 - 12, 2008 , Refereed
  DOI
• Epidemiology of hepatocellular carcinoma in Japan and Korea. A review., Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS, Organizing Committee of Japan-Korea Liver, Symposium, Oncology, Oncology, 75 Suppl 1, 13 - 16, 2008 , Refereed
  DOI
• Impact of interferon therapy after curative treatment of hepatocellular carcinoma., Kudo M, Oncology, Oncology, 75 Suppl 1, 30 - 41, 2008 , Refereed
  DOI
• Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT., Hatanaka K, Kudo M, Minami Y, Maekawa K, Oncology, Oncology, 75 Suppl 1, 42 - 47, 2008 , Refereed
  DOI
• Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoid. Comparison with superparamagnetic iron oxide magnetic resonance images., Inoue T, Kudo M, Hatanaka K, Takahashi S, Kitai S, Ueda T, Ishikawa E, Hagiwara S, Minami Y, Chung H, Ueshima K, Maekawa K, Oncology, Oncology, 75 Suppl 1, 48 - 54, 2008 , Refereed
  DOI
• Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinoma., Kudo M, Tochio H, Oncology, Oncology, 75 Suppl 1, 55 - 64, 2008 , Refereed
  DOI
• Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score., Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T, Oncology, Oncology, 75 Suppl 1, 83 - 90, 2008 , Refereed
  DOI
• PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy., Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K, Oncology, Oncology, 75 Suppl 1, 91 - 98, 2008 , Refereed
  DOI
• Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography., Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Kitai S, Takahashi S, Tatsumi C, Ueda T, Hayaishi S, Maekawa K, Oncology, Oncology, 75 Suppl 1, 99 - 105, 2008 , Refereed
  DOI
• Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma., Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H, Oncology, Oncology, 75 Suppl 1, 106 - 113, 2008 , Refereed
  DOI
• Case of rapidly progressed sarcomatoid hepatocellular carcinoma in a young female without risk factor., Inoue T, Kudo M, Minami Y, Chung H, Fukunaga T, Kawasaki T, Liver international : official journal of the International Association for the Study of the Liver, Liver international : official journal of the International Association for the Study of the Liver, 27(10), 1428 - 1430, Dec. 2007 , Refereed
  DOI
• Treatment of large and/or multiple hepatic malignancies: open surgical approaches of radiofrequency ablation., Minami Y, Kawasaki T, Kudo M, Haji S, Shiraishi O, Kawabe T, Yasuda C, Nakai T, Takeyama Y, Shiozaki H, Hepato-gastroenterology, Hepato-gastroenterology, 54(80), 2358 - 2360, Dec. 2007 , Refereed
• Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan., Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 37(9), 676 - 691, Sep. 2007 , Refereed
  DOI
• Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma., Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 37 Suppl 2, S166 - 71, Sep. 2007 , Refereed
  DOI
• International comparison of treatment outcomes based on staging systems., Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 37 Suppl 2, S216 - 22, Sep. 2007 , Refereed
  DOI
• Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: International consensus and controversies., Kudo M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 37 Suppl 2, S83 - 7, Sep. 2007 , Refereed
  DOI
• Radiofrequency ablation combined with reduction of hepatic blood flow: effect of Lipiodol on coagulation diameter and ablation time in normal pig liver., Chung H, Kudo M, Minami Y, Kawasaki T, Hepato-gastroenterology, Hepato-gastroenterology, 54(75), 701 - 704, Apr. 2007 , Refereed
• Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosis., Kim SR, Ikawa H, Ando K, Mita K, Fuki S, Sakamoto M, Kanbara Y, Matsuoka T, Kudo M, Hayashi Y, World journal of gastroenterology, World journal of gastroenterology, 13(8), 1271 - 1274, Feb. 2007 , Refereed
• Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC., Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y, Intervirology, Intervirology, 50(1), 24 - 31, 2007 , Refereed
  DOI
• Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation., Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, Tatsumi C, Minami Y, Ueshima K, Fukunaga T, Haji S, Digestive diseases (Basel, Switzerland), Digestive diseases (Basel, Switzerland), 25(4), 303 - 309, 2007 , Refereed
  DOI
• Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology., Kudo M, Okanoue T, Japan Society of, Hepatology, Oncology, Oncology, 72 Suppl 1, 2 - 15, 2007 , Refereed
  DOI
• Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm., Kim SR, Ando K, Mita K, Fuki S, Ikawa H, Kanbara Y, Imoto S, Matsuoka T, Hayashi Y, Kudo M, Oncology, Oncology, 72 Suppl 1, 58 - 66, 2007 , Refereed
  DOI
• Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy., Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S, Oncology, Oncology, 72 Suppl 1, 98 - 103, 2007 , Refereed
  DOI
• Regulatory failure of serum prohepcidin levels in patients with hepatitis C., Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, Dote K, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 36(4), 288 - 293, Dec. 2006 , Refereed
  DOI
• Cecal necrosis due to ischemic colitis mimicking an abscess on sonography., Watanabe T, Tomita S, Shirane H, Okabe Y, Orino A, Todo A, Chiba T, Kudo M, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 25(3), 393 - 396, Mar. 2006 , Refereed
• What is the best staging system for hepatocellular carcinoma?, Kudo M, Journal of gastroenterology, Journal of gastroenterology, 41(3), 290 - 291, Mar. 2006 , Refereed
  DOI
• Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial., Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M, Journal of gastroenterology, Journal of gastroenterology, 41(1), 70 - 76, Jan. 2006 , Refereed
  DOI
• Hepatic angiomyolipoma: identification of an efferent vessel as a hepatic vein by contrast-enhanced harmonic sonography., Zheng RQ, Kudo M, Ishikawa E, Chung H, Minami Y, Ogawa C, Sakaguchi Y, Kitano M, Kawasaki T, Maekawa K, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 32(4), 191 - 196, Dec. 2005 , Refereed
  DOI
• Hemodynamic and morphologic changes of peripheral hepatic vasculature in chronic liver disease: a preliminary study by contrast-enhanced coded phase-inversion harmonic sonography., Sakaguchi Y, Kudo M, Zheng RQ, Chung H, Minami Y, Ogawa C, Kitano M, Kawasaki T, Maekawa K, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 32(4), 197 - 204, Dec. 2005 , Refereed
  DOI
• Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals., Nomura M, Hata T, Naitoh S, Kuwano H, Moriyama K, Fukuoka M, Kudo M, Tohda Y, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 125(12), 997 - 1004, Dec. 2005 , Refereed
  DOI
• Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images., Inoue T, Kudo M, Watai R, Pei Z, Kawasaki T, Minami Y, Chung H, Fukunaga T, Awai K, Maenishi O, Journal of gastroenterology, Journal of gastroenterology, 40(12), 1139 - 1147, Dec. 2005 , Refereed
  DOI
• Hemodynamic and morphologic changes of peripheral hepatic vasculature in cirrhotic liver disease: a preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography., Zheng RQ, Zhang B, Kudo M, Sakaguchi Y, World journal of gastroenterology, World journal of gastroenterology, 11(40), 6348 - 6353, Oct. 2005 , Refereed
• Imaging findings of biliary hamartomas., Zheng RQ, Zhang B, Kudo M, Onda H, Inoue T, World journal of gastroenterology, World journal of gastroenterology, 11(40), 6354 - 6359, Oct. 2005 , Refereed
• Well-differentiated HCC manifesting hyperattenuation on CT during arterial portography., Kim SR, Kim KI, Maekawa Y, Imoto S, Ninomiya T, Mita K, Ando K, Fukuda K, Fuki S, Kudo M, Matsuoka T, Sasase N, Taniguchi M, Hayashi Y, Hepato-gastroenterology, Hepato-gastroenterology, 52(65), 1559 - 1562, Sep. 2005 , Refereed
• Ischemia of rat stomach mobilizes ECL cell histamine., Kitano M, Bernsand M, Kishimoto Y, Norlén P, Håkanson R, Haenuki Y, Kudo M, Hasegawa J, American journal of physiology. Gastrointestinal and liver physiology, American journal of physiology. Gastrointestinal and liver physiology, 288(5), G1084 - 90, May 2005 , Refereed
  DOI
• Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US., Fukuta N, Kitano M, Maekawa K, Chikugo T, Kudo M, Journal of gastroenterology, Journal of gastroenterology, 40(3), 247 - 255, Mar. 2005 , Refereed
  DOI
• [Current topics on therapy of hepatocellular carcinoma]., Kudo M, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 94(3), 464 - 472, Mar. 2005 , Refereed
• Primary sclerosing cholangitis and hepatitis C virus infection., Kim SR, Imoto S, Taniguchi M, Kim KI, Sasase N, Matsuoka T, Maekawa Y, Ninomiya T, Ando K, Mita K, Fuki S, Koterazawa T, Fukuda K, Kudo M, Sakamoto H, Hayashi Y, Intervirology, Intervirology, 48(4), 268 - 272, 2005 , Refereed
  DOI
• Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score., Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T, Hepatology (Baltimore, Md.), Hepatology (Baltimore, Md.), 40(6), 1396 - 1405, Dec. 2004 , Refereed
  DOI
• [Comparison of treatment methods for hepatocellular carcinoma--based on JIS score]., Kudo M, Chung H, Osaki Y, Kasugai H, Oka H, Seki T, Gan to kagaku ryoho. Cancer & chemotherapy, Gan to kagaku ryoho. Cancer & chemotherapy, 31(13), 2100 - 2104, Dec. 2004 , Refereed
• Anisakis in a biopsy specimen from the edge of a gastric ulcer: report of a case., Shiomi M, Kamisako T, Yutani I, Yoshimoto R, Kudo M, Fujii R, Gastrointestinal endoscopy, Gastrointestinal endoscopy, 60(5), 854 - 856, Nov. 2004 , Refereed
  DOI
• Hepatocellular carcinoma that ruptured during radiofrequency ablation therapy., Kawasaki T, Kudo M, Chung H, Minami Y, Journal of gastroenterology, Journal of gastroenterology, 39(10), 1015 - 1016, Oct. 2004 , Refereed
  DOI
• Hypervascular liver nodules in heavy drinkers of alcohol., Kim SR, Maekawa Y, Imoto S, Sugano M, Kudo M, Alcoholism, clinical and experimental research, Alcoholism, clinical and experimental research, 28(8 Suppl Proceedings), 174S - 180S, Aug. 2004 , Refereed
  DOI
• [Efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel]., Chung H, Kudo M, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 62 Suppl 7(Pt 1), 315 - 318, Jul. 2004 , Refereed
• Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome., Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H, AJR. American journal of roentgenology, AJR. American journal of roentgenology, 182(5), 1224 - 1226, May 2004 , Refereed
  DOI
• Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio., Wen YL, Kudo M, Zheng RQ, Ding H, Zhou P, Minami Y, Chung H, Kitano M, Kawasaki T, Maekawa K, AJR. American journal of roentgenology, AJR. American journal of roentgenology, 182(4), 1019 - 1026, Apr. 2004 , Refereed
  DOI
• Diagnosis of acute cholecystitis in patients with liver cirrhosis: waveform analysis of the cystic artery by color Doppler imaging., Tochio H, Nishiuma S, Okabe Y, Orino A, Kudo M, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 31(1), 21 - 28, Mar. 2004 , Refereed
  DOI
• Local ablation therapy for hepatocellular carcinoma: current status and future perspectives., Kudo M, Journal of gastroenterology, Journal of gastroenterology, 39(3), 205 - 214, 2004 , Refereed
  DOI
• Comparison of argon plasma coagulation and paravariceal injection sclerotherapy with 1% polidocanol in mucosa-fibrosing therapy for esophageal varices., Matsui S, Kudo M, Nakaoka R, Shiomi M, Kawasaki T, Journal of gastroenterology, Journal of gastroenterology, 39(4), 397 - 399, 2004 , Refereed
  DOI
• Hepatocellular carcinoma and NASH., Kudo M, Journal of gastroenterology, Journal of gastroenterology, 39(4), 409 - 411, 2004 , Refereed
  DOI
• Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: observation by color Doppler imaging., Tochio H, Kudo M, Intervirology, Intervirology, 47(3-5), 144 - 153, 2004 , Refereed
  DOI
• Detection of intratumoral vascularity in small hepatocellular carcinoma by coded phase inversion harmonics., Wen YL, Zhou P, Kudo M, Intervirology, Intervirology, 47(3-5), 169 - 178, 2004 , Refereed
  DOI
• Hepatobiliary and pancreatic: inflammatory pseudotumor of the liver., Zheng RQ, Kudo M, Journal of gastroenterology and hepatology, Journal of gastroenterology and hepatology, 18(8), 994, Aug. 2003 , Refereed
  DOI
• Characterization of focal hepatic lesions with contrast-enhanced C-cube gray scale ultrasonography., Wang WP, Ding H, Qi Q, Mao F, Xu ZZ, Kudo M, World journal of gastroenterology, World journal of gastroenterology, 9(8), 1667 - 1674, Aug. 2003 , Refereed
• Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography., Wen YL, Kudo M, Zheng RQ, Minami Y, Chung H, Suetomi Y, Onda H, Kitano M, Kawasaki T, Maekawa K, AJR. American journal of roentgenology, AJR. American journal of roentgenology, 181(1), 57 - 63, Jul. 2003 , Refereed
  DOI
• Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case report., Chung H, Kudo M, Kawasaki T, Kitano M, Minami Y, Suetomi Y, Onda H, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 26(3), 254 - 258, Jul. 2003 , Refereed
  DOI
• Contrast-enhanced agent detection imaging: Early experience in hepatocellular carcinoma., Wen YL, Kudo M, Minami Y, Chung H, Suetomi Y, Onda H, Kitano M, Kawasaki T, Maekawa K, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 30(2), 77 - 84, Jun. 2003 , Refereed
  DOI
• Assessment of image quality of contrast-enhanced power doppler imaging in hepatocellular carcinoma with the personal ultrasound imager: Comparison with the conventional machine., Wen YL, Kudo M, Minami Y, Chung H, Suetomi Y, Onda H, Kitano M, Kawasaki T, Maekawa K, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 30(1), 31 - 38, Mar. 2003 , Refereed
  DOI
• Hepatocellular carcinoma mimicking cavernous hemangioma on angiography and contrast enhanced harmonic ultrasonography. A case report., Kawasaki T, Kudo M, Inui K, Ogawa C, Chung H, Minami Y, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 25(2), 202 - 212, Feb. 2003 , Refereed
  DOI
• Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)., Kudo M, Chung H, Osaki Y, Journal of gastroenterology, Journal of gastroenterology, 38(3), 207 - 215, 2003 , Refereed
  DOI
• Stage IV hepatocellular carcinoma with portal venous tumor thrombus: complete response after combined therapy of repeated arterial chemoembolization and radiofrequency ablation., Zheng RQ, Kudo M, Minami Y, Inui K, Chung H, Journal of gastroenterology, Journal of gastroenterology, 38(4), 406 - 409, 2003 , Refereed
  DOI
• Scintigraphic study of regenerative nodules due to fulminant hepatic failure., Watanabe T, Kondo M, Hirasa M, Shirane H, Okabe Y, Ibuki Y, Tomita S, Orino A, Todo A, Wakatsuki Y, Chiba T, Kudo M, Journal of gastroenterology, Journal of gastroenterology, 38(7), 695 - 699, 2003 , Refereed
  DOI
• Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel., Chung H, Kudo M, Kumada T, Katsushima S, Okano A, Nakamura T, Osaki Y, Kohigashi K, Yamashita Y, Komori H, Nishiuma S, Journal of gastroenterology, Journal of gastroenterology, 38(9), 877 - 879, 2003 , Refereed
  DOI
• Contrast advanced dynamic flow imaging and contrast pulse subtraction imaging: Preliminary results in hepatic tumors., Wen YL, Kudo M, Maekawa K, Minami Y, Chung H, Suetomi Y, Onda H, Kitano M, Kawasaki T, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 29(4), 195 - 204, Dec. 2002 , Refereed
  DOI
• Somatic mutation and SNP in the promoter of dbpA and human hepatocarcinogenesis., Hayashi J, Kajino K, Umeda T, Takano S, Arakawa Y, Kudo M, Hino O, International journal of oncology, International journal of oncology, 21(4), 847 - 850, Oct. 2002 , Refereed
• Eosionophilic pseudotumor of the liver due to Ascaris suum infection., Kim S, Maekawa Y, Matsuoka T, Imoto S, Ando K, Mita K, Kim H, Nakajima T, Ku K, Koterazawa T, Fukuda K, Yano Y, Nakaji M, Kudo M, Kim K, Hirai M, Hayashi Y, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 23(4), 306, Aug. 2002 , Refereed
  DOI
• Intrahepatic huge hematoma due to rupture of small hepatocellular adenoma: a case report., Minami Y, Kudo M, Kawasaki T, Chung H, Matsui S, Kitano M, Suetomi Y, Onda H, Funai S, Kou K, Yasutomi M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 23(2), 145 - 151, Jun. 2002 , Refereed
  DOI
• CEA producing primary hepatic carcinoid., Kim SR, Imoto S, Maekawa Y, Matsuoka T, Hayashi Y, Ando K, Mita K, Shintani S, Kim HB, Ku K, Koterazawa T, Fukuda K, Yano Y, Nakaji M, Ikawa H, Ninomiya T, Kudo M, Kim KI, Hirai M, Hepatology research : the official journal of the Japan Society of Hepatology, Hepatology research : the official journal of the Japan Society of Hepatology, 22(4), 313 - 321, Apr. 2002 , Refereed
  DOI
• Proximal bifurcation of hepatic artery: Novel findings on hepatic arteries demonstrated by ultrasound Doppler imaging, B-flow, and US angiography., Tochio H, Iwasaki N, Nakamura H, Nakayama K, Soga T, Nishiuma S, Fukunaga T, Okabe Y, Kashida H, Hirasa M, Ibuki Y, Fujimoto T, Morimoto Y, Kudo M, Tomita S, Konishi Y, Orino A, Journal of medical ultrasonics (2001), Journal of medical ultrasonics (2001), 29(1), 11 - 17, Mar. 2002 , Refereed
  DOI
• Imaging blood flow characteristics of hepatocellular carcinoma., Kudo M, Oncology, Oncology, 62 Suppl 1, 48 - 56, 2002 , Refereed
  DOI
• Development of multicentric hepatocellular carcinoma after completion of interferon therapy., Kim SR, Matsuoka T, Maekawa Y, Yano Y, Imoto S, Kudo M, Shintani S, Ando K, Mita K, Fukuda K, Koterazawa T, Nakaji M, Ikawa H, Ninomiya T, Kim KI, Hirai M, Hayashi Y, Journal of gastroenterology, Journal of gastroenterology, 37(8), 663 - 668, 2002 , Refereed
  DOI
• A Randomised Phase 3 Trial of Lenvatinib vs. Sorafenib in First-line Treatment of Patients With Unresectable Hepatocellular Carcinoma, Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron AD, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL, Lancet, Lancet, in press, Refereed

Books etc

• IgG4-related disease and innate immunity. In “IgG4-Related Disease”, Curr Top Microbiol Immunol, Okazaki K, ed, Watanabe T, Yamashita K, Kudo M, 共著, Vol. 401, pp115-128, Springer,   2017
• WHO Classification of Tumours of the Digestive System (Blue Book), Hepatocellular carcinoma., 共著, WHO Press World Health Organization, Geneva, Switzerland,   2010
• “Textbook of Practical Ultrasound.” Ahuja B ed, USCON Academic Press, New Delhi, India, 2008, Pancreatic Ultrasound with esmphasis on EUS, 単著,   2008
• “Textbook of Practical Ultrasound.“ Ahuja B ed, USCON Academic Press, New Delhi, India, 2008, Ultrasonography of diffuse liver diseases, 単著,   2008
• Postgraqduate Course & Current Reviews in HEPATOLOGY. Clinico-patho-radiological Correlation., Newer imaging modality of hepatocellular carcinoma: role of contrast-enhanced coded phase inversion harmonics, 共著, CBS Publishers & Distributors, New Dehli, India,   2004
• Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors, 共著, Springer Verlag, Tokyo,   2003
• Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors, 単著, Springer Verlag, Tokyo,   2003
• Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors, 単著, Springer Verlag,   2003
• In Dynamic Study of Efferent Tumor Blood Fow, Itai Y, Miura Y, eds, Color Doppler observation of efferent blood flow in liver tumors, 共著, BRACCO, Italy,   2000
• "Hepatology in the 21st Century: Diagnosis and Therapy." Tanikawa K, Kojiro M, Gollan J, eds, Advances in diagnostic imaging of hepatocellular carcinoma, 共著, IASL, APASL, and JSH JOINT POST GRADUATE TEXTBOOK, IASL Publ, Fukuoka,   2000
• "Abdominal and Gastrointestinal Imaging Multimedia Virtual Textbook", Gourtsoyiannis NE, Yamada R, I, Liver Radiological Examination- Ultrasonography (including Biopsy), 共著, Medic-Online, Euromultimedia S.A., Luxembourg,   1999
• "Diagnosis and Treatment of Hepatocellular Carcinoma", Livraghi T, Makuuchi M, Buscarini, eds, Scintigraphy, 共著, Greenwich Medical Media Limited, London, UK,   1997
• Liver Cancer, Okuda K and Tabor E, eds, Ultrasound Diagnosis, 共著, Churchill Livingstone, London,   1997

Conference Activities & Talks

• RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro), Edeline J, Karwal M, Zhu AX, Finn RS, Cattan S, Ogasawara S, Verslype C, Zagonel V, Fartoux L, Vogel A, Rosmorduc O, Verset G, Chan SL, Knox J, Daniele B, Cheng AL, Goldmacher G, Jensen E, Siegel AB, Kudo M, 2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020),   2020 01
• A phase 1b study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) (Study 117), Kudo M, Ikeda M, Motomura K, Okusaka T, Kato N, Dutcus CE, Hisai T, Suzuki M, Ikezawa H, Iwata T, Kumada H, Kobayashi M, 2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020),   2020 01
• Phase 3 study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup, Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee DW, Chen E, Siegel A, Ryoo BY, 2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020),   2020 01
• Invited Lecture “Updates of targeted therapies for HCC, Masatoshi Kudo, Taiwan Association for the Study of the Liver (TASL 2019),   2019 12 14 , 招待有り
• Roche Symposium “Recent advances on cancer immunotherapy combination for advanced HCC”, Masatoshi Kudo, Taiwan Association for the Study of the Liver (TASL 2019),   2019 12 14 , 招待有り
• Keynote Lecture “Changing Paradigm of Treatment Strategy in Intermediate-stage HCC”, Masatoshi Kudo, 17th National Liver Cancer Conference,   2019 12 07 , 招待有り
• 司会; 招待講演「Recent advances in clinical research of HBV and HCC」, Masatoshi Kudo, 第23回日本肝臓学会大会,   2019 11 21 , 招待有り
• Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: a multicenter propensity-score matched study, Kudo M, Ueshima K, Chan SL, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N, American Association for the Study of Liver Diseases (AASLD 2019),   2019 11 11
• Checkmate 040: efficacy, hepatic safety, and biomarkers of Nivolumab + Ipilimumab combination therapy in patients with advanced hepatocellular carcinoma, Sangro B, Hsu C, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Neely J, Zhao H, Anderson J, Yau T, American Association for the Study of Liver Diseases (AASLD 2019),   2019 11 11
• Development of AI-aided us diagnosis system of liver tumor using deep neural network., Nshida N, Yamakawa M, Shiina T, Kudo M, American Association for the Study of Liver Diseases (AASLD 2019),   2019 11
• Clinical significance of tumor markers in surveillance for hepatocellular carcinoma in cirrhostic patients: a multicenter prospective cohort study in Japan., Ucnino K, Tateishi R, Fujiwara N, Moriyama M, Eguchi Y, Toyoda H, Ida Y, Karino Y, Kudo M, Chuma M, Takuma Y, Kaneko S, Kato N, Chayama K, Izumi N, Itoi T, Sakaida I, Komeda H, Umemura T, Ishikawa T, Nakamuta M, Takaki A, Terai S, Ido A, Enomoto N, Yoshida H, Baba T, Torimura T, Hiasa Y, Ogawa C, Takehara T, Kumada T, Koike K, American Association for the Study of Liver Diseases (AASLD 2019),   2019 11
• Objective response by mrecist is a prognostic factor for overall survival in unresectable hepatocellular carcinoma treated with systemic therapy: a systematic review and metaanalysis of randomized controlled trials., Kudo M, Ueshima K, Nishida N, American Association for the Study of Liver Diseases (AASLD 2019),   2019 11
• Lenvatinib for unresectable hepatocellular carcinoma in real-world practice: a multicenter analysis of prognostic factors., Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Ishikawa T, Tsuji K, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, American Association for the Study of Liver Diseases (AASLD 2019),   2019 11
• Safety and efficacy of Lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT, Okusaka T, Ikeda K, Kudo M, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H, 31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019),   2019 10 21
• Association between overall survival and adverse events with Lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT), Sung M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Kudo M, Tateishi R, Ikeda M, Breder V, Rau KM, Ma YT, Alsina A, Ryoo BY, Ren Z, Mody K, Dutcus C, Tamai T, Saito K, Piscaflia F, 31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019),   2019 10 21
• Invited Lecture “Construction of big database of US digital image; Platform for creating artificial intelligence-aided US: Work in progress”, Masatoshi Kudo, The 35th Annual Convention of Taiwan Society of US Medicine,   2019 10 18 , 招待有り
• Clinicopathological and immunohistochemical study of the mechanism of sporadic fundic gland polyp proliferation and enlargement in long-term PPI-users, Matsumura M, Tsuji N, Yoshida S, Tomooka M, Umehara Y, Kudo M, United European Gastroenterology (UEGW 2019),   2019 10
• Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein: an exposure-response analysis, Llovet JM, Kudo M, Kang YK, Yen CJ, Finn RS, Gale PR, Assenat E, Motomura K, Okusaka T, Berg T, Hsu CH, Ikeda M, Hsu Y, Liang K, Widau R, Schelman W, O’Braian L, Gao L, Zhu AX, European Society for Medical Oncology (ESMO 2019),   2019 09 29
• Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240, Merle P, Kulkarni AS, Ryoo BY, Cheng AL, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist J, Chen E, Siegel AB, Zhu AX, Finn RS, European Society for Medical Oncology (ESMO 2019),   2019 09 27
• Ramucirumab (RAM) effect on albumin-bilirubin (ALBI) grade during treatment of Japanese patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib from two randomized phase 3 studies (REACH, REACH-2), Kudo M, Okusaka T, Motomura K, Ikeda M, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Hirota S, Homma G, Chunxiao W, Shinozaki K, Yoshikawa R, Zhu AX, European Society for Medical Oncology (ESMO 2019),   2019 09
• LEAP-002: Phase 3 Study of First-Line Lenvatinib (len) Plus Pembrolizumab (pembro) for patients with advanced hepatocellular carcinoma (HCC), Llovet JM, Kudo M, Cheng AL, Finn RS, Galle PR, Kaneko S, Meyer T, Qin S, Dutcus CE, Chen E, Dubrovsky L, Siegel AB, Zhu AX, European Society for Medical Oncology (ESMO 2019),   2019 09
• Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial, Bruix J, Reig M, Merle P, Kudo M, Meinhardt G, Zhang M, Ozgurdal K, European Society for Medical Oncology (ESMO 2019),   2019 09
• Safety profile of Nivolumab (NIVO) plus Ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study, El-Khoueiry AB, Hsu C, Kang YK, Kim TY, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, He AR, El-Rayes B, Acosta-Rivera M, Neely J, Shen Y, Baccan C, Yau T, 13th Annual Conference International Liver Cancer Association (ILCA),   2019 09
• CheckMate 040: Health-related quality of life (HRQoL) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B status treated with nivolumab (NIVO), Sangro B, Matilla A, Santoro A, Cubillo A, El-Khoueiry AB, El-Rayes B, Numata K, Itoh Y, Taylor F, Thompson G, Blum S, Wisniewski T, Baccan C, Kudo M, 13th Annual Conference International Liver Cancer Association (ILCA),   2019 09
• A Phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC): EMERALD-1, Sangro B, Kudo M, Qin S, Ren Z, Chan S, Erinjeri J, Arai Y, Mann H, Morgan S, Cohen G, Vlahovic G, Lencioni R, 13th Annual Conference International Liver Cancer Association (ILCA),   2019 09
• A post hoc analysis of neutrophil-lymphocyte ratios (NLR) in the REFLECT study: First-line lenvatinib (LEN) or sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC), Evans TRJ, Kudo M, Cheng AL, Gomez-Martin C, Daniele B, Izumi N, Yamashita T, Tateishi R, Lim HJ, Chan SL, Rau KM, Alsina A, Misir S, Dutcus C, Sung MW, 13th Annual Conference International Liver Cancer Association (ILCA),   2019 09
• Pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) and complete radiological response following surgical resection or local ablation: Phase 3 KEYNOTE-937 trial, Zhu AX, Cheng AL, Vogel A, Yau T, Zhou J, Chen E, Malhotra U, Siegel AB, Kudo M, 13th Annual Conference International Liver Cancer Association (ILCA),   2019 09
• First-line combination therapy with lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma: Phase 3 Leap-002 study, Llovet JM, Kudo M, Cheng AL, Finn RS, Galle PR, Kaneko S, Meyer T, Qin S, Dutcus CE, Chen E, Dubrovsky L, Zhu AX, 13th Annual Conference International Liver Cancer Association (ILCA),   2019 09
• Chair ; Cheng AL; minar 6 “A combined approach for advanced HCC checkpoint inhibitor plus VEGF blockade”, Masatoshi Kudo, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31 , 招待有り
• A phase 3 study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab in patients with locoregional HCC: EMERALD-1, Kudo M, Sangro B, Qin S, Ren Z, Chan S, Erinjeri J, Arai Y, Mann H, Morgan S, Cohen G, Vlahovic G, Lencioni R, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies, Okusaka T, Kang YK, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Carton I, Abada P, Hsu Y, Zhu A, Yen CJ, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Subsequent anticancer medication following first-line lenvatinib: Post Hoc responder analysis from the Phase 3 REFLECT study in unresectable hepatocellular carcinoma, Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, Lopez C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT), Sung M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Kudo M, Tateishi R, Ikeda M, Breder V, Rau KM, Ma YT, Alsina A, Ryoo BY, Ren Z, Mody K, Dutcus C, Tamai T, Saito K, Piscaglia F, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Nivolumab in patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh (CP) B status: Japanese subanalysis from the CheckMate 040 study, Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Takahashi H, Shen Y, Neely J, Anderson J, Sangro B, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Safety and efficacy of lenvatinib by starting dose based on bodyweight in patients with unresectable hepatocellular carcinoma (uHCC) in REFLECT, Okusaka T, Ikeda K, Kudo M, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Role of the liver tumor board in early- and intermediate-stage HCC. Sponsored Symposium 4, Kudo M, Han KH, Chan SL, Chow P, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31 , 招待有り
• Challenging Precise Ablation: CEUS Guidance & Fusion Imaging Guidance. Symposium 7 “Ablation therapy for hepatocellular carcinoma in Asia”, Minami Y, Kudo M, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Changing paradigm of treatment strategy for intermediate stage HCC: APPLE expert consensus, Ikeda M, Han KH, Miyayama S, Lin HM, Choo SP, Huang YH, Chan S, Kudo M, Wang CK, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a Phase 3 study of lenvatinib (REFLECT), Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Piscaglia F, Ueshima K, Aikata H, Vogel A, Lopez C, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Dutcus C, Tamai T, Saito K, Lencioni R, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 31
• Luncheon Seminar “Real-world experience with lenvatinib in patients with uHCC from Japan”, Masatoshi Kudo, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 30 , 招待有り
• Current and future treatment strategy for TACE failure or refractoriness. Morning Workshop 3, Masatoshi Kudo, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 30 , 招待有り
• Association between tumor response by mRECIST and overall survival in patients with poorly differentiated hepatocellular carcinoma (HCC) in REFLECT study, Kudo M, Ueshima K, Aikata H, Tamai T, Saito K, Ikeda K, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 29
• Using workstation for diagnosis and treatment of hepatocellular carcinoma, Ogawa C, Kudo M, The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019),   2019 08 29
• Internation Symposium “Lenvatinib as an initial treatment in patiens with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A Multicentre propensity-score matched study., Masatoshi Kudo, The 55th Annual Meeting of Liver Cancer Study Group of Japan,   2019 07 05 , 招待有り
• Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH), Meyer T, Finn R, Kudo M, Kang YK, Yen CJ, Galle P, Llovet J, Assenat E, Brandi G, Motomura K, Okusaka T, Hubner R, Karwal M, Baron A, Ikeda M, Liang K, Wang C, Widau R, Schelman W, Zhu A, ESMO 21th World Congress on Gastrointestinal Cancer 2019 (ESMO-WCGC 2019),   2019 07 03
• Invited Lecture “Recent trends of treatment for intermediate stage HCC: Japanese experience”, Masatoshi Kudo, The Liver Week 2019,   2019 06 21 , 招待有り
• Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)., Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder VV, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox JJ, Daniele B, Ebbinghaus S, Chen E, Siegel AB, Zhu AX, Cheng AL, for the KEYNOT, Investigators, American Society of Clinical Oncology Annual Meeting (ASCO 2019),   2019 06 02
• A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma (SURF trial), Izumi N, Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N, American Society of Clinical Oncology Annual Meeting (ASCO 2019),   2019 06 02
• Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): outcomes from two randomized phase 3 studies (REACH, REACH2), Llovet JM, Yen CJ, Finn RS, Kang YK, Kudo M, Galle PR, Assenat E, Pracht M, Lim Y, Rau KM, Borg C, Hiriart JB, Daniele B, Berg T, Chung HC, Godinot N, Wang C, Hsu Y, Schelman WR, Zhu AX, American Society of Clinical Oncology Annual Meeting (ASCO 2019),   2019 06
• Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040, Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Neely J, Shen Y, Baccan C, Dela Cruz C, Hsu C, American Society of Clinical Oncology Annual Meeting (ASCO 2019),   2019 06
• First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100), Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J, American Society of Clinical Oncology Annual Meeting (ASCO 2019),   2019 06
• Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies, Borbath I, Kudo M, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Peck-Radosavljevic M, Girvan A, Gable J, Bowman L, Abada P, Hsu Y, Zhu AX, Lee SY, Osterreichische Gesellschaft fur Gastroenterologie und Hepatologie (OGGH 2019),   2019 06
• State-of-the-Art Lecture “IO in liver cancer therapy now and future.”, Masatoshi Kudo, 2019 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation: Precision medicine in HCC: research and treatment,   2019 05 26 , 招待有り
• Keynote Lecture “When is the best time for TKI (LEN) be used in BCLC B & C HCC patients.", Masatoshi Kudo, Expert Round Table Meeting for Unresectable Hepatocellular Carcinoma,   2019 05 26 , 招待有り
• Invited Lecture “Evolving roles of targeted therapy in HCC”, Masatoshi Kudo, the 3rd Symposium of the Singapore Liver Cancer Consortium (SLCC),   2019 05 03 , 招待有り
• Lenvatinib (lenva) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study, Llovet J, Kudo M, Cheng AL, Finn R, Galle P, Kaneko S, Meyer T, Qin S, Dutcus C, Chen E, Dubrovsky L, Zhu A, American Society of Clinical Oncology Annual Meeting (ASCO 2019),   2019 05
• Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis, Peck-Radosavljevic M, Lee HC, Kudo M, Nakajima K, Bayh I, Cheng AL, Raoul JL, The International Iiver Congress (EASL 2019),   2019 04
• A phase 1b trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results., Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, Kaneko S, Zhu AX, Kubota T, Kraljevic S, Ikezawa H, Dubrovsky L, Siegel AB, Kumada H, Okusaka T, American Association for Cancer Research Annual Meeting (AACR 2019),   2019 04 01
• Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis., Hiraoka A, Kumada T, Takaguchi K, Kariyama K, Tsuji K, Itobayashi E, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Itokawa N, Joko K, Atsukawa M, Imai M, Michitaka K, Hiasa Y, Kudo M, The International Iiver Congress (EASL 2019),   2019 04
• Efficacy and hepatic safety of Nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040, Sangro B, Matilla A, Santoro A, Melero I, Gracian AC, Acosta MR, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, dela Cruz C, Baccan C, Kudo M, The International Iiver Congress (EASL 2019),   2019 04
• Efficacy, safety, and patient-reported outcomes in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies, Borbath I, Kudo M, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Peck-Radosavljevic M, Girvan A, Gable J, Bowman L, Abada P, Hsu Y, Zhu AX, Belgian Week of Gastroenterology,   2019 02 22
• Practice patterns, response rates, and deterioration of liver function after transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC): Final analysis of OPTIMIS in China, Shan H, Lee HC, Raoul JL, Peck-Radosavljevic M, Kudo M, Nakajima K, Bayh I, Yang Y, Wang W, Cheng AL, The 28th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2019),   2019 02
• Invited Lecture “Ongoing trials in systemic therapies for HCC”, Masatoshi Kudo, Asian Pacific Association for the Study of the Liver (APASL 2019),   2019 02 , 招待有り
• Invited Lecture “Role of the hepatologist”, Masatoshi Kudo, Asian Pacific Association for the Study of the Liver (APASL 2019),   2019 02 , 招待有り
• Ramucirumab for patients with hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib treatment: exploratory analysis of REACH-2 trial results by albumin-bilirubin grade and Child-Pugh score, Brandi G, Kudo M, Kang Y, Yen C, Finn R, Galle P, Llovet J, Assenat E, Merle P, Jean-Baptiste H, Chan SL, Palmer D, Wang C, Widau R, Hsu Y, Abada PB, Zhu A, EASL HCC Summit 2019,   2019 02
• Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): an analysis of AFP kinetics in the phase 3 REACH-2 study., Finn RS, Kudo M, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin D, Gerken G, Abada P, Hsu Y, Zhu AX, American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study, Ogasawara S, Ueshima K, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• CheckMate-040: Nivolumab (NIVO) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status, Kudo M, Matilla A, Santoro A, Melero I, Gracian A, Acosta MR, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, dela Cruz C, Baccan C, Sangro B, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase 3 study of lenvatinib (REFLECT), Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Piscaglia F, Ueshima K, Aikata H, Vogel A, Lopez C, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Dutcus C, Tamai T, Saito K, Lencioni R, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• Subsequent anticancer medication following first-line lenvatinib: a posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma, Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TJ, Lopez CL, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• Safety and efficacy of lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT, Okusaka T, Ikeda K, Kudo M, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrxicz L, Yoon JH, Ren Z, Stepan D, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT), Sung M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Kudo M, Tateishi R, Ikeda M, Breder V, Rau KM, Ma YT, Alsina A, Ryoo BY, Ren Z, Mody K, Dutcus C, Tamai T, Saito K, Piscaglia F, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 18
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studi, Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019),   2019 01 17
• Invited Lecture “HCC and cholangiocarcinoma”, Masatoshi Kudo, Hot Topics at AASLD 2018,   2018 12 16 , 招待有り
• Invited Lecture “Newer diagnostic algorithm for a solid tumor <3 cm in a cirrhotic”, Masatoshi Kudo, Hot Topics at AASLD 2018,   2018 12 16 , 招待有り
• Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions, Heo J, Cheng AL, Raoul JL, Peck-Radosavljevic M, Kudo M, Nakajima K, Bayh I, Lin SM, Lee HC, European Society for Medical Oncology Congress (ESMO-Asia 2018),   2018 11 25
• Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies, Kang YK, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Carton I, Abada P, Hsu Y, Zhu A, Yen CJ, European Society for Medical Oncology Congress (ESMO-Asia 2018),   2018 11 25
• M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype, Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M, European Society for Medical Oncology Congress (ESMO-Asia 2018),   2018 11 24
• Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC), Chan SL, Finn RS, Zhu AX, Knox J, Cheng AL, Siegel AB, Bautista O, Kudo M, European Society for Medical Oncology (ESMO)-ASIA 2017,   2018 11 18
• Clinical efficacy and safety of EUS-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study in Japan, Minaga K, Yamashita Y, Ogura T, Takenaka M, Shimokawa Y, Hisa T, Itonaga M, Kato H, Nishikiori H, Okuda A, Matsumoto H, Uenoyama Y, Watanabe T, Chiba Y, Higuchi K, Kudo M, Kitano M, Asian Pacific Digestive Week (APDW 2018),   2018 11 17
• Nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma (aHCC) in the CheckMate-040 study, Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta MR, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, dela Cruz C, Baccan C, Sangro B, American Association for the study of liver diseases (AASLD 2018),   2018 11 12
• New diagnostic method for hepatic steatosis using attenuation measurement by ultrasound B mode: comparison with controlled attenuation parameter, Koizumi Y, Hirooka M, Yada N, Tamaki N, Izumi N, Kudo M, Hiasa Y, American Association for the study of liver diseases (AASLD 2018),   2018 11 12
• Stem cell feature and immune-suppressive microenvironment in human hepatocellular carcinoma, Nishida N, Kudo M, American Association for the study of liver diseases (AASLD 2018),   2018 11 12
• Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis, Peck-Radosavljevic, Kudo M, Raoul JL, Lee HC, Decaens T, Heo J, Lin SM, Shan H, Yang Y, Bayh I, Nakajima K, Cheng AL, American Association for the study of liver diseases (AASLD 2018),   2018 11 12
• Ramucirumab as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib: pooled results from two global phase 3 studies (REACH-2 and REACH), Llovet JM, Kudo M, Finn R, Galle PR, Blanc JF, Okusaka T, Chau I, Abada PB, Hsu Y, Zhu AX, American Association for the study of liver diseases (AASLD 2018),   2018 11 12
• Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: multicenter analysis, Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M, American Association for the study of liver diseases (AASLD 2018),   2018 11 10
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib (REACH-2): efficacy, safety, and patient-reported outcome results, Zhu A, Finn R, Galle P, Llovet J, Nipp R, Cella D, Girvan A, Gable J, Bowman L, Abada P, Hsu Y, Kudo M, Gastrointestinal Oncology Conference 2018 (ISGIO),   2018 11 01
• Special Remarks, International Session (Symposium) 2 “Hepatitis towards the control of HCC-the remaining issues and future directions in Japan and the world”, Masatoshi Kudo, Japan Digestive Disease Week 2018 (JDDW 2018)（the 60th Annual Meeting of the Japanese Society of Gastroenterology, the 96th Congress of the Japan Gastroenterological Endoscopy Society, the 22nd General Meeting of the Japan Society of Hepatology）,   2018 11 01 , 招待有り
• Independent imaging review analysis of REFLECT trial of lenvatinib in HCC, Aikata H, Kudo M, Ikeda K, Japan Digestive Disease Week (JDDW 2018)(The 60th Annual Meeting of the Japanese Society of Gastroenterolgy, the 22nd General Meeting of the Japan Society of Hepatology, the 96th Congress of the Japan Gastroenterological Endoscopy Society),   2018 11 01
• Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study, Ladron de, Guevara L, Dagher L, Miguel Viana, Arruda V, Nakajima K, Kudo M, Mexican Society of Oncology 36th National Congress 2018 (SMEO 2018),   2018 11
• Global phase 3 study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress, Qin S, Finn R, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla T, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu A, European Society for Medical Oncology (ESMO 2018),   2018 10 21
• Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada, Raoul JL, Decaens T, Burak K, Koskinas J, Villadsen GE, Heurgue-Berlot A, Bayh I, Cheng AL, Kudo M, Lee HC, Nakajima K, Peck-Radosavljevic M, European Society for Medical Oncology (ESMO 2018),   2018 10 21
• A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma, Cheng AL, Yen CJ, Okusaka T, Ikeda M, Hsu CH, Wu SY, Morizane C, Hashimoto Y, Ueshima K, Ohtomo T, Tanaka T, Kudo M, European Society for Medical Oncology (ESMO 2018),   2018 10 21
• Invited Lecture “HCC Meet the Expert”, Masatoshi Kudo, European Society for Medical Oncology (ESMO 2018),   2018 10 21 , 招待有り
• Final analysis of serum biomarkers in patients (pts) from the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT], Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan R, Blanc JF, Baron A, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus C, Funahashi Y, Evans TRJ, European Society for Medical Oncology (ESMO 2018),   2018 10 20
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH), Zhu AX, Finn R, Galle P, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Hsu Y, Abada P, Kudo M, European Society for Medical Oncology (ESMO 2018),   2018 10 19
• Invited Lecture “The Role of CEUS in the Detection and Diagnosis of FLL”, Masatoshi Kudo, The 2018 Convention of Taiwan Society of Ultrasound in Medicine (TSUM),   2018 10 14 , 招待有り
• M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial, Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M, European Society for Medical Oncology (ESMO 2018),   2018 10
• Stress response protein RBM3 promotes the development of colitis-associated cancer, Sakurai T, Kudo M, The 77th Annual Meeting of the Japanese Cancer Association,   2018 09 28 , 招待有り
• Systemic therapy for hepatocellular carcinoma: current status and future perspective. Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment”, Masatoshi Kudo, The 77th Annual Meeting of the Japanese Cancer Association,   2018 09 27 , 招待有り
• Chair: Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment”, Masatoshi Kudo, The 77th Annual Meeting of the Japanese Cancer Association,   2018 09 27 , 招待有り
• Hand-foot syndrome as a predictor of survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study, Ogawa C, Shibatoge M, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kudo M, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Urine protein: creatinine ratio (UPCR) vs 24-h urine protein for the management of proteinuria: results from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in hepatocellular carcinoma (HCC), Evans TR, Kudo M, Finn RS, Han KH, Cheng AL, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Acute and chronic deterioration in liver function after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): the final analysis of OPTIMIS, Cheng AL, Raoul JL, Lee HC, Bayh I, Nakajima K, Peck-Radosavljevic M, Kudo M, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Newly proposed tools for assessment of hepatic function for hepatocellular carcinoma staging and treatment planning-usefulness of modified ALBI grade, Izumoto H, Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Ninomiya T, Michitaka K, Kudo M, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (PTS) with unresectable hepatocellular carcinoma (UHCC), Lencioni R, Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Piscaglia F, Han G, Ikeda M, Simon K, Komov D, OuYang X, Evans TR, Sung M, Binder T, Damon A, Kraljevic S, Ren M, Ryoo BY, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Overall survival (OS) update: 2-year follow-up from the phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) progressing on sorafenib, Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Houmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G, on, behalf of the, RESORCE Investigators, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• A cost-effectiveness analysis of Lenvatinib compared with sorafenib in unresectable hepatocellular carcinoma allowing for AFP adjustment in overall survival in Japan from the reflect phase 3 clinical trial, Kudo M, Izumi N, Kaneko S, Kobayashi M, Azuma MK, Copher R, Meier G, Ishii M, Ikeda S, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial, Ueshima K, Kudo M, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Arai Y, TACTICS study group, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Outcomes of patients (PTS) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global optimis final analysis, Peck-Radosavljevic M, Kudo M, Raoul JL, Lee HC, Decaens T, Heo J, Lin SM, Shan H, Yang Y, Bayh I, Nakajima K, Cheng AL, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2): a phase 3, randomized, double-blind, placebo-controlled trial, Galle PR, Kudo M, Kang YK, Yen CJ, Finn R, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin DB, Gerken G, Abada P, Hsu Y, Zhu AX, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Chair: General Session 3 “Epidemiology, Diagnosis, Staging”, Masatoshi Kudo, Interntional Liver Cancer Association (ILCA) Annual Conference,   2018 09 15 , 招待有り
• Efficacy and safety of Tislelizumab, an anti-PD-1 antibody, versus sorafenib as a potential first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, multicenter study: A Trial-in-Progress, Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu AX, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09 15
• Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study, Ladron de, Guevara L, Dagher L, Miguel Viana, Arruda V, Nakajima K, Kudo M, ALEH 2018,   2018 09
• A prospective, observational study to assess the safety and effectiveness of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice (REFINE), Finn R, Frenette C, Granito A, Ikeda M, Lim HY, Merle P, Ozgurdal K, Kudo M, 12th Annual Conference International Liver Cancer Association (ILCA),   2018 09
• Hand–foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenibfor treatment of hepatocellular carcinoma (HCC) progressing on sorafenib, Silva M, Carrilho FJ, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Xu L, Baumhauer A, Meinhardt G, Han G, Bruix J, on behalf of, the, RESORCE Investigators, ALEH 2018,   2018 09
• Invited Lecture “Eastern perspective”, Masatoshi Kudo, Hepatocellular Carcinoma (HCC) Scientific Input Engagement,   2018 08 09 , 招待有り
• Educational Lecture “Phase 3 study of ramucirumab versus placebo in 2nd-line advanced HCC patients with high baseline AFP (REACH-2)”, Masatoshi Kudo, 16th Annual Meeting of the Japanese Society of Medical Oncology,   2018 07 19
• Chair: Oral Poster Presentation “Treatment: clinical trials”, Masatoshi Kudo, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07 07 , 招待有り
• Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE): final analysis of OPTIMIS in Asian regions, Masatoshi Kudo, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07 07
• Invited Lecture “TKI-Based combination therapy: the more the better?”, Masatoshi Kudo, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07 07 , 招待有り
• Invited Lecture “TACE refractoriness: definition and treatment options”, Masatoshi Kudo, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07 07 , 招待有り
• Invited Lecture “Role of contrast-enhanced ultrasound in diagnosis of early-stage HCC”, Masatoshi Kudo, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07 06 , 招待有り
• Chair: Session 1 “Update of HCC guidelines”, Masatoshi Kudo, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07 06 , 招待有り
• Safety and Effectiveness of Regorafenib in Patients with Unresectable Hepatocellular Carcinoma in Routine Clinical Practice: REFINE, a Prospective, Observational Study, Lim HY, Finn RS, Frenette C, Granito A, Ikeda M, Merle P, Ozgurdal K, Kudo M, The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2018 07
• Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”, Masatoshi Kudo, Next Symposium,   2018 06 10 , 招待有り
• Similar efficacy and safety of endoscopic ultrasound-guided biliary drainage via hepaticogastrostomy and choledochoduodenostomy approaches for malignant distal obstruction: a multicenter, prospective randomized trial. Topic Forum “Exploring Newer Indicati, Minaga K, Kitano M, Ogura, T, Shiomi H, Hoki N, Nishikiori H, Yamashita Y, Hisa Takeshi, Kato H, Kamada H, Takenaka, M, Higuchi, K, Chiba Y, Kudo M, Digestive Disease Week (DDW 2018),   2018 06 05
• REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe, Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin D, Gerken G, Abada P, Hsu Y, Kudo M, American Society of Clinical Oncology Annual Meeting (ASCO 2018),   2018 06 04
• A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma, Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Mercade TM, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu AX, American Society of Clinical Oncology Annual Meeting (ASCO 2018),   2018 06 04
• Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial, Kudo M, Ueshima K, Torimura T, Tanabe N, Ikeda M, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Isoda N, Yasui K, Kuzuya T, Okusaka T, Furuse J, Kokudo N, Okita K, Yoshimura K, Arai Y, TACTICS Trial Group, American Society of Clinical Oncology Annual Meeting (ASCO 2018),   2018 06 03
• Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis, Peck-Radosavljevic M, Kudo M, Raoul JL, Lee HC, Decaens T, Heo J, Lin SM, Shan H, Yang Y, Bayh I, Nakajima K, Cheng AL, American Society of Clinical Oncology Annual Meeting (ASCO 2018),   2018 06 03
• A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC), Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, Kaneko S, Zhu AX, Kubota T, Kraljevic S, Ishikawa K, Siegel AB, Kumada H, Okusaka T, American Society of Clinical Oncology Annual Meeting (ASCO 2018),   2018 06 03
• “Small HCCs”, Hot Issues: ACUCI “CEUS: how to maker it clear”, Masatoshi Kudo, The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018),   2018 05 25 , 招待有り
• Expansion of color fusion outside the liver, Ogawa C, Morita M, Shibatoge M, Kudo M, The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018),   2018 05 24
• Chair; Consensus Meeting “Guidelines for contrast-enhanced harmonic endoscopic ultrasonography”, Masatoshi Kudo, The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018),   2018 05 23 , 招待有り
• Hand-foot syndrome as predictor of survival in advanced HCC treated with sorafenib, Ogawa C, Morita M, Shibatoge M, Takaguchi K, Tani J, Masaki T, Moriya A, Deguchi A, Kudo M, Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference,   2018 05 13
• Keynote-224: Pembrolizumab in patients with advanced HCC previously treated with sorafenib, Kudo M, Zhu AX, Finn RS, Cattan S, Edeline J, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan S, Knox J, Daniele B, Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference,   2018 05 13
• Invited Lecture “Molecular targeted therapy”, Symposium 6 “Aging society and HCC: up to what age do we consider treating patients with HCC in general?”, Masatoshi Kudo, Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference,   2018 05 12 , 招待有り
• Studies on AFP, ALT abnormalities and hepatocarcinogenesis after SVR in chronic hepatitis C patients treated with direct acting antivirals, Kono M, Nishida N, Kudo M, Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference,   2018 05 11
• Chair: Symposium 3 “HCC with vascular invasion: HAIC, radioembolization, radiation therapy, surgery, or systemic therapy?”, Masatoshi Kudo, Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference,   2018 05 11 , 招待有り
• Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”, Masatoshi Kudo, Next Symposium,   2018 05 10 , 招待有り
• Keynote Lecture “The role of TKI in HCC in an immunotherapy world”, Masatoshi Kudo, 5th Asia-Pacific Gastroenterology Cancer Summit 2018,   2018 05 06 , 招待有り
• Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”, Masatoshi Kudo, Next Symposium,   2018 04 10 , 招待有り
• Invited Lecture “Novel management of advanced HCC”, Masatoshi Kudo, 5th Myanmar GI & Liver, International Scientific Meeting and ASEAN Perspective in Liver Diseases (APLD),   2018 02 17 , 招待有り
• Invited Lecture “Systemic therapy for hepatocellular carcinoma: 2018 update”, Masatoshi Kudo, The 33rd Nagoya International Cancer Treatment Symposium,   2018 02 10 , 招待有り
• Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib, Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder VV, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Xu L, Baumhauer A, Meinhardt G, Han G, on behalf of, the, RESORCE Investigators, Gastrointestinal Cancers Symposium (ASCO-GI 2018),   2018 01 19
• Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC), Lencioni R, Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Piscaglia F, Han G, Ikeda M, Simon K, Komov D, OuYang X, Evans TRJ, Sung MW, Binder TA, Damon A, Kraljevic S, Ren M, Ryoo BY, Gastrointestinal Cancers Symposium (ASCO-GI 2018),   2018 01 19
• KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib, Zhu AX, Finn RS, Cattan S, Edeline J, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Rosmorduc O, Vogel A, Sarker D, Verset G, Chan SL, Knox JJ, Daniele B, Ebbinghaus S, Ma J, Siegel AB, Cheng AL, Kudo M, Gastrointestinal Cancers Symposium (ASCO-GI 2018),   2018 01 19
• Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2), Zhu AX, Galle PR, Kudo M, Finn RS, Qin S, Xu Y, Abada P, Llovet J, Gastrointestinal Cancers Symposium (ASCO-GI 2018,   2018 01 19
• Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040, El-Khoueiry AB, Merero I, Yau TC, Crocenzi TS, Kudo M, Hsu C, Choo S, Trojan J, Welling T, Meyer T, Kang YK, Yeo W, Chopra A, Zhao H, Baakili A, dela Cruz CM, Sangro B, Gastrointestinal Cancers Symposium (ASCO-GI 2018),   2018 01 19
• Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial, Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Arai Y, for the TACTICS Trial Group, Gastrointestinal Cancers Symposium (ASCO-GI 2018),   2018 01 19
• Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS－An international observational study assessing the use of sorafenib after TACE, Kudo M, Raoul JL, Lee HC, Cheng AL, Nakajima K, Peck-Radosavljevic M, Gastrointestinal Cancers Symposium (ASCO-GI 2018),   2018 01 19
• Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross P, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Schlief S, Fiala-Buskes S, Meinhardt G, Bruix J on, ehalf, of, h, ESORCE Investigators, American Association for the study of liver diseases (AASLD 2017),   2017 10 22
• Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Shukui Qin, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Sarah Schlief, Sabine Fiala-Buskies, Gerold Meinhardt, Jordi Bruix, on behalf of, the, RESORCE Investigators, AASLD 2017,   2017 10 20
• Sonazoid-enhaunced US in the Management of HCC., Masatoshi Kudo,   2017 10 17 , 招待有り
• Special Lecture “CEUS for Pancreatobiliary Diseases.”, Masatoshi Kudo, The 9th Asian Conference on Ultrasound Contrast Imaging (ACUCI) 2017,   2017 10 13
• Special Lecture “US-US Overlay Fusion Imaging in the Evaluation of Treatment Response After RFA.”, Masatoshi Kudo, The 9th Asian Conference on Ultrasound Contrast Imaging (ACUCI) 2017,   2017 10 13 , 招待有り
• CEUS in the Diagnosis and Treatment for Malignant Liver Tumors., Masatoshi Kudo, The 16th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2017,   2017 10 13 , 招待有り
• A new strategy to personalize surveillance program for colitis-associated cancer. International Session (Symposium)9 (JGES・JSGE・JSGS) “Surveillance colonoscopy for ulcerative colitis; Up-to-date procedure and therapeutic strategy”, akurai T, Kashida H, Kudo M, Japan Digestive Disease Week (JDDW) 2017 Fukuoka,   2017 10 12 , 招待有り
• How to Improve Survival Outcome and Use Molecular Targeted Agent in HCC Patients? Symposium (XI) ”Innovation and New Approaches in Hepatocellular Carcinoma.”, Masatoshi Kudo, Taiwan Digestive Disease Week 2017 (TDDW),   2017 09 29 , 招待有り
• Special Lecture (V) “Impact of Surveillance and Diagnosis on Survival in HCC Patients”, Taiwan Digestive Disease Week 2017 (TDDW), Masatoshi Kudo, Taiwan Digestive Disease Week 2017 (TDDW),   2017 09 29 , 招待有り
• KEYNOTE-240: Phase 3, Randomized Study of, R.S. Finn, S.L. Chan, A.X. Zhu, J. Knox, A.-L. Cheng, A.B. Siegel, O. Bautista, M. Kudo, ESMO 2017,   2017 09 08
• Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): An Exploratory Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib after TACE, Han Chu Lee, Ann-Lii Cheng, Jean-Luc Raoul, Masatoshi Kudo, Keiko Nakajima, Markus Peck-Radosavljevic, ILCA 2017,   2017 07 19
• HCC treatnebt landscape-the Asian perspective- HCC treatment guidelines, Asian perspective- Experience sharing from Japan., Masatoshi Kudo, Necavar 10-years Anniversary,   2017 07 01 , 招待有り
• Speaker/ Chairperson: Master Class: Workshop: Master Class for Hepatocellular Carcinoma., Masatoshi Kudo, 24th Asia Pacific Cancer Conference (APCC),   2017 06 22 , 招待有り
• Systemic Therapy for Hepatocellular Carcinoma: current Status and Future Perspective. KEYNOTE LECTURE II (KL-2-1), Masatoshi Kudo, APASL Single Topic Conference 2017 Mongolia, 6th HCV Conference on HCV and CO-INFECTIONS,   2017 06 16 , 招待有り
• Invited Lecture “Molecular Targeted Therapy for HCC: Current Status and Future Perspective.” Luncheon Seminor 18 “Diagnosis and Treatment od Liver Cancer.”, Masatoshi Kudo, The 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association (6th A-PHPBA), The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery (29th JSHBPS),   2017 06 07 , 招待有り
• Treatment Strategy of Intermediate Stage HCC. Symposium 43 (Keynote) ”Strategy for Intermediate Stage of HCC”, Masatoshi Kudo,   2017 06 07 , 招待有り
• Phase 3 randomized study of pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: KEYNOTR-240, Finn RS, Chan SL, Zhu AX, Knox J, Cheng AL, Siegel AB, Bautista O, Kudo M, Annual Meeting of American Society of Clinical Oncology (ASCO 2017),   2017 06 02
• Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patien（pts) with unresectable hepatocellular carcinoma (uHCC)., Cheng AL, Finn RS, Qin F, Han KH, Ikeda K, Piscaglia F, Baron AD, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez-Lopez C, Dutcus CE, Ren M, Kraljevic S, Tamai T, Kudo M, Annual Meeting of American Society of Clinical Oncology (ASCO 2017),   2017 06 02
• Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study., Crocenzi TS, El-Khoueiry AB, Yau TC, Melero I, Sangro B, Kudo M, Hsu C, Trojan J, Kim TY, Choo SP, Meyer T, Kang YK, Yeo W, Chopra A, Baakili A, Dela Cruz CM, Lang L, Neely J, Welling T, Annual Meeting of American Society of Clinical Oncology (ASCO 2017),   2017 06 02
• Speaker/ Chairperson: Latest Advances in Using Molecular Targeted Therapy in Advanced HCC Patients. Concurrent Session 3 “Hepatocellular Cancer”, Masatoshi Kudo, Hong Kong International Oncology Forum 2017,   2017 05 19 , 招待有り
• Follow-up examination of the recurrence after endoscopic treatment of colorectal tumors., Komeda Y, Kashida H, Sakurai T, Asakuma Y, Nagai T, Matsui S, Watanabe T, Kudo M, Digestive Disease Week (DDW 2017),   2017 05 06
• Diagnosis of localized colorectal lesions with magnifying narrow band imaging (NBI) using Japan NBI Expert Team (JNET) classification: a cross sectional study., Komeda Y, Kashida H, Sakurai T, Asakuma Y, Nagai T, Matsui S, Watanabe T, Kudo M, Digestive Disease Week (DDW 2017),   2017 05 06
• Outcomes of biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter retrospective study in west japan., Yamao K, Kitano M, Takenaka M, Kayahara T, Ishida E, Yamamoto H, Yoshiawa T, Minaga K, Yamashita Y, Asada M, Okabe Y, Osaki Y, Ikemoto J, Hanada K, Kudo M, Digestive Disease Week (DDW 2017),,   2017 05 06
• Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study., Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Choo SP, Meyer T, Welling TH, Yeo W, Chopra A, Baakili A, dela Cruz C, Lang L, Neely J, Melero I, El-Khoueiry AB, Trojan J, The International Liver Congress 2017 (EASL 2017),   2017 04 19
• New HCC Diagnosis. Session5“HCC-2”, Masatoshi Kudo, The Asian Pacific Association for the Study of the Liver (APASL STC 2017),   2017 04 10 , 招待有り
• Regional use of sorafenib after transarterial chemoembolization (TACE) in Chinese patients with hepatocellular carcinoma (HCC): results from the second interim analysis of OPTIMIS, Hong S, Cheng AL, Raoul JL, Lee HC, Kudo M, Nakajima K, Peck-Radosavljevic M, on behalf of the, OPTIMIS Investigators, The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2017 02 17
• Analysis of overall survival (OS) by pattern of progression of hepatocellular carcinoma (HCC) during prior sorafenib treatment in the randomized phase 3 RESORCE trial comparing regorafenib with placebo, Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, LeBerre MA, Meinhardt G, Han G, on behalf of, the, RESORCE Investigators, The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2017 02 17
• Invited Lecture “TACE”, Masatoshi Kudo, the 26th Conference of Asian Pacific Association for the Study of the Liver (APASL 2017),   2017 02 17 , 招待有り
• Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study., Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Evans J, Pressiani T, Burlone ME, Pirisi M, Giordano L, Howell J, Kudo M, Thimme R, Park JW, Pinato DJ, The International Liver Congress 2017 (EASL 2017),   2017 02 02
• Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment., Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross P, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Schlief S, Fiala-Buskes S, Meinhardt G, Bruix J on, ehalf, of, h, ESORCE Investigators, EASL HCC Summit 2017,   2017 02 02
• Chair: Hepatocellular Carcinoma Symposium “Multidisciplinary Therapy for HCC”, Masatoshi Kudo, 2nd Eastern & Western Association Liver Tumors,   2017 01 27 , 招待有り
• Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo., Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Gerolami R, Masi G, Ross PF, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Le Berre MA, Beinhardt G, Han G, on behalf of, RESORCE investigators, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017),   2017 01 20
• Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy., Masatoshi Kudo, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017),   2017 01 20
• Subgroup analyses of a phase 2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC), Ikeda M, Ikeda K, Kudo M, Osaki Y, Okusaka T, Tamai T, Suzuki T, Hisai T, Miyagishi H, Okita K, Kumada H, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017),   2017 01 20
• Randomized phase 3 study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma, Finn RS, Chan SL, Zhu AX, Knox J, Cheng AL, Siegel AB, Bautista O, Kudo M, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017),   2017 01 20
• Phase 2 study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma., Zhu AX, Knox J, Kudo M, Chan S, Finn R, Siegel A, Ma J, Cheng AL, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017),   2017 01 20
• Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study, Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Welling TH, Yeo W, Chopra A, Anderson J, dela Cruz C, Lang L, Neely J, Tang H, El-Khoueiry AB, American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017),   2017 01 20
• Efficacy and safety of regorafnib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial, Kudo M, Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, LeBerre MA, Baumhauer A, Meinhardt G, Han G, on behalf of, the, RESORCE Investigators, 15th Japan Association of Molecular Targeted Therapy for HCC,   2017 01 14 , 招待有り
• Invited Lecture “Recent trends of TACE”, Masatoshi Kudo, 57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016),   2016 12 17 , 招待有り
• Invited Lecture “Classification and management algorithm of HCC”, Masatoshi Kudo, 57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016),   2016 12 17 , 招待有り
• Invited Lecture “Detection of early HCC-advance in diagnosis”, Masatoshi Kudo, 57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016),   2016 12 16 , 招待有り
• Invited Lecture “Immune checkpoint blockade in hepatocellular carcinoma”, Symposium 3 “Emerging Issues in the Management of Advanced Liver Disease”, Masatoshi Kudo, Seoul International Digestive Disease Symposium (SIDDS 2016),   2016 11 24 , 招待有り
• Invited Lecture “Contrast-enhanced EUS for pancreatobiliary disease”, Masatoshi Kudo, The Westlake International Forum on Ultrasound in Medicine and Biology (WIFUMB 2016) in conjunction with the International Contrast Ultrasound Society (ICUS) meeting,   2016 11 13 , 招待有り
• Invited Lecture “Fusion imaging for the treatment of liver cancer”., Masatoshi Kudo, The Westlake International Forum on Ultrasound in Medicine and Biology (WIFUMB 2016) in conjunction with the International Contrast Ultrasound Society (ICUS) meeting,   2016 11 13 , 招待有り
• Invited Lecture “HCC clinical practice and ongoing trials in Japan”, Masatoshi Kudo, Asia Advisory Board Meeting on GI Tumors,   2016 11 12 , 招待有り
• Nivolumab (Nivo) in patients (Pts) with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study., Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Welling TH, Yeo W, Chopra A, Anderson J, dela Cruz C, Lang L, Neely J, Tang H, El-Khoueiry AB, American Association for the Study of Liver Diseases (AASLD 2016),   2016 11 11
• Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: long-term outcomes after removal of a self-expandable metal stent, Kamata K, Takenaka M, Kudo M, Asian Pacific Digestive Week (APDW 2016),   2016 11 04
• Chair; Liver-S2 “Current therapeutic strategy for HCC”, Masatoshi Kudo, Asian Pacific Digestive Week (APDW 2016),   2016 11 03 , 招待有り
• Estimation of EUS findings of early chronic pancreatitis in comparison with clinical symptoms. International Session (Workshop) 1“Recent progress in chronic pancreatitis”, Takenaka M, Kitano M, Kudo M,   2016 11 03
• Identification of fetal liver-type hepatocellular carcinoma based on a methylome analysis and its associations with genetic alterations. International Session (Symposium) 1 “Genomics of hepatocellular carcinoma: hepatitis virus infection and hepatocarcino, Nishida N, Kudo M,   2016 11 03
• US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma, Minami Y, Kudo M, the 3rd Asian Conference on Tumor Ablation (ACTA),   2016 10 29
• Moderator; ACTA meets WCIO I: Challenges and solutions in ablation, Masatoshi Kudo, The 3rd Asian Conference on Tumor Ablation,   2016 10 28 , 招待有り
• Invited Lecture “CE-US guided RFA for HCC”, Luncheon Symposium I, Masatoshi Kudo, the 3rd Asian Conference on Tumor Ablation (ACTA),   2016 10 28 , 招待有り
• Invited Lecture “CEUS in the evaluation of RFA treatment efficacy”, Masatoshi Kudo, 2016 Annual Convention of Taiwan Society of Ultrasound in Medicine (TSUM),   2016 10 23 , 招待有り
• Invited Lecture “Value of EOB in clinical perspective: Japan”, Masatoshi Kudo, Asia Pacific Liver Imaging Symposium (APLIS 2016),   2016 10 21 , 招待有り
• Combination therapy with peginterferon and entecavir for persistent viral suppression in patients with chronic hepatitis B, Hagiwara S, Nishida N, Kudo M, 23rd International Symposium on Hepatitis C Virus and Related Viruses (HCV2016),   2016 10 13
• Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study, Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi T, Kim TY, Choo SP, Trojan J, Meyer T, Willing T, Yeo W, Chopra A, Anderson J, dela Cruz CX, Lang L, Neely J, El-Khoueiry A, ESMO 2016,   2016 10 09
• Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study, Zhu A, Knox J, Kudo M, Chan S, Finn R, Siegel A, Ma J, Watson P, Cheng AL, ESMO 2016,   2016 10 08
• Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study, Finn R, Chan S, Zhu A, Knox J, Cheng AL, Siegel A, Bautista O, Watson P, Kudo M, ESMO 2016,   2016 10 08
• A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2), Zhu A, Galle P, Kudo M, Finn R, Yang L, Abada P, Llovet J, ESMO 2016,   2016 10 08
• Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial, Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Isabelle Ollivier-Hourmang, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G, ESMO 2016,   2016 10 08
• The oncoprotein gankyrin promotes the development of colitis-associated cancer by mediating STAT3 and ERK activation, Sakurai T, Nagai T, Kashida H, Kudo M, The 75th Annual Meeting of the Japanese Cancer Association,   2016 10 06
• Chair: English Oral Sessions “Hepato-biliary-pancreatic cancer: translational research”, Masatoshi Kudo, The 75th Annual Meeting of the Japanese Cancer Association,   2016 10 06 , 招待有り
• Chair; Luncheon Seminar 3 “Significance of anti-viral therapy in patients with HCV-related HCC”, Masatoshi Kudo, 12th JSH Single Topic Conference,   2016 09 23 , 招待有り
• chair; The position of molecular target therapy in HCC, now and future, Masatoshi Kudo, 12th Japan Society of Hepatology,   2016 09 23 , 招待有り
• US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma, Minami Y, Nishida N, Kudo M, The 12th JSH Single Topic Conference,   2016 09 22
• Invited Lecture “New subclassification and treatment strategy for intermediate stage HCC”, Masatoshi Kudo, the 12th JSH Single Topic Conference,   2016 09 22 , 招待有り
• Treatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib), Ye SL, Lencioni R, Marrero JA, Venook AP, Nakajima K, Kudo M, The 19th Annual Meeting of Chinese Society of Clinical Oncology (CSCO),   2016 09 21
• Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma, Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Arai Y, Kanai F, Akazawa K, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 11
• Patients benefit from treatment with sorafenib for more than 28 weeks: analysis from the GIDEON study according to duration of treatment, Ye SL, Lencioni R, Nakajima K, Kudo M, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• Validation of a proposed substaging system for patients with intermediate hepatocellular carcinoma, Arizumi T, Ueshima K, Kudo M, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• New technology to detect of tumor-feeding branches and simulate embolization area of hepatocellular carcinoma with SYNAPSE VINCENT durint transcatheter arterial chemoembolization, Ogawa C, Shibatoge M, Kudo M, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2), Zhu AX, Galle PR, Kudo M, Finn RF, Yang L, Abada PB, Llovet JM, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS interim analysis, Cheng AL, Raoul JL, Lee HC, Kudo M, Nakajima K, Peck-Radosavljevic M on, behalf of the, OPTIMIS Investigators, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• A propensity score analysis on survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion using nationwide survey data in Japan, Kokudo N, Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Izumi N, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• Safety and antitumour activity of Nivolumab (Nivo) in patients with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 checkmate-040 study, Sangro B, Melero I, Yau T, Hsu C, Kudo M, Crocenzi T, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J, dela Cruz C, Lang L, Neely J, El-Khoueiry A, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• New subclassification of intermediate stage HCC: Analysis of 46,997 Japanese HCC patients from a nationwide survey of the Liver Cancer Study Group of Japan, Ueshima K, Kudo M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kokudo N, Takayama T, Sakamoto M, Nakashima O, Matsuyama Y, 10th Annual Conference International Liver Cancer Association (ILCA),   2016 09 10
• Chair: ILCA Symposium 2 “Controversies in Liver Cancer”, Masatoshi Kudo, ILCA 10th Annual Conference 2016,   2016 09 09 , 招待有り
• Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma”, Masatoshi Kudo, 14th Annual Meeting of the Japanese Society of Medical Oncology,   2016 07 30 , 招待有り
• Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma”, Masatoshi Kudo, 14th Annual Meeting of the Japanese Society of Medical Oncology,   2016 07 29 , 招待有り
• Chair; Poster Session “Hepatoma/HCC, Biliary Tract Cancer”, Masatoshi Kudo, 14th Annual Meeting of the Japanese Society of Medical Oncology,   2016 07 28 , 招待有り
• Special Lecture “Role of EOB-MRI in the management of HCC”, Masatoshi Kudo, Bayer Sponsored Meeting From Diagnosis to Treatment, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 10 , 招待有り
• Chair; Session 17: State-of-the Art Lecture “Systemic Therapy for HCC – The Future and Beyond”, Masatoshi Kudo, The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 10 , 招待有り
• A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line Sorafenib (REACH-2), Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada PB, Llovet JM, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 09
• Chair; Session 14: Debate Session, Masatoshi Kudo, The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 09 , 招待有り
• Chair; Consensus Workshop2 “Role of Chemotherapy in HCC”, Masatoshi Kudo, The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 09 , 招待有り
• Easy detection of tumor-feeding branches of hepatocellular carcinoma with SYNAPSE VINCENT during transcatheter arterial chemoembolization, Ogawa C, Shibatoge M, Kudo M, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 08
• Safety and antitumor activity of Nivolumab (Nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the Phase 1/2 CheckMate-040 study, Sangro B, Melero I, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J, dela Cruz C, Lang L, Neely J, El-Khoueiry AB, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 08
• State-of-the Art Lecture “Recent Advancement in HCC Treatment”, Masatoshi Kudo, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 08 , 招待有り
• Chair; Consensus Workshop2 “Role of Chemotherapy in HCC”, Masatoshi Kudo, The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2016 07 08 , 招待有り
• “Proposal of new BCLC stage B subclassification”, Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC”, Masatoshi Kudo, 52nd Annual Meeting of Liver Cancer Study Group of Japan,   2016 07 01 , 招待有り
• Chair: Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC”, Masatoshi Kudo,   2016 07 01 , 招待有り
• Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, randomized phase 3 RESORCE trial, Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Boucher E, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross P, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G, on behalf of, the, RESORCE investigators, ESMO 18th World Congress on Gastrointestinal Cancer 2016,   2016 06 30
• Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC), Abou-Alfa GK, Sangro B, Morse M, Zhu AX, Kim RD, Cheng AL, Kudo M, Kang YK, Chan SL, Antal J, Boice J, Xiao F, Morris SR, Bendell J, Study Group, 52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016),   2016 06 05
• Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey, Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N, 52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016),   2016 06 04
• A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2), Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Llovet JM, 52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016),   2016 06 04
• Safety and antitumor activity of Nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study, Sangro B, Melero I, Yau TC, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J, Dela Cruz C, Lang L, Neely J, El-Khoueiry AB, 52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016),   2016 06 04
• Usefulness of contrast-ehnaced ultrasonography with sonazoid in the preperative evaluation of histological differentiation and gross types of hepatocellular carcinoma, Ogawa C, Minami Y, Kudo M, 8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201,   2016 05 29
• EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」, Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Kudo M, 日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016),   2016 05 28
• Utility of endoscopic ultrasonography for follow-up of IPMN. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」, Kamata K, Kitano M, Kudo M, 日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016),   2016 05 28
• US-US image fusion in radiofrequency ablation therapy for hepatocellular carcinoma, Minami Y, Minami T, Kudo M, 8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201,   2016 05 27 , 招待有り
• New US technology using 3D volume analyzer synapse VINCENT, Ogawa C, Minami Y, Kudo M, 8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201,   2016 05 27 , 招待有り
• Contrast-enhanced harmonic EUS for pancreatic diseases, Kitano M, Kamata K, Omoto S, Minaga K, Yamao K, Imai H, Takenaka M, Kudo M, 8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201,   2016 05 26 , 招待有り
• An objective model to optimize treatment decisions in advanced hepatocellular carcinoma after sorafenib failure: the SORFA score, Pinato DJ, Yen C, Arizumi T, Giarda P, Howell J, Ramaswami R, Burlone ME, Kudo M, Pirisi M, Sharma R, The International Liver Congress 2016,   2016 04 16
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH patients by albumin-bilirubin (ALBI) grade, Blanc JF, Chan SL, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Baran A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Abada P, Chang SC, Yang L, Zhu A, The International Liver Congress 2016,   2016 04 16
• Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatine/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma, Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Arai Y, Kanai F, Akazawa K, SILIUS Study Group, The International Liver Congress 2016,   2016 04 16
• Invited Lecture “Hepatocellular cancer drug development”, Masatoshi Kudo, 8th Annual Asian Oncology Summit (AOS 2016),   2016 03 04 , 招待有り
• Practice patterns, sorafenib dosing and safety in Asian hepatocellular carcinoma patients in GIDEON, Kudo M, Venook A, Lencioni R, Ye SL, Nakajima K, Marrero J, 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2016 02 23
• Regional differences in practice patterns among countries, Luncheon Symposium “New light on the integration of evidence into practice”, Masatoshi Kudo, 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2016 02 23 , 招待有り
• Biomarker and Imaging Diagnosis of HCC. Symposium 11 “Update of HCC Treatment”, Masatoshi Kudo, 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2016 02 23
• Invited Lecture “Non-Curative Treatment (TACE/Sorafenib) of HCC”, Masatoshi Kudo, 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2016 02 23 , 招待有り
• Regional Differences in the Use of Transarterial Chemoembolization (TACE) in HCC: Interim Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib After TACE, Lee HC, Cheng AL, Raoul JL, Peck-Radosavljevic M, Nakajima K, Kudo M, on behalf of the, OPTIMIS Investigators, 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2016 02 23
• Invited Lecture “Immuno-oncology for HCC: Beyond the target therapy”, Masatoshi Kudo, the 1st anniversary International Symposium of Yonsei Liver Center,   2016 02 19 , 招待有り
• Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC), Masatoshi Kudo, American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016),   2016 01 22
• Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial, Kudo M, Okusaka T, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016),   2016 01 22
• A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2), Zhu A, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Chang SC, Llovet JM, American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016),   2016 01 22
• Usefulness of serum procalcitonin for diagnosis of acute pancreatitis, Omoto S, Kitano M, Sakamoto H, Imai H, Yamao K, Kamata K, Miyata T, Minaga K, Kadosaka K, Kudo M, Asian Pacific Digestive Week (APDW 2016),   2015 12 03
• The analysis of three cases that gastrointestinal bezoars have history of gastrointestinal surgery, Okamoto K, Matsui S, Tanaka R, Yamada M, Adachi T, Takayama M, Mine H, Nagai T, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Kashida H, Kudo M, Asian Pacific Digestive Week (APDW 2016),   2015 12 03
• Treatment of colorectal LST: focus on EMR techniques, Komeda Y, Kashida H, Sakurai T, Asakuma Y, Okazaki Y, Nagai T, Mine H, Adachi T, Tanaka R, Yamada M, Kono M, Okamoto K, Matsui S, Kudo M, Asian Pacific Digestive Week (APDW 2016),   2015 12 03
• A case of endoscopic mucosal resection for gastric perineurioma, Kono M, Matsui S, Okamoto K, Yamada M, Tanaka R, Adachi T, Mine H, Nagai T, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Kashida H, Kudo M, Asian Pacific Digestive Week (APDW 2016),   2015 12 03
• Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR (EMR), Yamada M, Kashida H, Komeda Y, Okamoto K, Kono M, Tanaka R, Adachi T, Mine H, Nagai T, Okazaki Y, Asakuma Y, Sakurai T, Matsui S, Kudo M, Asian Pacific Digestive Week (APDW 2016),   2015 12 03
• Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinoma, Nishida N, Kaido T, Kudo M, 66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015),   2015 11 17
• PALBI-an objective score based on platelets, albumin & Bilirubin Stratifies HCC patients undergoing resection & ablation better than Child’s classification, Roayaie S, Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Kudo M, Roberts LR, Sherman M, Johnson P, 66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015),   2015 11 14
• Predictive factors for outcomes of through-the-scope gastroduodenal stenting in patients with gastric outlet obstruction; a large multicenter retrospective study in West Japan, Yamao K, Kitano M, Kayahara T, Ishida E, Minaga K, Yamashita Y, Nakajima J, Asada M, Okabe S, Chiba Y, Imai H, Kudo M, 23rd United European Gastroenterology Week (UEGW 2015),   2015 10 27
• Evaluation of anti-migration properties of biliary covered self-expandable metal stents, Minaga K, Kitano M, Harwani Y, Imai H, Kamata K, Miyata T, Yamao K, Kadosaka K, Omoto S, Kudo M, 23rd United European Gastroenterology Week (UEGW 2015),   2015 10 26
• Invited Lecture “Ultrasound fusion imaging of liver tumor: recent progress and clinical relevance”, Masatoshi Kudo, IEEE International Ultrasonics Symposium,   2015 10 23 , 招待有り
• EUS guided biliary drainage for treatment of biliary obstruction. International Session (Panel Discussion) 2 “Strategy of treatment for biliary stenosis”, Imai H, Kitano M, Kudo M, 第90回日本消化器内視鏡学会総会,   2015 10 10
• Discussant, International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”, Masatoshi Kudo,   2015 10 08 , 招待有り
• Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma. International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”, Nishida N, Kudo M,   2015 10 08
• Invited Lecture “Hepatologists’ perspectives on EOB-MRI: Pre-& post-operative evaluation in malignant lesions”, Masatoshi Kudo, Asila Pacific Liver Imaging Symposium (APLIS),   2015 09 17 , 招待有り
• Invited Lecture; Luncheon Satellite Symposium “Treatment strategies to optimize outcome and experience of patients with HCC”, Masatoshi Kudo, The Liver Week 2015,   2015 09 12 , 招待有り
• KLCSG & LCSGJ Joint Symposium “HCC nationwide surveillance and out come in Japan”, Masatoshi Kudo, The Liver Week 2015,   2015 09 12 , 招待有り
• Invited Lecture “HCC nationwide surveillance and outcome in Japan”, Masatoshi Kudo, The Liver Week 2015,   2015 09 12 , 招待有り
• Chairs: “KLCSG & JLCSG Joint Symposium”, Masatoshi Kudo, The Liver Week 2015,   2015 09 12 , 招待有り
• Special Lecture 2”The evolution of HCC treatment”, Masatoshi Kudo, The Liver Week 2015,   2015 09 11 , 招待有り
• Invited Lecture “The evolution of HCC treatment”, Masatoshi Kudo, The Liver Week 2015,   2015 09 11 , 招待有り
• A randomized phase 2 trial of sorafenib plus intraarterial cisplatin versus sorafenib alone for advanced hepatocellular carcinoma, Morimoto M, Ikeda M, Shimizu S, Inaba Y, Kojima Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• Objective response by mRECIST predicts survival in hepatocellular carcinoma: a multivariate, time-dependent analysis from the phase 3 BRISK-PS study, Lencioni R, Park JW, Torres F, Decaens T, Boucher E, Raoul JL, Kudo M, Chang C, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• Platelet count improves prognostic value of A-L-B-I grade: introducting a new P-A-L-B-I score, Roayaie S, Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Roberts L, Kudo M, Sherman M, Johnson P, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• Evaluation of detection rate of liver tumor existing deep location from the surface using second generation agent, sorafenib, Izuta M, Ogawa C, Shibatoge M, Kudo M, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2), Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Chang SC, Llovet JM, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patiens with hepatocellular carcinoma (HCC): OPTIMIS interim analysis, Peck-Radosavljivic M, Raoul JL, Lee HC, Kudo M, Nakajima K, Cheng AL, on behalf of the, OPTIMIS Investigators, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• Survival benefit of locoregional therapy for hepatocellular carcinoma with Child-Pugh C liver function: a multicenter nation-wide study, Kudo M, Kitai S, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver, Cancer Study, Group of Japan, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma, Minami Y, Minami T, Kudo M, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 05
• Chair: General Session 2 “Molecular Pathogenesis of Liver Cancer II”, Masatoshi Kudo, International Liver Cancer Association 9th Annual Conference (ILCA) 2015,   2015 09 04 , 招待有り
• Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized Phase III REACH study: analysis ofα-fetoprotein (AFP) kinetics during treatment, Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Eduardo T, Pfiffer F, Hatano E, Chung HC, Kubackova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Yang L, Abada PB, Zhu AX, European Cancer Congress 2015 (18th ECCO-40th ESMO),   2015 09
• Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the phase III REACH trial., Kudo M, Hatano E, Okusaka T, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Arai K, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Asou H, Abada PB, Yang L, Zhu AX, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09
• Invited Lecture “Assessing treatment effect and treatment failure: when to stop LRTs”, Masatoshi Kudo, 9th Annual Conference International Liver Cancer Association (ILCA),   2015 09 , 招待有り
• State of Art Lecture “Benefit of early diagnosis of liver cancer with changed therapeutic paradigm in HCC”, Masatoshi Kudo, 23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD),   2015 08 02 , 招待有り
• Invited Lecture “Imaging in early HCC-MR advances”, Masatoshi Kudo, 23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD),   2015 08 01 , 招待有り
• Invited Lecture“HCC: early diagnosis impacts prognosis”, Masatoshi Kudo, 23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD),   2015 07 31 , 招待有り
• Invited Lecture“Molecular targeted therapy for HCC: current status and future perspectives”, Masatoshi Kudo, 23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD),   2015 07 31 , 招待有り
• Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial, Ohkawa S, Okusaka T, Kudo M, Hatano E, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Arai K, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Asou H, Abada PB, Yang L, Zhu AX, The 13th Annual Meeting of Japanese Soceity of Medical Oncology,   2015 07 17
• Activin signal in pancreatic cancer, Togashi Y, Sakamoto H, Kogita A, de Velasco M, Sakai K, Fujita Y, Tomida S, Kitano M, Kudo M, Nishio K, The 13th Annual Meeting of Japanese Soceity of Medical Oncology,   2015 07 17
• Chair "Poster Session: Biliary Tract and Pancreatic Cancer 2 FOLFIRINOX(2)", Masatoshi Kudo, The 13th Annual Meeting of Japanese Society of Medical Oncology,   2015 07 16 , 招待有り
• Moderator and Commentator “Non-surgical treatment of HCC: achievement from Taiwan over the past quarter century”, Masatoshi Kudo, Taiwan Association for the Study of the Liver 2015 (TASL),   2015 07 12 , 招待有り
• Moderator and Commentator “Androgen pathway in the mechanisms of liver carcinogenesis and targets for future therapy”, Masatoshi Kudo, Taiwan Association for the Study of the Liver 2015 (TASL),   2015 07 12 , 招待有り
• Invited Lecture “Subclassification of intermediate stage HCC and treatment strategy”, APPLE Consensus Workshop “Searching consensus for controversies”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2015 07 05 , 招待有り
• Chair; State-of-the-Art Lecture III “Cholangiocarcinoma: new trends and emerging targets”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 05 , 招待有り
• Chair; State-of-the-Art Lecture II “Design of clinical trial in advanced HCC: trial enrichment and stratification”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 05 , 招待有り
• Chair; The BCLC B Stage: Debate, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 04 , 招待有り
• Chair; Memorial Award Ceremony “Prof. Ichio Honjo Award Lecture”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 04 , 招待有り
• Chair; Luncheon Seminar “Efficacy & Safety of Lipiodol for Improved Overall Survival in HCC”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 04 , 招待有り
• Invited Lecture “Management of intermediate/advanced HCC in Japan”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2015 07 03 , 招待有り
• US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma, Minami Y, Minami T, Kudo M, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2015 07 03
• Epigenetics in HCC pathogenesis, Nishida N, Kudo M, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2015 07 03 , 招待有り
• Chair; New Aspects of Locoregional/Surgical Therapy, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 03 , 招待有り
• Chair; State-of-the-Art Lecture I, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 03 , 招待有り
• Chari: Sponsored Seminar“Diagnostic Imaging with EOB-MRI for Malignancy Grade of HCC”, Masatoshi Kudo, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting,   2015 07 03 , 招待有り
• Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score, Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone C, Okusaka T, Wada Y, Park J, Ryoo B, Cho JY, Chung HC, Li C, Yen C, Lee K, Yang L, Chau I, Annual Meeting of American Society of Clinical Oncology (ASCO 2015),   2015 06 01
• Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study, Llovet JM, Park J, Torres F, Decaens T, Boucher E, Raoul J, Kudo M, Chang C, Boige V, Assenat E, Kang Y, Lim H, Walters I, Lencioni R, Annual Meeting of American Society of Clinical Oncology (ASCO 2015),   2015 06 01
• Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study, Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz J, Park J, Ryoo B, Yen C, Kudo M, Poon RT, Pastorelli D, Blanc J, Chung H, Baron AD, Okusaka T, Cui ZL, Girvan AC, Abada P, Yang L, Zhu AX, Annual Meeting of American Society of Clinical Oncology (ASCO 2015),   2015 06 01
• Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial, Ikeda M, Shimizu S, Sato T, Morimoto M, Inaba Y, Kojima Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T, Annual Meeting of American Society of Clinical Oncology (ASCO 2015),   2015 06 01
• Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan, Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, The Liver Cancer Study, Group of Japan, Annual Meeting of American Society of Clinical Oncology (ASCO 2015),   2015 06 01
• A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib refractory advanced hepatocellular carcinoma (S-CUBE), Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Okusaka T, Annual Meeting of American Society of Clinical Oncology (ASCO 2015),   2015 06 01
• Contrast-enhanced harmonic EUS for differential diagnosis of pancreatic tumors. International Video Session 2 “Advances and education of endoscopic diagnosis and treatment-biliary tract, pancreas-“, Kamata K, Kitano M, Kudo M, 第89回日本消化器内視鏡学会総会,   2015 05 29
• Invited Lecture “Surveillance, treatment and outcome of HCC in Japan”, Masatoshi Kudo, Joint Workshop EASL-JSH, 50th International Liver Congress of the European Association for the Study of the Liver (EASL),   2015 04 25 , 招待有り
• An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS, Peck-Radosavljevic M, Raoul JL, Lee HC, Kudo M, Nakajima K, Cheng AL, 50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015),   2015 04 24
• Combined sequential use of HAP and ART scores to predict transarterial chemoembolization failure in hepatocellular carcinoma: a multicenter comparative study, Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah P, Smirne C, Grossi G, Pirisi M, Kudo M, Sharma R, 50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015),   2015 04 24
• GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib): A retrospective analysis of prognostic factors for survival, Bronowicki JP, Kudo M, Lencioni R, Chen XP, Dagher L, Furuse J, Geschwind JFH, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Ye SL, Marrero JA, 50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015),   2015 04 24
• Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer, Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Kudo M, Nishio K, American Association for Cancer Research Annual Meeting (AACR 2015),   2015 04 21
• Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer, Kang YK, Seery TE, Kato M, Chakrabarti D, Valota O, Chen Y, Jie T, Pithavala Y, Kudo M, American Association for Cancer Research Annual Meeting (AACR 2015),   2015 04 19
• A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (Orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma, Park JW, Cheng AL, Kudo M, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y, 50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015),   2015 04
• Invited Lecture “WFUMB Guidelines”, Masatoshi Kudo, American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015),   2015 03 21 , 招待有り
• Invited Lecture “Liver strain”, Masatoshi Kudo, American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015),   2015 03 21 , 招待有り
• Multicenter Observational Study of Reactivation of Hepatitis B Virus Caused by Chemotherapy with Sorafenib, Furuse J, Ikeda M, Kondo S, Kudo M, Nadano S, Osaki Y, Kumada T, Ohkawa K, Mizokami M, 24th Conference of APASL,   2015 03 14
• Multicenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors, Furuse J, Ikeda M, Kondo S, Kudo M, Nadano S, Osaki Y, Kumada T, Ohkawa K, Mizokami M, 24th Conference of APASL,   2015 03 14
• Invited Lecture “Recent advances in therapy for advanced hepatocellular carcinoma”, Masatoshi Kudo, The 24th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL),   2015 03 13 , 招待有り
• Invited Lecture “The Eastern point of view”, Masatoshi Kudo, Eastern & Western Association Liver Tumors (1st ewalt),   2015 01 22 , 招待有り
• Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC), Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen, W, Yang TS, Wu CC, Chao Y, Chang L, Kudo M, Ikeda M, Kang Y, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT, 2015 Gastrointeritinal Cancers Symposium (ASCO-GI 2015),   2015 01 15
• Invited Lecture “Molecular targeted therapy for HCC: Past, present and future perspective”, Masatoshi Kudo, 24th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO 2014),   2014 12 06 , 招待有り
• Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR, Yamada M, Kashida H, Tanaka R, Adachi T, Mine H, Takayama M, Okazaki Y, Nagata Y, Nagai T, Kawasaki M, Komeda N, Asakuma Y, Sakurai T, Matsui S, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 23
• Small-intestinal mucosal injury induced by non-steroidal anti-inflammatory drugs or antiplatelet agents in our hospital, Nagai T, Tanaka R, Yamada M, Adachi T, Takayama M, Mine H, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Matsui S, Kashida H, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 23
• The clinical characteristics and treatment of eosinophilic esophagitis, Matsui S, Kashida H, Kawasaki M, Asakuma Y, Sakurai T, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 23
• Two cases of gastric amyloidosis, Matsui S, Kashida H, Okamoto K, Asakuma Y, Sakurai T, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 23
• Colorectal endoscopic submucosal dissection is useful and safe, Kashida H, Adachi T, Komeda Y, Sakurai T, Asakuma Y, Takayama M, Mine H, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 23
• Comparison of Japanese primary and secondary regimen of Helicobacter pylori eradication, Adachi T, Tanaka R, Yamada M, Takayama M, Mine H, Nagai T, Kawasaki M, Asakuma Y, Okazaki Y, Komeda Y, Sakurai T, Matsui S, Kashida H, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 23
• The usefulness of single-balloon endoscopy for the small bowel lesions, Adachi T, Tanaka R, Yamada M, Takayama M, Mine H, Nagai T, Kawasaki M, Asakuma Y, Okazaki Y, Komeda Y, Sakurai T, Matsui S, Kashida H, Kudo M, Asian Pacific Digetive Week (APDW 2014),   2014 11 22
• Chair "Session 5: Hepatocellular carcinoma, basic and therapy", Masatoshi Kudo, The 11th JSH Single Topic Conference,   2014 11 21 , 招待有り
• Involvement of stress response protein crip in refractory inflammatory bowel diseases and colitis-associated cancer. Symposium 1 “Cancer prevention and early diagnosis”, Sakurai T, Kashida H, Kudo M, The 25th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis,   2014 11 13
• How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained?, Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts LR, Sherman M, 65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014),   2014 11 10
• Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT, Minami Y, Kudo M, 65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014),   2014 11 10
• Pathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in nonalcoholic fatty liver disease, Nishida N, Yada N, Chishina H, Arizumi T, Takita M, Kitai S, Inoue T, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kudo M, 65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014),   2014 11 09
• Invited Lecture “Interventaional and contrast EUS for pancreatobiliary disease”, Masatoshi Kudo, The 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014),   2014 10 31 , 招待有り
• Invited Lecture “Fusion imaging for treatment guidance of hepatic tumours”, Masatoshi Kudo, The 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014),   2014 10 31 , 招待有り
• Predictive factors for pain relief after EUS-guided neurolysis in patietnts suffering from upper abdominal cancer pain. International Session (Symposium) 6 “EUS-guided therapy: current status and future directions”, Kitano M, Sakamoto H, Kudo M, Japan Digestive Disease Week 2014 (JDDW),   2014 10 26
• Prospective multicenter randomized controlled trial of histological diagnostic yield comparing 25G EUG-FNA needles with and without a core trap in solid pancreatic masses: analysis of factors affecting tissue acquisition and diagnostic accuracy, Nebiki H, Yanagisawa A, Yasukawa S, Kamata K, Kudo M, Ogura T, Higuchi K, Fukutake N, Ashida R, Yamasaki T, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Kitano M, United European Gastroenterology Week (UEGW 2014),   2014 10 18
• Validation of staging systems for hepatocellular carcinoma: a comparison of the BM-JIS score, the JIS score and the BCLC staging, Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, Liver Cancer Study, Group of Japan, United European Gastroenterology Week (UEGW 2014),   2014 10 18
• An International observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS, Raoul JL, Peck-Radosavljevic M, Lee HC, Kudo M, Nakajima K, Cheng AL, on behalf of the, OPTIMIS investigators, European Society for Medical Oncology Congress (ESMO 2014),   2014 09 29
• Randomised study of axitinib (Axi) plus best supportive care (BSC) versus placebo (Pbo) plus BSC in patients with advanced hepatocellular carcinoma (HCC) following prior antiangiogenic therapy, Kang YK, Yau T, Park JW, Boucher E, Lim HY, Poon RTP, Lee TY, Obi S, Chan SL, Qin SK, Kim RD, Tang J, Valota O, Chakrabarti D, Kudo M, European Society for Medical Oncology Congress (ESMO 2014),   2014 09 28
• Ramucirumab (RAM; IMC-1121B) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib: Results from the Randomized Phase III REACH Study, Zhu A, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung H, Baron A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada P, Yang L, Schwartz J, Park J, European Society for Medical Oncology Congress (ESMO 2014),   2014 09 28 , 招待有り
• Chair “e-poster viewing tour and networking break”, Masatoshi Kudo, 8th ILCA Annual Conference,   2014 09 06 , 招待有り
• STORM: A phase III, randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma, Llovet JM, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roaayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre MA, Meinhardt G, Bruix J, on behalf of the, STORM investigators, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• Newly simulated virtual ultrasound sonography software before RFA, Ogawa C, Kudo M, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• Proposals for improvement of the AJCC/UICC and Japanese staging systems for intrahepatic cholangiocarcinoma in review of the Japanese nationwide database, Sakamoto Y, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Ku Y, Kudo M, Sakamoto M, Takayama T, Nakashima O, Matsui O, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT, Minami Y, Murakami T, Kudo M, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained? Answers from the Bridge database, Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts LR, Sherman M, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• Tumor response to transarterial chemoembolization in unresectable hepatocellular carcinoma patients in clinical practice: findings from the GIDEON database, Kudo M, Marrero J, Lencioni R, Nakajima K, Ye SL, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC) (NCT01507168), Kudo M, Yen CJ, Daniele B, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Rutman O, Chen YC, Lee R, Abou-Alfa GK, 8th Annual Conference, International Liver Cancer Association (ILCA 2014),   2014 09 06
• Invited Lecture “Surveillance, treatment and outcome of HCC in Japan”, ILCA Symposium 3 “Noevel opportunities for treatment in HCC”, Masatoshi Kudo, The 8th Annual Conference, International Liver Cancer Association (ILCA),   2014 09 06 , 招待有り
• Chair "Symposium 2 “Treatment strategy for advanced stage hepatocellular carcinoma after approval of sorafenib”, Masatoshi Kudo, The 12th Annual Meeting of Japanese Society of Medical Oncology,   2014 07 17 , 招待有り
• Chair "Session 10 “APPLE consensus workshop: searching consensus for controversies”, Masatoshi Kudo, The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2014 07 13 , 招待有り
• Chair "Session 5 “Prof. Juei-Low Sung Award Lecture”, Masatoshi Kudo, The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2014 07 12 , 招待有り
• Invited Lecture “Lessons from the TACE trials”, Masatoshi Kudo, The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2014 07 12 , 招待有り
• Chair "Session 6 “Future treatment for HCC”, Kudo M, The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2014 07 12 , 招待有り
• Chair "Session 4 “State-of-the art lecture: HCC prevention: looking into the future”, Kudo M, The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2014 07 12 , 招待有り
• Value of semi-annual follow-up of EUS in patients with IPMN. International Teleconference 2 “Intraductal papillary mucinous neoplasm of the pancreas: clinical experiences in Asian countries”, Kamata K, Kitano M, Kudo M, the 45th Annual Meeting of the Japan Pancreas Society,   2014 07 11
• Invited Lecture “Case-study sharing: sorafenib use in intermediate HCC”, Kudo M, Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC),   2014 07 10
• Chair: Guideline of CEUS, Masatoshi Kudo, The 6th Asian Conference on Ultrasound Contrast Imaging (ACUCI 2014),   2014 05 10 , 招待有り
• Contrast-enhanced endoscopic ultrasound in pancreatobiliary diseases., The 6th Asian Conference on Ultrasound Contrast Imaging (ACUCI 2014),   2014 05 10
• Final analysis of GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma [HCC] and of its treatment with sorafenib): factors influencing treatment duration and outcomes, 49th Annual Meeting of the European Association for the Sudy of the Liver (EASL),   2014 04 , 49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
• Once-daily oral lusutrombopag, alternative to platelet transfusion inthrombocytopenic patients with chronic liver disease undergoingradiofrequency ablation: results from a phase 2B, randomized, double-blind study., 49th Annual Meeting of the European Association for the Sudy of the Liver (EASL),   2014 04 , 49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
• Final analysis of GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): treatment practices, safety and outcomes by race, Asian Pacific Association for the Study of the Liver (APASL 2014),   2014 03 , Asian Pacific Association for the Study of the Liver (APASL 2014)
• Invited Lecture “Current evidence and future perspective of molecular targeted therapies in HCC”, The 11th World Congress of the International Hepato-Pancreato-Biliary Association,   2014 03 , The 11th World Congress of the International Hepato-Pancreato-Biliary Association
• Invited Lecture “Contrast enhanced ultrasound of gastrointestinal disorders”, Masatoshi Kudo, 12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop,   2014 03 01 , 招待有り
• Contrast-enhanced ultrasound of hepatic tumours with Sonazoid, Masatoshi Kudo, 12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop,   2014 03 01 , 招待有り
• Invited Lecture “Interventional EUS for pancreatobiliary tumours”, Masatoshi Kudo, 12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop,   2014 02 28 , 招待有り
• Invited Lecture “Ultrasound evaluation of diffuse liver diseases”, Masatoshi Kudo, 12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop,   2014 02 28 , 招待有り
• Moderator "Keynote session", Masatoshi Kudo, 3rd Investigators Meeting for ORIENTAL,   2014 02 22
• Invited Lecture “Recent trends of management of HCC”, Masatoshi Kudo, The 22nd International Seoul Radiology Symposium (ISRS 2015),   2014 02 14 , 招待有り
• Invited Lecture “Lessons from other TKI trials combined with TACE (tentative)”, 3rd Investigators Meeting for ORIENTAL,   2014 02 , 3rd Investigators Meeting for ORIENTAL
• Invited Lecture “Ongoing trial with Sonazoid in Japan”, Workshop for a Clinical Trial of HCC Screening with Sonazoid,   2013 12 , Workshop for a Clinical Trial of HCC Screening with Sonazoid
• Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): regional trends, safety, and outcomes in patients receiving concomitant transarterial chemoembolization., 99th Scientific Assembly and Annual Meeting (RSNA 2013),   2013 12 , 99th Scientific Assembly and Annual Meeting (RSNA 2013)
• B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial, The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD),   2013 11 , The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
• Role of oxidative stress and epigenetic alteration on chronic hepatitis C-related human hepatocarcinogenesis, The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD),   2013 11 , The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
• Safety and outcomes by disease etiology in sorafenib-treated uHCC patients in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib), The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD),   2013 11 , The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
• Chair: Treatment of advanced HCC with macro-vascular invasion (Surgery vs Sorafenib). JDDW International debte session (featured lecture) 1-2 (JDDW), Japan Digestive Disease Week 2013 (JDDW),   2013 10 , Japan Digestive Disease Week 2013 (JDDW)
• EUS-guided hepaticogastrostomy for treatment of obstructive jaundice in patients with malignant hilar biliary stricture after transpillary drainage is ineffective or unsuccessful, Japan Digestive Disease Week 2013 (JDDW),   2013 10 , Japan Digestive Disease Week 2013 (JDDW)
• The role of EUS in diagnosis and treatment of autoimmune pancreatitis, Japan Digestive Disease Week 2013 (JDDW),   2013 10 , Japan Digestive Disease Week 2013 (JDDW)
• The usefulness of the epoch method “Defect re-perfusion imaging”to diagnose HCC using new agent sonazoid, The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI 2013),   2013 10 , The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI 2013)
• The learning curve of endoscopic submucosal dissection in the colorectum, 21th United European Gastroenterology Week (UEGW),   2013 10 , 21th United European Gastroenterology Week (UEGW)
• Invited Lecture “Diagnosis of Gross Pathological Classification of HCC by Kupffer phase CEUS”, The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI),   2013 10 , The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)
• Invited Lecture “Contrast-enhanced EUS of GI disorders”, The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI),   2013 10 , The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)
• Multimodal treatment of hepatocellular carcinoma. Symposia on specific tumors〝Cancer research on digestive organs: yesterday, today, and tomorrow",   2013 10
• Special Lecture “Management of Hepatocellular Carcinoma: Recent Progress” “Special Lecture (III)”, Taiwan Digestive Disease Week 2013 (TDDW),   2013 10 , Taiwan Digestive Disease Week 2013 (TDDW)
• Predictive factors for pain relief after endoscopic ultrasound-guided upper plexus neurolysis., 21th United European Gastroenterology Week (UEGW),   2013 10 , 21th United European Gastroenterology Week (UEGW)
• Differential diagnosis of SMT and evaluation of malignant potential GISTS by contrast enhanced harmonic EUS, 21th United European Gastroenterology Week (UEGW),   2013 10 , 21th United European Gastroenterology Week (UEGW)
• Lecture “Diagnosis of diffuse liver diseases.”, Medical ultrasound society, Singapore 11th Annual Seminar in conjunction with AFSUMB Workshop 2013,   2013 09 , Medical ultrasound society, Singapore 11th Annual Seminar in conjunction with AFSUMB Workshop 2013
• Final analysis of GIDEON (Global Investigation of therapeutic DE-cisions in hepatocellular carcinoma and Of its treatment with sorafeNib) in>3000 sorafenib-treated patients: prognostic value of baseline characteristics and staging systems, Poster presented at the European Cancer Congress 2013 (EC-CO-ESMO-ESTRO),   2013 09 , Poster presented at the European Cancer Congress 2013 (EC-CO-ESMO-ESTRO)
• Sorafenib treatment for non-hypervascular hepatocellular carcinoma, Seventh Annual Conference International Liver Cancer Association (ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Association (ILCA)
• The factors related to the vascularization of border line lesions detected as low intensity on hepatobiliary phase image of GD-EOB-DTPA MRI, Seventh Annual Conference International Liver Cancer Association (ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Association (ILCA)
• Updated results from phase1/2 trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, and biomarker correlative analyses in patients (Pts) with advanced hepatocellular carcinoma (HCC)., Seventh Annual Conference International Liver Cancer Association (ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Association (ILCA)
• Effects on survival prognosis by peretinoin, an acyclic retinoid: five-year follow-up of phase 2/3 randomized placebo-controlled trial., Seventh Annual Conference International Liver Cancer Association (ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Association (ILCA)
• Invited Lecture“Resection vs. ablation in very early HCC”, Seventh Annual Conference International Liver Cancer Association (ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Association (ILCA)
• A randomized, double-blind, multicenter phase 3 study of Brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization (TACE)in patients with unresectable hepatocellular carcinoma (HCC): Initial results., Seventh Annual Conference International Liver Cancer Association (ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Association (ILCA)
• Validation of staging systems for hepatocellular carcinoma: a comparison of the Bm-Jis score, the Jis score and the Bclc staging, Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
• Regional differences in treatment history, practices and outcomes: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib), Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
• Unique association between global dna hypomethylation and chromosomal alterations in human hepatocellular carcinoma., Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA),   2013 09 , Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
• Estimation of EUS features of choronic pancreatitis in comparison with clinical symptoms, International Pancreatic Research Forum 2013 (IPRF),   2013 07 , International Pancreatic Research Forum 2013 (IPRF)
• Invited Lecture “Interventional and contrast-enhanced EUS for pancreatobiliary diseases.”, Program of WFUMB COE Launching Workshop,   2013 07 , Program of WFUMB COE Launching Workshop
• Invited Lecture “Ultrasound elastography for non-invasive diagnosis of liver fibrosis.”, Program of WFUMB COE Launching Workshop,   2013 07 , Program of WFUMB COE Launching Workshop
• Invited Lecture “Imaging assessment of tumor response” “Controversial issues in early HCC”, The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2013 07 , The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Invited Lecture “What is TACE failure/refractory? Literature update and arriving at consensus” “EPOIHCC”, The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2013 07 , The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Invited Lecture “Treatment strategy for early stage of HCC” “APPLE Consensus Workshop”, The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2013 07 , The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Invited Lecture “Sorafenib in patients with liver dysfunction:Final analysis of GIDEON” “Unresolved Issues for Advanced HCC ”, The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2013 07 , The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Invited Lecture “How to evaluate treatment response in HCC: a mRESIST criterion enough?” “Unresolved Issues for Advanced HCC ”, The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2013 07 , The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Invited Lecture “New druggable targets in HCC” “Early Morning Work Shop 1 II. Hepatocellular Carcinoma: Genomics, Pathways & Targets”, The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2013 07 , The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Role of contrast-enhanced harmonic EUS in differentiating malignant from benign lymphadenopathy, Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013),   2013 06 , Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)
• The role of EUS in diagnosis and treatment of autoimmune pancreatitis, Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013),   2013 06 , Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)
• Quantitative assessment of liver fat with dual energy CT: comparison with MR spectroscopy, Computer Assisted Radiology and Surgery, 27th Intemational Congress and Exhibition,   2013 06 , Computer Assisted Radiology and Surgery, 27th Intemational Congress and Exhibition
• Regoranib in patients with hepatocellular carcinoma (HCC) progressing following Sorafenib: an ongoing randomized, double-blind, phase Ⅲ trial, Cheng AL, Finn R, Kudo M, Llovet JM, Qin S, Berre ML, Krissel H, Bruix J, American Society of Clinical Oncology (ASCO) 49th Annual Meeting,   2013 05 31
• Special Lecture “a) Liver (Strain)” “Elastography”, 14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013,   2013 05 , 14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013
• Coordinator: Elastography, 14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013,   2013 05 , 14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013
• Diagnostic performance of liver fibrosis with real-time tissue elastography in chronic viral hepatitis C. International Symposium“Elastography of the liver in Asia”, The 86th Annual Scientific Meeting of the Japan Society of Ultrasonics in Medicine,   2013 05 , The 86th Annual Scientific Meeting of the Japan Society of Ultrasonics in Medicine
• Time trends for helicobactor pylori eradication rate of the first-line and second-line Japanese regimens and clarithromycin resistance., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• Verrucous antral gastritis is not related to H. pylori-positive chronic gastritis, but is related to a high BMI and barrett's esophagus., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• Role of contrast-enhanced harmonic EUS in differentiating malignant from benign lymphadenopathy., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• EUS-guided drainage for treatment of postoperative complications after pancreatic surgery., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• The clinical characteristics and endoscopic treatment of hemorrhagic duodenal varices., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• Heat shock protein 27 expression is inversely correlated with intraepithelial neoplasia and positively correlated with poor differentiation of gastris cancer., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• Noninvasive assessment of liver fibrosis by measurement of LF index in patients with chronic viral hepatitis., Digestive Disease Week(DDW) 2013,   2013 05 , Digestive Disease Week(DDW) 2013
• Chair "Luncheon Seminar; Jordi Bruix “Recent progress of chemotherapy for HCC”, Masatoshi Kudo, The 8th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences,   2013 02 01 , 招待有り
• First-line Brivanib (BRIV) Versus Sorafenib (SOR) in Unresectable, Advanced Hepatocellular Carcinoma (HCC): Asia/Non-Asia Survival Results in Phase 3 BRISK-FL Study, Asian Pacific Association for the Study of the Liver (APASL) 2013,   2013 , Asian Pacific Association for the Study of the Liver (APASL) 2013
• Comparison of different proton pump inhibitors (PPI)in helicobacter pylori eradication., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• A prospective randomized controlled study of a rebamipid monotherapy in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• Albumin levels can be a predictive factor for the short-term complications after percutaneous endoscopic gastrostomy in retrospective study., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• The clinical characteristics and endscopic treatment of duodenal varices., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• Utility of EUS-guided gallbladder drainage for rescue treatment of malignant biliary obstruction., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• Endoscopic submucosal dissection for the colorectum: usefulness and feasibility., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• Trans-catheter endoscopy for pancreaticobiliary duct diseases., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• A prospective feasibility study on EUS guided broad plexus neurolysis in combination with celiac ganglion neurolysis., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• Diffrential diagnosis of SMT and evaluation of malignant potentioal gists by contrast enhanced harmonic EUS., Asian Pacific Digestive Week (APDW) 2012,   2012 12 , Asian Pacific Digestive Week (APDW) 2012
• Invited Lecture “Sonazoid-enhanced US in the management of HCC.”, The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB),   2012 11 , The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
• Invited Lecture “Double contrast US for surveillance of HCC.”, The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB),   2012 11 , The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
• Invited Lecture “Interventional US for liver tumors.”, The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB),   2012 11 , The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
• HCC challenges: Definition on TACE failure and refractoriness., HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management-,   2012 11 , HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management-
• Chairs: Session 5: Diagnosis and treatment of HCV-associated HCC, The 10th JSH Single Topic Conference”Hepatitis C: Best practice based on science.”,   2012 11 , The 10th JSH Single Topic Conference”Hepatitis C: Best practice based on science.”
• GIDEON (Global Investigation of therapeutic DEcisions in he-patocellular carcinoma and Of its treatment with SoraeNib) second interim analysis: subgoup analysis by disease aetiology., The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD),   2012 11 , The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
• Invited Lecture “The potential of surveillance -the Japanese experience.”, Falk Symposium 186,   2012 10 , Falk Symposium 186
• Comparison of four different proton pump inhibitors in helicobacter pylori eradication treatment., 20th United European Gastroenterology Week (UEGW),   2012 10 , 20th United European Gastroenterology Week (UEGW)
• Usefulness of rebamipide for endoscopic submucosal dissection (ESD) -induces ulcer in early gastric cancer: prospective randomized study., 20th United European Gastroenterology Week (UEGW),   2012 10 , 20th United European Gastroenterology Week (UEGW)
• GIDEON (Global Investigation of therapeutic DEcisions in he-patocellular carcinoma and of its treatment with soraeNib) second interim analysis: subgoup analysis by disease aetiology., ESMO 2012,   2012 09 , ESMO 2012
• Final results of a randomized Phase II study of TSU-68 after transarterial chemoembolisation in Japanese patients with unresectable hepatocellular carcinoma. Chemoembolization., ESMO 2012,   2012 09 , ESMO 2012
• Phase I/II trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC), ESMO 2012,   2012 09 , ESMO 2012
• Invited Lecture "Liver biopsy: Is it useful for staging?", Sixth Annual Conference International Liver Cancer Association(ILCA),   2012 09 , Sixth Annual Conference International Liver Cancer Association(ILCA)
• Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: global comprison of outcomes by staging system., Sixth Annual Conference International Liver Cancer Association(ILCA),   2012 09 , Sixth Annual Conference International Liver Cancer Association(ILCA)
• Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: assessment of baseline and on-treatment alpha-fetoprotein levels in the phase III Brisk-Ps study., Sixth Annual Conference International Liver Cancer Association(ILCA),   2012 09 , Sixth Annual Conference International Liver Cancer Association(ILCA)
• The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma., Sixth Annual Conference International Liver Cancer Association(ILCA),   2012 09 , Sixth Annual Conference International Liver Cancer Association(ILCA)
• Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase III Brisk-Ps Study., Sixth Annual Conference International Liver Cancer Association(ILCA),   2012 09 , Sixth Annual Conference International Liver Cancer Association(ILCA)
• Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE Study: An interim analysis of HCC burden of illness in the Asia-Pacific (AP) cohort., International Society for Pharmaco-economics and Outsomes Research (ISPOR) 5th Asia-Pacific Conferen,   2012 09 , International Society for Pharmaco-economics and Outsomes Research (ISPOR) 5th Asia-Pacific Conferen
• Invited Lecture “Controversies on the role of TACE” “Intermediate HCC”, Advances in HCC management in Asia,   2012 08 , Advances in HCC management in Asia
• Invited Lecture “Real life experience with Nexavar: GIDEON 2nd IA” “Advanced HCC: rich evidence for Nexavar”, Advances in HCC management in Asia,   2012 08 , Advances in HCC management in Asia
• Chairs：International Session 1: Hepato-biliary-pancreatic, The 10th Annual Meeting of Japanese Society of Medical Oncology,   2012 07 , The 10th Annual Meeting of Japanese Society of Medical Oncology
• Invited Lecture "Japanese treatment algorithm." Session XII "Algorithm Consensus Discussion", The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2012 07 , The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Chair: Session XII: Algorithm Consensus Discussion, The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2012 07 , The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Chair: Session XI: Novel Therapy ＆ Ongoing Trials, The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2012 07 , The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Chair: Management of TACE Failure, Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC),   2012 07 , Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC)
• Chair: Evening Symposium: Recent Observations in the mangement of HCC, The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2012 07 , The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Invited Lecture "Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: an analysis of the Asian cohort." Evening Symposium "Recent observation in the management of HCC", The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2012 07 , The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Phase 1b dose-escalation study of a phase 2 randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)., ASCO 2012 Annual Meeting,   2012 06 , ASCO 2012 Annual Meeting
• Effect of rebamipide for endoscopic submucosal dissection (ESD)-induced ulcer in early gastric cancer: a randomized controlled trial., Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• A prospective feasibility study on EUS guided broad plexus in combination of celiac ganglion neurolysis in pancreatic cancer pain, Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• Usefulness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: comparison with contrast-enhanced CT, Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced sonography using perfluorocarbon microbubbles (sonazoid), Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma, Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• Activation of JNK in the Non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma, Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• Percutaneous endoscopic gastrostomy with gastropexy greatly reduces the risk of peristomal infection and eases pain after the operation., Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• Detection of small concomitant carcinomas distinct from intraductal papillary mucinous neoplasms under surveillance of the whole pancreas using EUS, Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• Novel association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma, Digestive Disease Week(DDW) 2012,   2012 05 , Digestive Disease Week(DDW) 2012
• Invited Lecture "CEUS as a screening tool of HCC in cirrhotic liver.", ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging,   2012 05 , ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging
• Invited Lecture "CEUS in the pancreatobiliary intervention.", ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging,   2012 05 , ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging
• Role of contrast-enhanced harmonic EUS in differentiating malignant from benigh lymphadenopathy., The 83rd Congress of the Japan Gastroenterological Endoscopy Society,   2012 05 , The 83rd Congress of the Japan Gastroenterological Endoscopy Society
• EUS-guided drainage for biliary obstruction after unsuccessful ERCP. International Symposium “EUS-FNA: Current status and new developments”, Tokyo,   2012 05 , Tokyo
• A prospective study feasibility combination of EUS guided broad plexus-neuro lysis and celiac ganglion neurolysis. International Symposium “EUS-FNA: Current status and new developments”, The 83rd Congress of the Japan Gastroenterological Endoscopy Society,   2012 05 , The 83rd Congress of the Japan Gastroenterological Endoscopy Society
• A prospective study feasibility combination of EUS guided broad plexus-neuro lysis and celiac ganglion neurolysis. Symposium “EUS-FNA: Current status and new developments”,   2012 05
• Invited Lecture "Endoscopic ultrasound in the differential diagnosis of cystic pancreatic lesions: do we always need it?", EFSUMB Annual Meeting EUROSON 2012,   2012 04 , EFSUMB Annual Meeting EUROSON 2012
• Invited Lecture "The role of TACE & Nexavar in HCC treatment.", HCC Expert Symposium on Tumor Therapy,   2012 04 , HCC Expert Symposium on Tumor Therapy
• Invited Lecture "Management of hepatocellular carcinoma.,   2012 04
• The management of HCC in Japan. The role of TACE in management of HCC: Korea and Japan, 2012 BESTT symposium,   2012 04 , 2012 BESTT symposium
• Observed patterns of systemic therapy use in hepatocellular carcinoma (HCC) patients from the multinational HCC BRIDGE Study: Results of a second interim analysis., 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL),   2012 04 , 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
• GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with SoraenibB) Second interim analysis: Clinical findings in Child-pugh B score subgourps., 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL),   2012 04 , 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
• Opening Lectures “Contrast-enhanced EUS of pancreatic tumors”, EFSUMB Annual Meeting EUROSON 2012,   2012 04 , EFSUMB Annual Meeting EUROSON 2012
• Management of hepatocellular carcinoma: Recent progress., the 42nd Annual Meeting of GEST and The 21st Annual Meeting of DEST,   2012 03 , the 42nd Annual Meeting of GEST and The 21st Annual Meeting of DEST
• From JSH treatment guideline to combination therapy., HCC Expert Meeting ?New Advances in HCC Management,   2012 03 , HCC Expert Meeting ?New Advances in HCC Management
• Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma., AACR 103rd Annual Meeting 2011,   2012 03 , AACR 103rd Annual Meeting 2011
• Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): second interim analysis [1500 patients] of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study., SIR 2012,   2012 03 , SIR 2012
• Real life experience with Sorafenib: GIDEON, the largest prospective global study in HCC. Satellite symposium Advances in HCC management : from diagnosis to treatment, The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012),   2012 02 , The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
• Hepatocellular carcinoma. APASL-AASLD symposium-When east meets west: Management of the complications of cirrhosis, The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012),   2012 02 , The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
• Evolving strategies on the treatment of HCC: Physician’s perspective., The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012),   2012 02 , The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
• CEUS, EOB-MRI, targeted therapy and Japanese HCC guideline., Cancer Genomics: a way to personalized medicine,   2012 02 , Cancer Genomics: a way to personalized medicine
• Observations of hepatocellular carcinoma (HCC) management ptterns from the Global HCC BRIDGE Study: An interim analysis of the Asia-Pacific (AP) Cohort., Asian Pacific Association for the Study of the Liver (APASL) 2012,   2012 02 , Asian Pacific Association for the Study of the Liver (APASL) 2012
• GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its Treatment with sorafeNib) second interim analysis (IA): subgroup analysis by race., Asian Pacific Association for the Study of the Liver (APASL) 2012,   2012 02 , Asian Pacific Association for the Study of the Liver (APASL) 2012
• Invited Lecture "Intravascular treatment (TACE, HAIC)", 10th International Conference ofthe Asian Clinical Oncology Society (ACOS),   2012 , 10th International Conference ofthe Asian Clinical Oncology Society (ACOS)
• Estination of EUS features of chronic pancreatitis in comparison with clinical symptoms, The 83rd Congress of the Japan Gastroenterological Endoscopy Society,   2012 , The 83rd Congress of the Japan Gastroenterological Endoscopy Society
• Observations of Hepatocellular Carcinoma (HCC) Management Patterns from the Global HCC BRIDGE Study: First Characterization of the Full Study Population., ASCO 2012 Annual Meeting,   2012 , ASCO 2012 Annual Meeting
• Percutaneous endoscopic gastrostomy with gastropexy greatly reduces the risk of peristomal infection., Clinical Nutrition Week 2012,   2012 01 , Clinical Nutrition Week 2012
• Percutaneous Endoscopic Gastrostomy with Gastropexy Greatly Reduces the Risk of Peristomal Infection, CNW2012 (Clinical Nutrition Week) (ASPEN),   2012 01 , CNW2012 (Clinical Nutrition Week) (ASPEN)
• Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): second interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study., 2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012),   2012 01 , 2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)
• Second interim analysis of GIDEON (Global Investigation of therapeutic DEcisions in unresectable hepatocellular carcinoma and Of its treatment with sorafeNib): differences in adverse-event reporting across physician specialties., 2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012),   2012 01 , 2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)
• Diagnosis of gross pathology of HCC: Value of Kupffer phase of Sonazoid-enhanced US., 3rd Asia-Pacific Conference on Ultrasound Contrast Imaging, 13th International Symposium on Ultrasou,   2011 12 , 3rd Asia-Pacific Conference on Ultrasound Contrast Imaging, 13th International Symposium on Ultrasou
• Molecular targeting therapy., Session “HCV and HCC I”, The 7th APASL single topic conference,   2011 12 , Session “HCV and HCC I”, The 7th APASL single topic conference
• Clinical staging systems for HCC. Symposium “HCC staging and response assessment”, APASL 2nd Hepatocellular catcinmoma conference (APASL STC),   2011 12 , APASL 2nd Hepatocellular catcinmoma conference (APASL STC)
• Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: An interim analysis from a South Korean Referral Center., APASL 2nd Hepatocellular catcinmoma conference (APASL STC),   2011 12 , APASL 2nd Hepatocellular catcinmoma conference (APASL STC)
• How to Use Liver Imaging Reporting and Data System (LI-RADS) in Patients with Hepatocellular Carcinoma (HCC), RSNA - Educational Poster Session,   2011 11 , RSNA - Educational Poster Session
• Analysis of Elasticity Image of Chronic Hepatitis Based on Dynamic Model of Fibrosis Progression., The 32nd Symposium on Ultrasonic Electronics (USE 2011),   2011 11 , The 32nd Symposium on Ultrasonic Electronics (USE 2011)
• Lecture “Sonazoid-enhanced US in the management of HCC.”, 9th ABDA teaching course in conjuction with AFSIMB Workshop,   2011 11 , 9th ABDA teaching course in conjuction with AFSIMB Workshop
• Lecture “Interventional EUS for pancreatobiliary tumors.”, 9th ABDA teaching course in conjuction with AFSIMB Workshop,   2011 11 , 9th ABDA teaching course in conjuction with AFSIMB Workshop
• Second interim analysis of GIDEON (Global investigation of therapeutic decisions in unresectable HCC [UHCC] and of its treatment with Sorafenib): subgroup analysis by initial sorafenib (Sor) dose., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Second interim analysis of GIDEON (Global investigation of ther-apeutic decisions in unresectable HCC [UHCC] and of its treatment with Sorafenib): multiregional variation in patient (pt) characteristics, previous treatment history, and sorafenib (Sor) use, The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Assessment of hepatobiliary phase Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection ability versus MDCT., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Impact on aberrant methylation of an unique subset of tumor suppressor genes on the initial steps of human hepatocarcinogenesis., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Phase I study of Sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Efficacy and safety of sorafenib for hepatocellular carcinoma: a multicenter retrospective study in Japan., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Drastic improvement of survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: Comparion with multidetector row CT., The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2011 11 , The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Updated Liver Function Imaging by MRI and CT: Quantification Analysis for Hepatic Steatosis, Fibrosis, and Siderosis., RSNA - Educational Poster Session,   2011 11 , RSNA - Educational Poster Session
• Advanced CT Evaluation for Liver Imaging: Perfusion CT, Ultrafast Arterial Scanning of Whole Liver and Dual-Energy CT., RSNA - Educational Poster Session,   2011 11 , RSNA - Educational Poster Session
• Atypical Imaging of Liver Hemangioma: Pictorial Review by Gd-EOB-DTPA-enhanced MRI, Dynamic CT and Sonography., RSNA - Scientific Poster Session,   2011 11 , RSNA - Scientific Poster Session
• Hepatocellular Carcinoma: Pictorial Review for the Planning of Therapy and the Evaluation after Therapy., RSNA - Educational Poster Session,   2011 11 , RSNA - Educational Poster Session
• Evaluation of Angiogenesis after Antiangiogenic Therapy Using Liver CT Perfusion: Additional Detailed Capillary-level Hemodynamics in Patients with Advanced Hepatocellular Carcinoma., RSNA - Scientific Poster Session,   2011 11 , RSNA - Scientific Poster Session
• Evaluation of Degree of Hepatic Fibrosis: Comparison T1 Mapping Technique of Gd-EOB-DTPA Enhanced MRI with US Elastography., RSNA - Scientific Poster Session,   2011 11 , RSNA - Scientific Poster Session
• Mechanical model analysis for quantitative evaluation of liver fibrosis based on real-time tissue elastography., The 10th International Tissue Elasticity Conference,   2011 10 , The 10th International Tissue Elasticity Conference
• “Establishing treatment algorithms for hepatocellular carcinoma: What tests do we need?” , Symposium “When East meets West: Management of hepatocellular carcinoma”,, 19th United European Gastroenterology Week (UEGW),   2011 10 , 19th United European Gastroenterology Week (UEGW)
• Verrucous antral gastritis is not related to H. pylori-positive chronic gastritis, but is related to a high BMI., APDW2011,   2011 10 , APDW2011
• Diagnostic utility of contrast enhanced harmonic EUS imaging in patients with submucosal tumor of gastrointersinal tract., 19th United European Gastroenterology Week (UEGW),   2011 10 , 19th United European Gastroenterology Week (UEGW)
• Long duration of stable disease may improve the overall survival in the patients with advanced hepa-tocellular carcinoma treated with Soraenib., United European Gastroenterology Week (UEGW),   2011 10 , United European Gastroenterology Week (UEGW)
• Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma; comparion eith MDCT., 19th United European Gastroenterology Week (UEGW),   2011 10 , 19th United European Gastroenterology Week (UEGW)
• Endoscopic ultrasonograph (EUS)-guided choledochoduo-denostomy and hepatogastrostomy for treatment of biliary obstruction., 19th United European Gastroenterology Week (UEGW),   2011 10 , 19th United European Gastroenterology Week (UEGW)
• Hepatocellular carcinoma: Recent development of molecular targeted agent.,   2011 10
• Does wire guided cannulation reduce the risk of pancreatic disorder?, Asian Pacific Digestive Week (APDW) 2011,   2011 10 , Asian Pacific Digestive Week (APDW) 2011
• Endoscopic ultrasonography (EUS)-guided biliary drainage for treatment of biliary obstruction., Asian Pacific Digestive Week (APDW) 2011,   2011 10 , Asian Pacific Digestive Week (APDW) 2011
• Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma., 70th Annual Meeting of the Japanese Cancer Association,   2011 10 , 70th Annual Meeting of the Japanese Cancer Association
• Second interim results of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its Treatment with sorafeNib) study: Barcelona-Clinic Liver Cancer (BCLC) stage subgroup analysis., 16th ECCO-36th ESMO Multidisciplinary cancer congress,   2011 09 , 16th ECCO-36th ESMO Multidisciplinary cancer congress
• Observations of hepatocellular carcinoma (HCC) management patterns from the HCC BRIDGE Study: An interim analysis of the European cohort., 16th ECCO-36th ESMO Multidisciplinary cancer congress,   2011 09 , 16th ECCO-36th ESMO Multidisciplinary cancer congress
• Preferred strategies for inclusion in comprehensive liver cancer control in Asia., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Long duration of stable disease may improve the overall survival in the patients with advanced hepatocellular carcinoma treated with Sorafenib., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Phase I study of Sorafenib in combination with low-dose cisplatin and flurouracil intra-arterilal infusion chemotherapy., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Assessment of hepatobiliary phase Gd-EOB-DTPA-Enhanced MRI for HCC and dysplastic nodules and comparison of detection ability versus MDCT., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Second interim analysis of GIDEON (Global investigation of therapeutic decisions in HCC and of its treatment with Sorafenib): Regional variation in patient characteristics and treatment history., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Benefit and nonsense in oncologic follow-up imaging and the role of US., 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011,   2011 09 , 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
• A randomized, double-blind, placebo-controlled phase III study (EVOLVE-1) evaluating the efficacy and safety of everolimus in advanced HCC after failure of sorafenib treatment., International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Observed Patterns of Systemic Therapy Use in Hepatocellular Carcinoma (HCC) Patients From the Multinational HCC BRIDGE Study: An Initial Overall Analysis, International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Observations of Hepatocellular Carcinoma (HCC) Management Patterns From the Multinational HCC BRIDGE Study: An Interim Overall Analysis, International Liver Cancer Association Fifth Annual Conference (ILCA) 2011,   2011 09 , International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
• Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib)., 66th Annual Meeting of the German Society for Digestive and Metabolic Diseases,   2011 09 , 66th Annual Meeting of the German Society for Digestive and Metabolic Diseases
• Future prospectcs of ultrasound diagnosis for diffuse liver disease. Symposium“Hitachi Aloka Medical Ltd.: The next generation in high-resolution imaging technology and elastography”, 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011,   2011 08 , 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
• US-guided ablation of HCC. “US-guided tumor theraphy”, 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011,   2011 08 , 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
• Lecture “Future prospects of ultrasound diagnosis for diffuse liver disease.", The next generation in high-resolution imaging technology and elastgraphy,   2011 08 , The next generation in high-resolution imaging technology and elastgraphy
• Interventional EUS for pancreatic tumours., 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011,   2011 08 , 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
• Cirrhotic liver., 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011,   2011 08 , 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
• Comparative study between EUS-guided celiac plezus neurolysis and EUS-guided broad neurolysis. VTRシンポジウム「Interventional EUSの最前線」,   2011 08
• Special Lecture “Design and conduct of clinical trials for the design and rational of clinical tirals for the combination of hepatic arterial infusion chemotherapy with molecular targeted agents.”, The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2011 07 , The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Special Lecture “Current situation of HCC management in Japan.”, The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2011 07 , The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Special Lecture “EVOLVE-1 trial.”, The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2011 07 , The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Special Lecture “RECICL.”, The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE),   2011 07 , The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
• Phase I/II study of Sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy. International Session “Hepato-biliary-pancreatic Cancer”, The 9th Annual Meeting of Japanese Society of Medical Ocology,   2011 07 , The 9th Annual Meeting of Japanese Society of Medical Ocology
• Special Invited Lecture “Sonazoid-enhanced US in the management of HCC”, XV Congress of the Latin American Federation for Ultrasound in Medicine and Biology (FLAUS),   2011 06 , XV Congress of the Latin American Federation for Ultrasound in Medicine and Biology (FLAUS)
• Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients., American Society of Clinical Oncology (ASCO) 2011 Annual Meeting,   2011 06 , American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
• GIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma [HCC] And Of Its Treatment With Sorafenib) 2nd interim analysis in >1500 patients: clinical findings in patients with liver dysfunction., American Society of Clinical Oncology (ASCO) 2011 Annual Meeting,   2011 06 , American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
• Phase 3 trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)., American Society of Clinical Oncology (ASCO) 2011 Annual Meeting,   2011 06 , American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
• Randomized trial of axitinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) following failure of one prior antiangiogenic therapy., American Society of Clinical Oncology (ASCO) 2011 Annual Meeting,   2011 06 , American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
• Luncheon “Hepatocellular carcinoma: prevention and treatment by interferon.”, The Japanese Society for Interferon and Cytokine Research-The Japanese Society for Macrophage Molecu,   2011 05 , The Japanese Society for Interferon and Cytokine Research-The Japanese Society for Macrophage Molecu
• Special Invited Lecture “Sonazoid-enhanced US in the management of HCC”, The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM),   2011 05 , The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)
• Role of EUS in detection and follow-up of intraductal papillary mucinous neoplasms and concomitant invasive carcinomas., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• Dynamic imaging of gallbladder diseases by contrast-enahanced harmonic EUS., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• EUS-guided gallbladder drainage as an alternative treatment for malignant biliary obstruction after unsuccessful ERCP: Outcomes of long term follow-up., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• P38alpha inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• Assessment of hepatobilliary phase Gd-EOB-DTPA-Enhanced MRI for HCC and borderline lesions and comparison of detection ability versus MDCT., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• The usefulness of helicobacter pylori eradication therapy for the healing artifical gastric ulcer after endoscopic submucosal dissection for early gastric cancer., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• Evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• Prevention of delayed bleeding after endoscopic submucosal dissection (ESD) for gastric tumors., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• Peginterferon alfa-2a (40KD) plus ribavirin for the treatment of patients with chronic hepatitis C and compensated liver cirrhosis in Japan., Digestive Disease Week (DDW) 2011Chicago, USA,   2011 05 , Digestive Disease Week (DDW) 2011Chicago, USA
• Special Focus Session “Update on endoscopic USG: hoe much for imaging, needling, or therapy?”, The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM),   2011 05 , The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)
• Contrast enhanced harmonic EUS imaging of submucosal tumor of gastrointestinal tract., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• EUS-guided broad plexus-neurolysis over the superior mesenteric artery., Digestive Disease Week (DDW) 2011,   2011 05 , Digestive Disease Week (DDW) 2011
• Expression levels of EMT-related genes in hepatocellular carcinoma., AACR 102th Annual Meeting 2011,   2011 04 , AACR 102th Annual Meeting 2011
• Serum concentrations of Angiogenesis-related molecules in Patients with Pancreatic Cancer., AACR 102th Annual Meeting 2011,   2011 04 , AACR 102th Annual Meeting 2011
• GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study first interim results, Sorafenib dosing across regions and disease subgroups., 46th Annual Meeting of the European Association for the Sudy of the Liver (EASL),   2011 03 , 46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
• Stakeholder involvement in priority setting of strategies to improve liver cancer control policy in Asia., 46th Annual Meeting of the European Association for the Sudy of the Liver (EASL),   2011 03 , 46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
• Special lecture “Treatment guideline of hepatocellular carcinoma: Asian perspective.”, Asan Liver Center Opening Symposium,   2011 03 , Asan Liver Center Opening Symposium
• Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): first interim analysis of the Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib (GIDEON) study., SIR 36th Annual Scientific 2011 Meeting,   2011 03 , SIR 36th Annual Scientific 2011 Meeting
• Special lecture “Interventional US for pancreatic malignancy.”, Innovative Practive in Ultrasound With Live Demonstration,   2011 02 , Innovative Practive in Ultrasound With Live Demonstration
• Special lecture “Sonazoid enhanced US for the management of liver cancer.”, Innovative Practive in Ultrasound With Live Demonstration,   2011 02 , Innovative Practive in Ultrasound With Live Demonstration
• Special lecture "Double contrast US for surveillance of hepatoma.”, Innovative Practive in Ultrasound With Live Demonstration,   2011 02 , Innovative Practive in Ultrasound With Live Demonstration
• GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) interim results: Child-Pugh status subgroup analysis., The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL),   2011 02 , The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL)
• Special lecture “Contrast enhanced endoscopic ultrasound value in the diagnosis of small pancreatic cancer.”, World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop,   2011 02 , World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop
• Special lecture “Sonazoid-enhanced US for hepatoma: Value of defect re-perfusion of imaging.”, World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop,   2011 02 , World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop
• Special lecture “Double contrast US for surveillance of hepatoma.”, World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop,   2011 02 , World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop
• First interim results of the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma (HCC) and Of its treatment with sorafeNib (GIDEON) study: Oncologists and non-oncologists appear to use sorafenib (Sor) differently in the management of, 2011 Gastrointeritinal Cancers Symposium (ASCO-GI 2011),   2011 01 , 2011 Gastrointeritinal Cancers Symposium (ASCO-GI 2011)
• Special lecture “On going trial and future role of molecular targeted agent in HCC.”, All India Institute of Medical Science (AIIMS),   2010 11 , All India Institute of Medical Science (AIIMS)
• Special lecture “Current role of sorafenib in the management of HCC.”, All India Institute of Medical Science (AIIMS),   2010 11 , All India Institute of Medical Science (AIIMS)
• Special lecture “Interventional US for GI & pancreatico biliary disease.”, 9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology,   2010 11 , 9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology
• Special lecture “Endoscopic CEUS for pancreatic lesions.”, 9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology,   2010 11 , 9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology
• Special lecture “Sonazoid-enhanced US in the management of HCC.”, Medanta University Hospital,   2010 11 , Medanta University Hospital
• Special lecture “Imaging diagnosis of early-stage HCC: Role of EOB-MRI.”, Medanta University Hospital,   2010 11 , Medanta University Hospital
• Special lecture “Molecular targeted therapy for HCC: Current situation and future prospective.”, Medanta University Hospital,   2010 11 , Medanta University Hospital
• Percutaneous endoscopic gastrosotmy with Funada-style gastropexy, an easy and safe technique, greatly reduce the risk of peristomal infection (Travel Grant), UEGW 2010,   2010 10 , UEGW 2010
• Colonoscopic polypectomy in the very elderly, is it safe?, UEGW 2010,   2010 10 , UEGW 2010
• Special lecture “Imaging diagnosis of early HCC.”, 4th International Forum for Liver MRI,   2010 10 , 4th International Forum for Liver MRI
• First Interim Results of The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) Study., Europian Society for Medical Oncology (ESMO) congress,   2010 10 , Europian Society for Medical Oncology (ESMO) congress
• Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib)., American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010,   2010 10 , American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010
• Examination of factors of delayed bleeding after endoscopic submucosal dissection (ESD) for gastric tumors., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• The efficacy of helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection early gastric cancer: Prospective randomized study., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Is the combination therapy of ecabet sodium and proton pump inhibitor (PPI) useful for treating the artificial ulcer after endoscopic submucosal dissection (ESD) treatment of early gastric cancer? : Prospective randomized study., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Estimation of malignant potential gist by contrast-enhanced harmonic endoscopic ultrasonography., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Can Gd-EOB-DTPA-enhanced MRI discriminate between dysplastic nodules and early-to- well-differentiated HCC?, 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Usefulness of hepatocyte phase imaging of Gd-EOB-DTPA-MRI in detecting borderline lesions which are difficult to detect other imaging modalities., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Characterization of small pancreatic neoplasms by contrast-enhanced harmonic EUS., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Utility of evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS using Sonazoid., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit., 18th United European Gastroenterology Week (UEGW) 2010,   2010 10 , 18th United European Gastroenterology Week (UEGW) 2010
• The usefulness of the post-vascular phase of contrast-enhanced ultrasonography with Sonazoid in the evaluation of gross type of hepatocellular carcinoma., American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010,   2010 10 , American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010
• Luncheon workshop “Novel concepts in HCC staging.”, 4th Annual Conference International Liver Cancer Association (ILCA),   2010 09 , 4th Annual Conference International Liver Cancer Association (ILCA)
• Special Lecture “Management and outcome of HCC in Japan: Analysis of 51,430 HCC cases registerd in nationwide survey program of Liver Cancer Study Group of Japan.”, 4th Annual Conference International Liver Cancer Association (ILCA),   2010 09 , 4th Annual Conference International Liver Cancer Association (ILCA)
• The usefulness of helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection for early gastric cancer., Asian Pacific Digestive Week (APDW) 2010,   2010 09 , Asian Pacific Digestive Week (APDW) 2010
• Special lecture “Ultrasound diagnosis of pancreatic tumors.”, 8 AFSUMB Workshop: 2010,   2010 08 , 8 AFSUMB Workshop: 2010
• Branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma in patients with liver cirrhosis., The 7th Japan-Korea Liver Symposium,   2010 07 , The 7th Japan-Korea Liver Symposium
• EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle., Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010,   2010 07 , Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
• Management of IPMNs by endoscopic ultrasonography., Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010,   2010 07 , Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
• Endoscopic ultrasound-guided drainage for pancreatic diseases. JPS Video Symposium 1 “Cutting edge endoscopic procedures for diagnosis and treatment of panvreatic diseases”, Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010,   2010 07 , Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
• Contrast-enhanced harmonic endosonography in diagnosing pancreatic diseases. JPS Symposium 1 “Recent advances in the imaging studies of pancreatic diseases”, Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010,   2010 07 , Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
• Workshop “Treatment algorithm for intermediate and advanced stage of HCC: Japan.”, The 1st Asia-Pacific Primary Liver Cancer Expert Meeting,   2010 07 , The 1st Asia-Pacific Primary Liver Cancer Expert Meeting
• Workshop “Report from working group.”, The 1st Asia-Pacific Primary Liver Cancer Expert Meeting,   2010 07 , The 1st Asia-Pacific Primary Liver Cancer Expert Meeting
• Special lecture “Clinical classification in Asia.”, Europian Association for the Study of the Liver,   2010 06 , Europian Association for the Study of the Liver
• Special lecture “Defect re-perfusion imaging for HCC.”, Korean Society of Ultrasound in Medicine 2010 Open,   2010 05 , Korean Society of Ultrasound in Medicine 2010 Open
• Special lecture “Sonazoid-enhanced US as a treatment-guidance for HCC.”, Korean Society of Ultrasound in Medicine 2010 Open,   2010 05 , Korean Society of Ultrasound in Medicine 2010 Open
• Special lecture “Imaging diagnosis of very early stage HCC.”, Seoul Laennec meeting 2010,   2010 05 , Seoul Laennec meeting 2010
• Special lecture “Management of HCC in Japan.”, Global HCC investigator’s meeting in Taiwan,   2010 05 , Global HCC investigator’s meeting in Taiwan
• EUS-guided choledochoduodenostomy followed by endoscopic antegrade biliary stenting via the fistula for treatment of obstructive jaundice with duodenal stenosis., 2010 Digestive Disease Week,   2010 05 , 2010 Digestive Disease Week
• EUS-guided gallbladder drainage for treatment of acute cholecystitis and obstructive jaundice., 2010 Digestive Disease Week,   2010 05 , 2010 Digestive Disease Week
• Special lecture “Imaging diagnosis of every stage HCC.”, Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo,   2010 04 , Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo
• Special lecture “Advanced in US techniques for treatment guidance for liver tumours.”, JPR 2010,   2010 04 , JPR 2010
• Special lecture “Enhanced sonography of hepatic nodules.”, JPR 2010,   2010 04 , JPR 2010
• Special Lecture “Contrast-enhanced US: its role in the management of HCC.”, 26th International Congress of Radiology,   2010 04 , 26th International Congress of Radiology
• Special Lecture “The use of TACE in the treatment of hepatocellular carcinoma.”, The 8th ASIA PACIFIC ONCOLOGY SUMMIT,   2010 03 , The 8th ASIA PACIFIC ONCOLOGY SUMMIT
• Special Lecture “Imaging diagnosis of early HCC: Recent advance.”, Choshu International Liver Smposium 2010,   2010 02 , Choshu International Liver Smposium 2010
• Special lecture “Earlier HCC diagnosis: US, CT and MRI aspects ?anatomopathological correlation―US aspects-.”, JPR 2010,   2010 , JPR 2010
• Malignancy grading of primary hepatocellular carcinoma by liver-specific contrast agent and hemodynamic alteration, Radiological Society of North America 2009 95th Scientific Assembly and Annual Meeting(RSNA),   2009 12 , Radiological Society of North America 2009 95th Scientific Assembly and Annual Meeting(RSNA)
• Contrast-enhanced harmonic endosonography in pancreatobiliary diseases., 11th International Symposium on Ultrasound Contrast Imaging,   2009 12 , 11th International Symposium on Ultrasound Contrast Imaging
• Special Lecture “RF Ablation of HCC under CEUS guideline.”, 11th International Symposium on Ultrasound Contrast Imaging,   2009 12 , 11th International Symposium on Ultrasound Contrast Imaging
• Special Lecture “Defect-Re-perfusion imaging for liver tumors and CEUS in the diagnosis of macroscopic classification of HCC.”, 11th International Symposium on Ultrasound Contrast Imaging,   2009 12 , 11th International Symposium on Ultrasound Contrast Imaging
• Special Lecture “EOB-MRI in liver tumors: Its role in differentiation berween early HCC and dysplastic nodule.”, All India Institute of Medical Science (AIIMS),   2009 12 , All India Institute of Medical Science (AIIMS)
• Special Lecture and Live Demonstration“Contrast-enhanced US of liver tumors.”, Institute of Hepatobiliary and Pancreatic Science,   2009 12 , Institute of Hepatobiliary and Pancreatic Science
• Special Lecture “Management of HCC: Recent advances.”, Indian Society of Gastroenterology,   2009 12 , Indian Society of Gastroenterology
• Special Lecture “Recent advances in the imaging of HCC.”, 9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue,   2009 12 , 9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue
• Special Lecture “Management of HCC: Role of molecular targeted agents. ", 9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue,   2009 12 , 9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue
• Estimation of the malignant potential of gastrointestinal stromal tumors: for a precise management of SMT by CHE-EUS., UEGW,   2009 11 , UEGW
• Detection rates of pancreatic tumors according to location by contrast-enhanced ultrasonography, endosonography and multidetector row CT., East Meets West 40th Anniversary,   2009 11 , East Meets West 40th Anniversary
• Pancreas by EUS-guided in vivo microdialysis., East Meets West 40th Anniversary,   2009 11 , East Meets West 40th Anniversary
• EUS-assisted drainage of pancreatic duct for obstructive pancreatitis., East Meets West 40th Anniversary,   2009 11 , East Meets West 40th Anniversary
• Special Lecture “Hepatocellular Carcinoma in Japan: Epidemiology, Diagnosis and RF Ablatiom.”, “HBV Now in Asia” The 8th JSH Single Topic Conference by The Japan Society of Hepatolog (JSH),   2009 11 , “HBV Now in Asia” The 8th JSH Single Topic Conference by The Japan Society of Hepatolog (JSH)
• Special Lecture “Defect re-perfusion imaging for HCC.”, Italian Society of Ultrasound in Medicine (ISUM),   2009 11 , Italian Society of Ultrasound in Medicine (ISUM)
• Special Lecture “Consensus statement of management of HCC in Asia.”, 20th Asia Pacific Cancer Conference (APCC) 2009,   2009 11 , 20th Asia Pacific Cancer Conference (APCC) 2009
• Special Lecture “Ultrasound diagnosis of pancreatic tumors.”, 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB),   2009 11 , 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)
• Special Lecture “Color doppler imaging of liver tumors.”, 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB),   2009 11 , 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)
• Special Lecture “Sonazoid-enhanced US of Liver Tumors.”, 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB),   2009 11 , 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)
• Special Lecture “Radiological diagnosisi of very early-stage HCC.”, Mini-Symposium “Very-Early HCC”, American Association of Study of the liver Disease (AASLD),   2009 11 , Mini-Symposium “Very-Early HCC”, American Association of Study of the liver Disease (AASLD)
• EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle. Awarded as a (Best submit abstract), UEGW,   2009 11 , UEGW
• Estimation of the malignant potential of gastrointestinal stromal tumors: imaging, UEGW,   2009 11 , UEGW
• The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+PEG-IFN α-2b therapy against advanced hepatocellular carcinoma, The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD),   2009 11 , The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)
• Usefulness of hepatocyte phase imaging of Gd-EOB-DTPA-MRI in detecting HCCs which are difficult to detect other imaging modalities., The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),   2009 11 , The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
• Special Lecture “Current advances in the management of HCC.”, HCC Asian Expert Meeting,   2009 10 , HCC Asian Expert Meeting
• Special Lecture “Concept of early HCC and its imaging finding.”, The 3rd International Forum for Liver MRI,   2009 10 , The 3rd International Forum for Liver MRI

Misc

• 肝胆膵の線維化up‐to‐date 肝臓の線維化―臨床・病理―非侵襲的線維化マーカーによる経時的線維化評価(SWE,VTQなども含めて), 青木智子, 飯島尋子, 工藤正俊, 肝胆膵, 79, 5, 873‐878,   2019 11 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902240758862919
• NATIONWIDE LIVER CANCER REGISTRY, 工藤正俊, 工藤正俊, 泉並木, 久保正二, 國土典宏, 坂元亨宇, 椎名秀一朗, 高山忠利, 建石良介, 中島収, 松山裕, 村上卓道, 日本外科学会雑誌, 120, 6, 663‐670,   2019 11 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902271864332329
• 分子標的治療薬の併用療法 2 TACEと分子標的治療薬の併用療法, 上嶋一臣, 工藤正俊, Liver Cancer Journal, 11, 2, 84‐90,   2019 10 31 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902260933381022
• 遭遇の機会が増えたIPMN/膵嚢胞―現状と課題 2 IPMN/膵嚢胞の診療(4)悪性IPMNとIPMN併存膵癌の診断におけるEUSの役割, 鎌田研, 原茜, 山雄健太郎, 竹中完, 工藤正俊, 臨床消化器内科, 34, 12, 1476‐1481,   2019 10 20 , 10.19020/CG.0000000968, https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902221651242990
• 慢性膵炎, 渡邉智裕, 三長孝輔, 工藤正俊, 検査と技術, 47, 10, 1160‐1165,   2019 10 01 , 10.11477/mf.1543207764, https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902237927197582
• 術後内視鏡診療のすべて[各論 消化器手術後の内視鏡検査―サーベイランスと異時性病変の診断―]消化管再建術後における超音波内視鏡を用いたスクリーニング検査, 鎌田研, 原茜, 田中秀和, 石川嶺, 岡本彩那, 中井敦史, 大本俊介, 三長孝輔, 山雄健太郎, 竹中完, 工藤正俊, 消化器内視鏡, 31, 9, 1331‐1336,   2019 09 25 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902217229348136
• 膵癌における内視鏡診断・治療の最前線 術後膵液瘻に対する内視鏡的ドレナージの現状, 竹中完, 中井敦史, 吉川智恵, 石川嶺, 岡本彩那, 山崎友裕, 大本俊輔, 三長孝輔, 鎌田研, 山雄健太郎, 亀井敬子, 松本逸平, 竹山宜典, 工藤正俊, 胆と膵, 40, 9, 807‐814,   2019 09 15 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902230237493547
• IgG4関連疾患病態解明への挑戦―臓器横断的研究からみえてきたもの!IgG4とはどのような分子か?, 渡邉智裕, 三長孝輔, 吉川智恵, 原茜, 鎌田研, 工藤正俊, 消化器病学サイエンス, 3, 3, 142‐148,132,   2019 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902277296422132
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)ラムシルマブ 日本人肝細胞癌患者におけるラムシルマブの有用性, 工藤正俊, 肝胆膵, 79, 2, 320‐326,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902210820198891
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)レンバチニブ REFLECT試験のresponder解析の結果―分子標的治療の奏効は予後の規定因子である―, 南康範, 工藤正俊, 肝胆膵, 79, 2, 187‐190,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902217908194052
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)ラムシルマブ AFP<400ng/mL症例におけるラムシルマブの有効性, 青木智子, 工藤正俊, 肝胆膵, 79, 2, 327‐337,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902224917370729
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)ラムシルマブ ラムシルマブはレンバチニブの二次治療薬として有効か, 工藤正俊, 肝胆膵, 79, 2, 350‐355,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902235941610779
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)レンバチニブ レンバチニブ導入早期の肝性脳症の機序と対策, 工藤正俊, 肝胆膵, 79, 2, 239‐246,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902239168210037
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)レンバチニブ レンバチニブの奏効とALBI Grade, 上嶋一臣, 工藤正俊, 肝胆膵, 79, 2, 227‐231,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902251803350445
• 進化する肝細胞癌の薬物療法―2019 Update(Part 1)ソラフェニブ ソラフェニブにおける奏効と予後の関係―SILIUS trialの結果より―, 工藤正俊, 肝胆膵, 79, 2, 270‐277,   2019 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902277858090829
• 肝細胞癌の新たな治療選択肢とは―肝細胞癌治療におけるラムシルマブの位置づけ―, 工藤正俊, Therapeutic Research, 40, 8, 625‐626,   2019 08 20 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902281953797845
• 消化管疾患と緊急内視鏡 上部消化管出血(非静脈瘤), 松井繁長, 樫田博史, 高島耕太, 岡元寿樹, 山田光成, 正木翔, 米田頼晃, 永井知行, 本庶元, 櫻井俊治, 辻直子, 工藤正俊, 月刊消化器・肝臓内科, 6, 1, 7‐13,   2019 07 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902248279332749
• 肝炎・肝癌 5 肝癌内科治療の最前線, 上嶋一臣, 工藤正俊, Bio Clinica, 34, 7, 686‐690,   2019 07 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902287865346609
• こんなにある薬剤性消化管傷害[各論 小腸および大腸]免疫チェックポイント阻害薬による大腸病変, 櫻井俊治, 樫田博史, 永井知行, 米田頼晃, 川上尚人, 中川和彦, 工藤正俊, 消化器内視鏡, 31, 6, 928‐933,   2019 06 25 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902285994953596
• 肝疾患を取り巻くAI・技術革新 6.肝細胞癌に対する焼灼療法におけるナビゲーション, 南康範, 南知宏, 田北雅弘, 萩原智, 依田広, 上嶋一臣, 西田直生志, 工藤正俊, 肝臓クリニカルアップデート, 5, 1, 39‐42,   2019 05 15 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902263781847645
• 超音波画像診断装置の到達点と今後 最新超音波技術の有用性と将来展望 AI(人工知能)による超音波診断の現状と将来像, 南康範, 西田直生志, 工藤正俊, 月刊新医療, 46, 5, 92‐94,   2019 05 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902249075582953
• 肝と免疫2019 5 肝細胞癌治療と免疫(1)肝細胞癌に対する免疫チェックポイント阻害薬開発の現況, 工藤正俊, 臨床消化器内科, 34, 5, 543‐554,   2019 04 20 , http://jglobal.jst.go.jp/public/201902245677928015
• エキスパートへの道―胆・膵 ERCP関連 挿管手技 膵管ガイドワイヤー留置法―確実に成功させるコツ―, 竹中完, 中井敦史, 工藤正俊, 消化器内視鏡, 31, 3, 348‐353,   2019 03 25 , http://jglobal.jst.go.jp/public/201902242592293892
• 薬の知識 レンパチニブメシル酸塩(レンビマ), 上嶋一臣, 工藤正俊, 臨床消化器内科, 34, 4, 448‐450,   2019 03 20 , 10.19020/CG.0000000718, http://jglobal.jst.go.jp/public/201902266690884006
• 自己免疫性膵炎2019 AIPの病因・病態 腸内細菌叢からみた発症機序, 渡邉智裕, 鎌田研, 吉川智恵, 三長孝輔, 工藤正俊, 肝胆膵, 78, 2, 189‐195,   2019 02 28 , http://jglobal.jst.go.jp/public/201902221962489636
• 肝細胞癌の薬物療法, 工藤正俊, 医学のあゆみ, 268, 2, 146‐148,   2019 01 12 , http://jglobal.jst.go.jp/public/201902274956746143
• Response Evaluation Criteria in Cancer of the Liver (RECICL 2019 revised version), 工藤正俊, 工藤正俊, 池田公史, 上嶋一臣, 坂元亨宇, 椎名秀一朗, 建石良介, 長谷川潔, 古瀬純司, 宮山四朗, 村上卓道, 山下竜也, 國土典宏, 國土典宏, 肝臓, 60, 2, 55‐62(J‐STAGE),   2019 , 10.2957/kanzo.60.55, http://jglobal.jst.go.jp/public/201902225192660832
• 膵管内乳頭粘液性腫瘍(IPMN)の診断と経過観察法 3 IPMNに合併・併存する膵癌とその診断法, 鎌田研, 竹中完, 工藤正俊, 週刊日本医事新報, 4940, 36‐40,   2018 12 29 , http://jglobal.jst.go.jp/public/201902245060413005
• EUSによる消化管疾患の診断―現状と最新の話題 造影ハーモニックEUSによる消化管粘膜下腫瘍の診断, 鎌田研, 竹中完, 石川嶺, 吉川智恵, 岡本彩那, 山崎友裕, 中井敦史, 大本俊介, 三長孝輔, 山雄健太郎, 櫻井俊治, 松井繁長, 渡邉智裕, 西田直生志, 樫田博史, 工藤正俊, 胃と腸, 53, 13, 1795‐1799,   2018 12 25 , http://jglobal.jst.go.jp/public/201802234340821253
• 胆膵ドレナージupdate[3.困難例とトラブルシューティング]胆管・膵管プラスチックステント迷入への対処, 竹中完, 三長孝輔, 鎌田研, 山雄健太郎, 工藤正俊, 消化器内視鏡, 30, 11, 1605‐1611,   2018 11 25 , http://jglobal.jst.go.jp/public/201802282333712805
• Biliary access大辞典 III.経乳頭的biliary access~salvage technique~Uneven Double Lumen Cannulaを用いた胆管カニュレーションテクニック(Uneven method)【動画付】, 竹中完, 吉川智恵, 石川嶺, 岡本彩那, 山崎友祐, 中井敦史, 大本俊介, 三長孝輔, 鎌田研, 山雄健太郎, 有坂好史, 工藤正俊, 胆と膵, 39, 1013‐1020,   2018 11 10 , http://jglobal.jst.go.jp/public/201802250502947678
• A case of gallbladder carcinoma with interesting contrast-enhanced harmonic EUS image, 吉川智恵, 鎌田研, 竹中完, 大本俊介, 三長孝輔, 山雄健太郎, 今井元, 榎木英介, 木村雅友, 松本逸平, 竹山宜典, 工藤正俊, 胆道, 32, 4, 775‐781,   2018 10 31 , http://jglobal.jst.go.jp/public/201802278017394530
• IgG4関連疾患の最近の知見 IgG4関連疾患の病因と自然免疫, 渡邉智裕, 鎌田研, 三長孝輔, 工藤正俊, 月刊リウマチ科, 60, 4, 347‐352,   2018 10 28 , http://jglobal.jst.go.jp/public/201802246405521889
• 胆膵疾患内視鏡アトラス I.膵臓 1.充実性 特殊型膵癌―腺扁平上皮癌,退形成性膵管癌,腺房細胞癌―, 竹中完, 筑後孝章, 工藤正俊, 消化器内視鏡, 30, 54‐57,7,   2018 10 20 , http://jglobal.jst.go.jp/public/201802272450064760
• 外科医が知っておきたい化学放射線療法・癌免疫療法 原発性肝癌(肝細胞癌), 工藤正俊, 消化器外科, 41, 11, 1537‐1546,   2018 10 10 , http://jglobal.jst.go.jp/public/201802232911632655
• ここまで“見える”最新超音波診断装置[Part2]今“超音波”に求められるものとは 肝癌に対するPrecision RFAと超音波による早期治療効果判定 US‐US overlay fusionの有用性, 南康範, 工藤正俊, 月刊新医療, 45, 9, 114‐117,   2018 09 01 , http://jglobal.jst.go.jp/public/201802240914277838
• 知っておこう!遺伝性消化器疾患 常染色体優性多嚢胞性肝疾患(ADPLD), 田北雅弘, 南知宏, 千品寛和, 河野匡志, 萩原智, 南康範, 依田広, 上嶋一臣, 西田直生志, 工藤正俊, 消化器内視鏡, 30, 8, 1086‐1089,   2018 08 25 , http://jglobal.jst.go.jp/public/201802283804762985
• 【レンビマで変わる肝細胞癌の診断と治療】 レンビマ徹底解剖 Phase 3 REFLECT試験, 工藤 正俊, クリニシアン, 65, 7, 593, 612,   2018 07
• 急激に変貌する肝癌の薬物療法 肝細胞癌における免疫チェックポイント阻害薬とその他の治療法との組み合わせ治療, 工藤 正俊, The Liver Cancer Journal, 10, 1, 49, 55,   2018 07
• 【どうする膵嚢胞】 IPMN IPMNの経過観察におけるEUSの今後, 鎌田 研, 竹中 完, 中井 敦史, 大本 俊介, 宮田 剛, 三長 孝輔, 山雄 健太郎, 今井 元, 樫田 博史, 工藤 正俊, 消化器内視鏡, 30, 5, 606, 610,   2018 05
  Summary:膵管内乳頭粘液性腫瘍(IPMN)を疑う病変に対する初回精査として、腹部造影CTや磁気共鳴胆道膵管造影(MRCP)が用いられる。IPMNと診断されれば、次にhigh-risk stigmataやworrisome featureなどの悪性を示唆する所見の有無に関する診断が重要となる。IPMN/MCN国際診療ガイドライン2012年版(GL2012)では、worrisome featureを有する分枝型IPMNに対しては、超音波内視鏡(EUS)による精査が推奨されている。EUSにて悪性を疑う所見がなければ、経過観察の方針となる。GL2012年では、EUSによる経過観察の対象は、嚢胞径2cm以上の分枝型IPMNである。このように比較的大きな病変に対しては、IPMNの詳細な観察が可能なEUSを用いる方針となっている。一方、IPMNの経過観察を行ううえではIPMN併存膵癌の発生にも注意を要する。経過観察群からのIPMN併存膵癌の診断においても、EUSは重要性の高い検査であると考えられる。IPMN併存膵癌の発生の可能性を考慮した場合、EUSによる経過観察の対象や検査間隔については再考の余地がある。本当にリスクの高い症例に対して積極的にEUSを行うこと、これが未来のIPMNの経過観察の形になるであろう。(著者抄録)
• 【膵癌update】 トピックス 膵癌の癌性疼痛に対するEUSガイド下神経叢ブロック(融解)術の有用性, 宮田 剛, 竹中 完, 工藤 正俊, 臨床消化器内科, 33, 7, 950, 957,   2018 05 , 10.19020/CG.0000000420
• 膵NETの最新の画像診断と治療 造影ハーモニックEUSによる膵神経内分泌腫瘍の悪性度評価, 石川 嶺, 鎌田 研, 竹中 完, 田中 秀和, 中井 敦史, 大本 俊介, 宮田 剛, 三長 孝輔, 山雄 健太郎, 今井 元, 工藤 正俊, 膵臓, 33, 3, 346, 346,   2018 05
• 術後膵液瘻(POPF)に対するEUS下ドレナージの有用性, 中井 敦史, 竹中 完, 山雄 健太郎, 松本 逸平, 竹山 宜典, 工藤 正俊, 膵臓, 33, 3, 399, 399,   2018 05
• 重症急性膵炎の予後不良予測因子および被包化壊死(WON)合併予測因子の検討, 大本 俊介, 竹中 完, 松本 逸平, 竹山 宜典, 工藤 正俊, 膵臓, 33, 3, 410, 410,   2018 05
• 造影ハーモニックEUSは膵癌の術前治療の効果判定に有用か?, 田中 秀和, 鎌田 研, 竹中 完, 石川 嶺, 中井 敦史, 大本 俊介, 三長 孝輔, 宮田 剛, 山雄 健太郎, 今井 元, 工藤 正俊, 膵臓, 33, 3, 505, 505,   2018 05
• 【知っておきたい神経感染症】 C型肝炎ウイルス関連クリオグロブリン血管炎, 南 康範, 工藤 正俊, BRAIN and NERVE: 神経研究の進歩, 70, 2, 133, 137,   2018 02
  Summary:C型肝炎ウイルス(HCV)関連クリオグロブリン血管炎では過剰な免疫応答によってクリオグロブリンが血中に増加し,これがさまざまな臓器の小血管を障害することで症状が生じる。主な症状は紫斑,関節痛,末梢性神経障害,レイノー現象がある。検査所見では血中クリオグロブリン陽性,赤沈亢進,C反応性蛋白の上昇,リウマチ因子陽性,補体価の低下が認められる。治療法として抗ウイルス療法,B細胞抑制療法,免疫抑制療法,血漿交換療法がある。(著者抄録)
• 膵・胆管合流異常に合併した共通管内乳頭状腫瘍の1例, 幕谷 悠介, 松本 逸平, 大本 俊介, 筑後 孝章, 川口 晃平, 松本 正孝, 村瀬 貴昭, 亀井 敬子, 里井 俊平, 中居 卓也, 竹中 完, 工藤 正俊, 竹山 宜典, 日本消化器外科学会雑誌, 51, 2, 114, 121,   2018 02 , 10.5833/jjgs.2017.0066
  Summary:膵・胆管合流異常に合併した共通管内乳頭状腫瘍の1例を報告する.症例は75歳の男性で,6ヵ月間に2度の急性膵炎を発症し保存的加療で軽快した.急性膵炎の原因精査および加療目的で当院へ紹介となった.ERCPでは膵・胆管合流異常を認め,共通管内に7mmの結節様陰影欠損像を認めた.上部内視鏡検査では乳頭部からの粘液排出は認めず,超音波内視鏡検査では共通管内に乳頭状の腫瘍が描出された.造影CTでは膵頭部に拡張した共通管と内部に増強効果を持つ8mmの腫瘤を認めた.尾側の主膵管の拡張は認めなかった.膵・胆管合流異常に合併した共通管内乳頭状腫瘍と診断し,亜全胃温存膵頭十二指腸切除術を施行した.病理肉眼所見では共通管内に発育する有茎性の乳頭状腫瘍で,組織像は管状構造増生を主体とする腺腫であった.免疫組織学的染色ではMUC1,MUC2陰性,MUC5AC陽性で胃型腺腫と最終診断した.(著者抄録)
• 肝細胞癌に対するUS-US overlay fusionを用いたラジオ波焼灼術の有用性, 南 知宏, 南 康範, 千品 寛和, 有住 忠晃, 田北 雅弘, 矢田 典久, 萩原 智, 依田 広, 上嶋 一臣, 西田 直生志, 工藤 正俊, 肝臓, 59, 2, 142, 144,   2018 02 , 10.2957/kanzo.59.142
  Summary:肝細胞癌に対しUS-US overlay fusionを用いてラジオ波焼灼術(RFA)を行った53例68結節を対象に、US-US overlay fusionの有用性を検討した。早期の治療効果判定として、RFA後2〜3日以内に造影CTを撮像し、US-US overlay fusionでの評価と比較した。その結果、US-US overlay fusionガイドでFRA治療を行ったところ、全例が1セッションでtechnical successを達成した。穿刺回数は平均1.9回であり、造影CT/MRIによる早期治療効果判定として、5mm以上のsafety marginが確保できたのは86.5%(56/68結節)であった。早期効果判定をgold standardとして、US-US overlay fusionによるablative margin評価の正診率は92.6%(63/68結節)であった。術後に重篤な早期合併症は認めなかった。以上、US-US overlay fusionによって超音波画像での3次元的なablative marginの評価がRFA治療中に行えるようになり、精度の高いRFA治療(precision RFA)を提供することが可能であると考えられた。
• キーワード(No.3) パターン認識受容体, 渡邉 智裕, 工藤 正俊, 消化器病学サイエンス, 1, 3, 150, 152,   2017 12
  Summary:微生物に対する免疫防御反応は、自然免疫反応と獲得免疫反応によって担われている。獲得免疫反応が効率よく誘導されるためには、自然免疫反応が不可欠である。自然免疫担当細胞に発現するパターン認識受容体(PRRs)は微生物由来抗原の認識を通して、自然免疫反応を誘導する。PRRsによる自然免疫反応は免疫防御だけでなく、慢性炎症にもかかわることが明らかになりつつある。(著者抄録)
• Contrast-enhanced endoscopic ultrasound, Digest Endosc, 26, 79, 85,   2014 01 , 10.1111/den.12179
• Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 10, 4067, 4075,   2013 11 , 10.1200/JCO.2012.45.8372
• Molecular link between liver fibrosis and hepatocellular carcinoma, Liver Cancer, 31, 365, 366,   2013 11
• Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?, Liver Cancer, 2, 151, 152,   2013 11
• Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase 3 BRISK-FL study, J Clin Oncol, 31, 3517, 3524,   2013 10 , 10.1200/JCO.2012.48.4410
• Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan, Brit J Cancer, 109, 1904, 1907,   2013 10 , 10.1038/bjc.2013.542
• Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments, Digest Dis, 31, 490, 498,   2013 10 , 10.1159/000355259
• Radiofrequency ablation for hepatic malignancies: is the needle tract cauterization necessary for preventing iatrogenic bleeding?, Digest Dis, 31, 480, 484,   2013 10 , 10.1159/000355254
• CD-34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma, Digest Dis, 31, 467, 471,   2013 10 , 10.1159/000355246
• Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis, Digest Dis, 31, 459, 466,   2013 10 , 10.1159/000355245
• Oxidative stress and epigenetic instability in human hepatocarcinogenesis, Digest Dis, 31, 447, 453,   2013 10 , 10.1159/000355243
• Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species Production, Digest Dis, 31, 440, 446,   2013 10 , 10.1159/000355242
• Outcome of double-filtration plasmapheresis plus IFN treatment in non-responders to pegylated IFN plus ribavirin combination therapy, Digest Dis, 31, 434, 439,   2013 10 , 10.1159/000355241
• Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load, Digest Dis, 31, 426, 433,   2013 10 , 10.1159/000355381
• Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance, Digest Dis, 31, 421, 425,   2013 10 , 10.1159/000355239
• Autoimmune hepatitis and immunoglobulin G4-associated autoimmune Hepatitis, Digest Dis, 31, 415, 420,   2013 10 , 10.1159/000355238
• Clinical and histological features of different types of Budd-Chiari syndrome: A Comparison of 4 cases, Digest Dis, 31, 408, 414,   2013 10 , 10.1159/000355237
• [Preface] Chronic liver diseases and hepatocellular carcinoma: update in 2013, Digest Dis, 31, 405, 407,   2013 10 , 10.1159/000355379
• Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers, World J Gastroenterol, 19, 5706, 5712,   2013 09 , 10.3748/wjg.v19.i34.5706
• Association of gankyrin and stemness factor expression in human colorectal cancer, Dig Dis Sci, 58, 2337, 2344,   2013 08 , 10.1007/s10620-013-2627-8
• Senile systemic amyloidosis mimicking gastric cancer, Digest Endosc, 25, 468, 469,   2013 07
• Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm., Liver Int, 33, 762, 770,   2013 05 , 10.1111/liv.12130
• FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma., Hepatology, 57, 4, 1407, 1415,   2013 04 , 10.1002/hep.25956
• Inhibition of hepatocellular carcinoma by PegIFNα2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study., J Gastroenterol, 48, 382, 390,   2013 03 , 10.1007/s00535-012-0641-9
• Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma, Oncology, 84, 93, 97,   2013 02 , 10.1159/000345897
• Expression of E-Cadherin and Vascular Endothelial Growth Factor in Noncancerous Liver Is Associated with Recurrence of Hepatocellular Carcinoma after Curative Resection, Oncology, 84, Suppl. 1, 88, 92,   2013 02 , 10.1159/000345896
• Quantification of Tumor DNA in Serum and Vascular Invasion of Human Hepatocellular Carcinoma, Oncology, 84, 82, 87,   2013 02 , 10.1159/000345895
• The Prognostic Value of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma for Predicting Metastasis after Curative Resection, Oncology, 84, Suppl. 1, 75, 81,   2013 02 , 10.1159/000345894
• Therapeutic Response Assessment of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Ultrasonography, CT and MR Imaging, Oncology, 84, 58, 63,   2013 02 , 10.1159/000345891
• Role of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in the Management of Hepatocellular Carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan, Oncology, 84, 21, 27,   2013 02 , 10.1159/000345885
• Assessment of Liver Fibrosis with Real-Time Tissue Elastography in Chronic Viral Hepatitis, Oncology, 84, 13, 20,   2013 02 , 10.1159/000345884
• Novel Image Analysis Method Using Ultrasound Elastography for Noninvasive Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis C, Oncology, 84, 3, 12,   2013 02 , 10.1159/000345883
• Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013. Preface, Oncology, 84, 1, 2,   2013 02 , 10.1159/000345882
• Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations, Digest Dis, 31, 454, 458,   2013 , 10.1159/000355244
• Early Hepatocellular Carcinoma: Definition and Diagnosis, Liver Cancer, 2, 69, 72,   2013
• Usefulness of contrast-enhanced ultrasonography to evaluate the post treatment responses of radiofrequency ablation for hepatocellular carcinoma; comparison with dynamic CT, Oncology, 84, 51, 57,   2013 , 10.1159/000345890
• Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)., Liver Int, 33, 3, 327, 337,   2013 , 10.1111/liv.12083
• Heat shock protein 27 expression is inversely correlated with atrophic gastritis and intraepithelial neoplasia., Digest Dis Sci, 58, 381, 388,   2013 , 10.1007/s10620-012-2342-x
• Toll-like receptor activation in basophils contributes to the development of IgG4-related disease., J Gastroenterol, 48, 247, 253,   2013 , 10.1007/s00535-012-0626-8
• Hypovascular Nodules in Chronic Liver Disease: Risk Factors for Developing hypervascular Hepatocellular Carcinoma, Radiology, 266, 2, 480, 490,   2013 , 10.1148/radiol.12112677
• Usefulness of Contrast-Enhanced Ultrasonography to Evaluate the Post-Treatment Responses of Radiofrequency Ablation for Hepatocellular Carcinoma: Comparison with Dynamic CT, Oncology, 84, 51, 57,   2013 , 10.1159/000345890
• Impact of peginterferon Alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B, J Med Virol, 85, 987, 995,   2013 01 , 10.1002/jmv.23564
• Radiofrequency ablation of liver metastases from colorectal cancer: a literature review., Gut Liver, 7, 1, 6,   2013 01
• Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS., Ultraschall Med, 34, 11, 29,   2013 01
• Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance., Liver Cancer, 1, 141, 143,   2012 12
• Septicemia due to vibrio cholerae serogroup non-O1/non-O139 strain in a cirrhotic patient, Clin J Gastroenterol, 5, 383, 387,   2012 12 , 10.1007/s12328-012-0332-3
• Real-life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single Center Experience., Digest Dis, 30, 609, 616,   2012 11 , 10.1159/000343091
• Novel Non-Trocar Technique for Laparoscopic Radiofrequency Ablation, Digest Dis, 30, 588, 591,   2012 11
• Histopathological Diagnosis of Early HCC through Biopsy: Efficacy of Victoria Blue and Cytokeratin 7 Staining, Dig Dis, 30, 574, 579,   2012 11 , 10.1159/000343069
• Risk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFN -2a, Dig Dis, 30, 561, 567,   2012 11 , 10.1159/000343065
• Retreatment with peginterferon alfa-2a plus ribavirin in patients who failed previous peginterferon alfa-2b plus ribavirin combination therapy., 30, 554, 560,   2012 11
• Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection., Digest Dis, 30, 547, 553,   2012 11 , 10.1159/000343057
• Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers., Digest Dis, 30, 541, 546,   2012 11 , 10.1159/000343056
• Preface, Digest Dis, 30, 539, 540,   2012 11 , 10.1159/000343053
• Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function ?, Hepatobiliary Pancreat Dis Int., 11, 3, 307, 313,   2012 11 , 10.1016/S1499-3872(12)60165-9
• Transcatheter endoscopy for pancreaticobiliary duct diseases (with video)., Gastrointest Endosc, 76, 892, 899,   2012 09 , 10.1016/j.gie.2012.06.012
• Welcome to the first issue of Liver Cancer., Liver Cancer, 1, 1, 1, 1,   2012 07
• Ramucirumab, 64, 5, 697, 700,   2012 05
• Brivanib, 64, 5, 669, 675,   2012 05
• Plasma concerntrations of angiogenesis-related molecules in patients with pancreatic cancer., Jpn J Clin Oncol, 42, 2, 105, 12,   2012 02 , 10.1093/jjco/hyr178
• Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma, Hepatology, 56, 994, 1003,   2012 , 10.1002/hep.25706
• Hypovascular Nodules in Chronic Liver Disease: Risk Factors for Developing Hypervascular Hepatocellular Carcinoma., Radiology,   2012
• Case of Peutz-Jeghers syndrome with depressed-type early duodenal carcinoma, Digest Endosc, 24, 489,   2012 , 10.1111/j.1443-1661.2012.01361.x
• p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expressions, Free Radical Bio Med, 52, 2284, 2291,   2012 , 10.1016/j.freeradbiomed.2012.03.010
• Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy., Liver Cancer, 1, 62, 70,   2012
• Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?, Liver Cancer, 1, 59, 60,   2012
• Sensing of commensal organisms by the intracellular sensor NOD1 Mediates experimental pancreatitis, Immunity, 37, 326, 338,   2012 , 10.1016/j.immuni.2012.05.024
• Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging, Jpn J Appl Phys, 51, 11,   2012 , 10.1143/JJAP.51.07GF11
• Closing remarks., Clin Drug Invest, 32, 52,   2012 , 10.2165/1163025-S0-000000000-00000
• Activation of JNK and high expression level of CD133 predict a poor response to Sorafenib in hepatocellular carcinoma., Brit J Cancer, 106, 1997, 2003,   2012 , 10.1038/bjc.2012.145
• First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study., Int J Clin Pract, 66, 675, 683,   2012 , 10.1111/j.1742-1241.2012.02940.x
• Endoscopic ultrasound: contrast enhancement., Gastrointest Endosc Clin N Am, 22, 349, 358,   2012 , 10.1016/j.giec.2012.04.013
• Well-differentiated hepatocellular carcinoma detected as hypovascularity by only CT during hepatic arteriography., Intern Med, 51, 8, 885, 890,   2012 , 10.2169/internalmedicine.51.6904
• Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report., Lancet Oncol, 13, 1, e11, 22,   2012 , 10.1016/S1470-2045(11)70175-9
• Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines., J Hepatol, 56, 886, 892,   2012 , 10.1016/j.jhep.2011.10.021
• Involvement activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis., Arthritis Rheum, 64, 3, 914, 924,   2012 , 10.1002/art.33386
• Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation., Eur J Radiol, 81, e277, 280,   2012 , 10.1016/j.ejrad.2011.02.026
• Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer., Jpn J Clin Oncol, 42, 2, 105, 112,   2012 , 10.1093/jjco/hyr178
• Characterization of small solid tumors in the pancreas: The value of contrast-enhanced harmonic endoscopic ultrasonography., Am J Gastroenterol, 107, 303, 310,   2012 , 10.1038/ajg.2011.354
• Treatment of advanced hepatocellular carcinoma, KUDO Masatoshi, Nippon Shokakibyo Gakkai Zasshi, 109, 8, 1327, 1334,   2012 , 10.11405/nisshoshi.109.1327, http://ci.nii.ac.jp/naid/130001915725
• A flare of hepatitis B in a patient with HBV-HCV co-infection during the combination therapy of pegylated interferon (PEG-IFN) α2a and ribavirin, Miyata Hiroshi, Miyata Satoru, Kudo Masatoshi, Kanzo, 53, 12, 846, 852,   2012 , 10.2957/kanzo.53.846, http://ci.nii.ac.jp/naid/130003343869
  Summary:In Japan the number of patients who are co-infected with hepatitis B and C virus is little. On the other hand there are many reports in the world that HBV reactivation often occur in the co-infected patients at the end of treatment or after IFN with ribavirin therapy. But the flare of hepatitis B is rare during combination therapy. In this case report, hepatitis B virus was reactivated and the flare happened in the middle of the therapy of IFNα2a with ribavirin, although HBV-DNA before treatment had been negative. To avoid the next flare entecavir was medicated. And then hepatitis B settled down. It suggests that entecavir would be effective if the flare of hepatitis B occurred.
• The status of polycystic liver disease in Japan : a questionnaire survey of patients, OGAWA Koichi, FUKUNAGA Kiyoshi, TAKEUCHI Tomoyo, KAWAGISHI Naoki, KUDO Masatoshi, OHKOUCHI Nobuhiro, Kanzo, 52, 11, 709, 715,   2011 11 25 , 10.2957/kanzo.52.709, http://ci.nii.ac.jp/naid/10030240464
  Summary:Polycystic liver disease (PLD) is genetic disorder characterized by the progressive development of multiple liver cysts. Because of rarity of PLD, therapeutic consensus is controversial. The aim of this study was to investigate a situation of PLD treatment by a questionnaire survey. In this study, 422 patients with PLD participated, and 223 patients underwent treatment. The most common symptom was abdominal distension (73%). The treatments were performed as follows; percutaneous aspiration in 27% of patients, liver resection in 12%, cyst fenestration in 9%, and liver transplantation in 3%. The efficacies of these treatments were recognized in 77%, 96%, 92%, and 100% of each patient, respectively. Because of no effect of primary therapy, additional treatment was performed in only 4.3% of patients. In general, the choice of primary treatment for PLD was considered reasonable and proper, in Japan.
• 2Pa5-4 Analysis of Elasticity Image of Chronic Hepatitis Based on Dynamic Model of Fibrosis Progression(Poster Session), Maki Tomonori, Shiina Tsuyoshi, Yamakawa Makoto, Mitake Tsuyoshi, Kudo Masatoshi, Fujimoto Kenji, Proceedings of Symposium on Ultrasonic Electronics, 32, 141, 142,   2011 11 08 , http://ci.nii.ac.jp/naid/110008913344
• Antitumor activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker., Clin Cancer Res, 17, 6, 1373, 1381,   2011 03 , 10.1158/1078-0432.CCR-09-2755
• HEPATOCELLULAR CARCINOMA, Kudo Masatoshi, Journal of Japan Surgical Society, 112, 2, 122, 129,   2011 03 01 , http://ci.nii.ac.jp/naid/110008513590
• Utility of contrast-enhanced harmonic endoscopic ultrasonography for diagnosis of pancreatic diseases, KITANO Masayuki, KOMAKI Takamitsu, SAKAMOTO Hiroki, IMAI Hajime, KAMATA Ken, KUDO Masatoshi, YASUDA Takeo, TAKEYAMA Yoshifumi, 26, 1, 23, 28,   2011 02 25 , 10.2958/suizo.26.23, http://ci.nii.ac.jp/naid/10029435262
• THE KNACK OF PERFORMING CONTRAST-ENHANCED EUS, KITANO Masayuki, KUDO Masatoshi, GASTROENTEROLOGICAL ENDOSCOPY, 53, 1, 76, 86,   2011 01 20 , 10.11280/gee.53.76, http://ci.nii.ac.jp/naid/10027867212
  Summary:The development of the second generation ultrasound contrast Sonazoid which produces a second harmonic component with low acoustic power has enabled vascular assessment in the field of EUS. With the use of the echoendoscope provided by OLYMPUS-ALOKA, contrast-enhanced EUS is performed in the eFLOW mode which depicts fine vessels without Doppler-related artifacts or in the ExPHD mode which enables perfusion imaging by selective depiction of signals from microbubbles. The echoendoscope should be manipulated in order to position it as close to the target lesion as possible. Contrast-enhanced harmonic EUS depicts fine vessels in the lesions 10-20 seconds after the infusion, and subsequently parenchymal perfusion with strong contrast with the pancreatic duct, biliary system and surrounding tissue. In the pancreato-biliary region, contrast-enhanced harmonic EUS is useful for detection and characterization of small lesions, particularly discrimination between benign and malignant lesions. In GISTs, specific tumor vessels can be observed with contrast-enhanced harmonic EUS. It is also useful for differentiation between benign and malignant lymphadenopathy. Visualization of the microcirculation and perfusion imaging in EUS which has high spatial resolution may further improve imaging of the digestive organs.
• Identifying and prioritizing strategies for comprehensive liver cancer control in Asia., BMC Health Serv Res, Nov, 298,   2011 , 10.1186/1472-6963-11-298
• Needs for hepatocellular carcinoma control policy in the Asia-pacific region., Asian Pac J Cancer Prev, 12, 2585, 2591,   2011
• Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with Sorafenib: A case report., Oncology, 81, 152, 157,   2011 , 10.1159/000333279
• Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia., Oncology, 81, 158, 164,   2011 , 10.1159/000333280
• Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma., J Gastroenterol, 46, 1219, 1229,   2011 , 10.1007/s00535-011-0432-8
• Demonstration of quality of care measurement using the Japanese liver cancer registry., Hepatol Res, 41, 1208, 1212,   2011 , 10.1111/j.1872-034X.2011.00880.x
• Recent advances in the management of chronic hepatitis B., Hepat Mon, 11, 8, 601, 611,   2011 , 10.5812/kowsar.1735143X.657
• Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography, Oncology, 81, S1, 66, 72,   2011 , 10.1159/000333264
• Adriamycin enhances proteasome-mediated generation of the proapoptotic processed form of MAGE-A4 in hepatoma cells., Oncology, 81, S1, 30, 35,   2011 , 10.1159/000334307
• Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma., World J Gastroenterol, 17, 45, 4952, 4959,   2011 , 10.3748/wjg.v17.i45.4952
• Diagnostic imaging of hepatcocellular carcinoma: Recent progress., Oncology, 81, S1, 73, 85,   2011 , 10.1159/000333265
• Adjubant therpy after curative treatment for hepatocellular carcinoma., Oncology, 81, S1, 50, 55,   2011 , 10.1159/000333259
• Signaling pathways governing tumor angiogenesis., Oncology, 81, S1, 24, 29,   2011 , 10.1159/000333256
• Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy., Oncology, 81, S1, 1, 10,   2011 , 10.1159/000333252
• Endoscopic characteristics of colorectal serrated lesions., Hepato gastroenterology, 58, 1163, 1167,   2011
• Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy., Digestion, 84, S1, 56, 61,   2011 , 10.1159/000333215
• Clinical characteristics of non-B non-C hepatocellular carcinoma: A single-center retrospective study., Digestion, 84, S1, 43, 49,   2011 , 10.1159/000333212
• Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy., Digestion, 84, S1, 10, 16,   2011
• Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load., Digestion, 84, S1, 5, 9,   2011 , 10.1159/000333208
• Tailor-made therapy for viral hepatitis: Recent advances., Digestion, 84, S1, 1, 4,   2011 , 10.1159/000333207
• Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma., Liver Transplant, 17, S61, 71,   2011 , 10.1002/lt.22340
• Phase III study of Sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma., Eur J Cancer, 47, 2117, 2127,   2011 , 10.1016/j.ejca.2011.05.007
• Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection., J Viral Hepat, 18, 10, e561, 567,   2011 , 10.1111/j.1365-2893.2011.01478.x
• PIVKA-IIはSorafenibの治療効果予測因子になりうる., 51, 11, 681, 683,   2011 , 10.2957/kanzo.51.681
• Effect of vitamin K2 on the recurrence of hepatocellular carcinoma., Hepatology, 54, 532, 540,   2011 , 10.1002/hep.24430
• 胆道疾患における造影ハーモニックEUSの有用性., 32, 8, 695, 700,   2011
• Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version., Digest Dis, 29, 339, 364,   2011 , 10.1159/000327577
• Oral branched-chaun amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis., Digest Dis, 29, 326, 332,   2011 , 10.1159/000327571
• Future treatment option for hepatocellular carcinoma: a focus on brivanib., Digest Dis, 29, 316, 320,   2011 , 10.1159/000327568
• mTOR inhibitor for the treatment of hepatocellular carcinoma., Digest Dis, 29, 310, 315,   2011
• Signaling pathway and molecular-taegeted therapy for hepatocellular carcinoma., Digest Dis, 29, 289, 302,   2011 , 10.1159/000327562
• Molecular targeted therapy for hepatocellular carcinoma: bench to bedside., Digest Dis, 29, 273, 277,   2011 , 10.1159/000327558
• Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of Soraenib for hepatocellular carcinoma., Digest Dis, 29, 321, 325,   2011 , 10.1159/000327570
• New techniques and future perspective of EUS for the differential diagnosis of pancreatic malignancies; Contrast harmonic imaging., Digest Endosc, 23, 46, 50,   2011 , 10.1111/j.1443-1661.2011.01146.x
• Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma., Br J Surg, 98, 552, 557,   2011 , 10.1002/bjs.7393
• Estimation of liver function using T1 mapping onGd-EOB-DTPA-enhanced magnetic resonance imaging., Invest Radiol, 46, 4, 277, 283,   2011 , 10.1097/RLI.0b013e318200f67d
• Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR., J Magn Reson Imaging, 33, 4, 864, 871,   2011 , 10.1002/jmri.22487
• Radiofrequency ablation of hepatocellular carcinoma: A literature review., International Journal of Hepatology, 2011, 9,   2011
  Summary:Minami Y, Kudo M: 2011: 9pages, 2011.
• Endoscopic ultrasound-guided neurolysis in pancreatic cancer., Pancreatology, 11, 52, 58,   2011 , 10.1159/000323513
• Endoscopic ultrasonography-guided biliary drainage: evaluation of a choledochoduodenostomy technique., Pancreatology, 11, 47, 51,   2011 , 10.1159/000323508
• Endoscopic ultrasonography and contrast-enhanced endoscopic., Pancreatology, 11, 28, 33,   2011 , 10.1159/000323493
• Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis., Pancreatology, 11, 7, 13,   2011 , 10.1159/000323478
• The prognosis of patients with pancreatic cancer is extremely poor. Prefece., Pancreatology, 11, 1, 2,   2011
• Management of hepatitis B: Consensus of Japan Society of Hepatology 2009., Hepatol Res, 41, 1, 1, 21,   2011 , 10.1111/j.1872-034X.2010.00739.x
• The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+pegylated interferon α-2b therapy against advanced hepatocellular carcinoma., J Gastroenterol, 46, 2, 212, 221,   2011 , 10.1007/s00535-010-0294-5
• Antitumor activity of BIBF 1120, a vascular endothelial growth factor-2 inhibitor and use of VEGR2+pTYR+leucocyte as a pharmacodynamic biomarker., Clin Cancer Res, 17, 1373, 1381,   2011 , 10.1158/1078-0432.CCR-09-2755
• Double-contrast ultrasoud: a novel surveillance tool for hepatocellular carcinoma., Am J Gastroenterol, 106, 2, 368, 370,   2011 , 10.1038/ajg.2010.432
• Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma., Mol Cancer Ther, 10, 1, 169, 177,   2011 , 10.1158/1535-7163.MCT-10-0544
• Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma, Mol Cancer Ther, 10, 1, 169, 177,   2011 01 , 10.1158/1535-7163.MCT-10-0544
• PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinoma, UESHIMA Kazuomi, KUDO Masatoshi, Kanzo, 51, 11, 681, 683,   2010 11 25 , 10.2957/kanzo.51.681, http://ci.nii.ac.jp/naid/10027661655
  Summary:Fifty patients with advanced hepatocellular carcinoma (HCC) were treated with sorafenib. In 25 of the patients, serum levels of protein induced by vitamin K absence or antagonist II (PIVKA-II) were evaluated at two time points (pretreatment and within 2 weeks from initial treatment). The time to progression in the "PIVKA-II-elevated group" (PIVKA-II more than two times pretreatment levels) was significantly longer than that in the "non-elevated group" (10.0 months [95%CI: 8.5-11.5] vs 5.7 months [95%CI: 3.3-8.1]; p=0.0296). It has been reported that hypoxia induces PIVKA-II in HCC cells. HCC treated with sorafenib are exposed to hypoxia caused by an antiangiogenic effect. Therefore, serum levels of PIVKA-II are a surrogate marker of tissue hypoxia and accordingly a predictive marker of treatment response by sorafenib.
• Non-invasive evaluation method of the liver fibrosis using Real-time tissue elastograpy : Usefulness of judgment liver fibrosis stage by Liver fibrosis index (LF index), FUJIMOTO Kenji, KATO Michio, TONOMURA Akiko, YADA Norihisa, TATSUMI Chie, OSHITA Masahide, WADA Shigeo, UESHIMA Kazuomi, ISHIDA Tetsushi, FURUTA Tomoko, YAMASAKI Masaru, TSUJIMOTO Masahiko, MOTOKI Mitsuru, MITAKE Tsuyoshi, KIM Shigehiro, YAMAMOTO Keiji, SHIINA Tsuyoshi, KUDO Masatoshi, HAYASHI Norio, Kanzo, 51, 9, 539, 541,   2010 09 25 , 10.2957/kanzo.51.539, http://ci.nii.ac.jp/naid/10027469802
  Summary:To evaluate the effectiveness of Real-time Tissue Elastography (RTE) in staging of liver fibrosis non-invasively, we performed RTE on 310 patients with chronic hepatitis C (and/or liver cirrhosis) and 15 healthy volunteers. Nine image features were extracted from each RTE image and a multiple regression analysis was then performed to derive the regression equation. This equation calculates Liver Fibrosis Index (LF Index), which in turn predicts F stage of the liver. LF Index not only correlates highly with the F stage (r=0.68) of the liver fibrosis, but also it shows significant differences in LF Index values (p<0.001) between each stage of the fibrosis. Thus, we can conclude that RTE is a promising method to evaluate the liver fibrosis noninvasively.
• Elevated serum ALT levels following hyperferritinemia in CHC patients receiving pegylated interferon (PEG-IFN) therapy and availability of phlebotomy, MIYATA Hiroshi, MIYATA Satoru, KUDO Masatoshi, Kanzo, 51, 7, 371, 378,   2010 07 25 , 10.2957/kanzo.51.371, http://ci.nii.ac.jp/naid/10026515290
  Summary:Elevated serum ALT levels sometimes have been observed in CHC patients receiving pegylated interferon (PEG-IFN) therapy. However the reason for this elevation hasn't been clarified and in these cases we often hasitate to continue PEG-IFN therapy. We experienced three ALT-elavated cases following hyperferritinemia. And in one of them phlebotomy was performed. PEG-IFN therapy is very useful for viral elimination, remission of hepatitis, and suppression of HCC. However when serum ALT levels elevate following hyperferritinemia, it is speculated that activity of hepatitis and liver fibrosis become worse. In such cases phlebotomy may be effective.
• JSH Consensus Kobe 2009 : Diagnosis and Treatment of Hepatitis B, MIZOKAMI Masashi, TANAKA Eiji, CHAYAMA Kazuaki, TANAKA Yasuhito, KUROSAKI Masayuki, IZUMI Namiki, ARASE Yasuji, KUMADA Hiromitsu, IMAZEKI Fumio, YOKOSUKA Osamu, KUDO Masatoshi, Kanzo, 51, 5, 243, 260,   2010 05 25 , 10.2957/kanzo.51.243, http://ci.nii.ac.jp/naid/10026393724
• Diagnosis of subepithelial tumors in the upper gastrointestinal tract by EUS., World J Radiol, 2, 289, 297,   2010
• Phase I/II study of the pharmacokinetics, safety, and efficacy of S-1 in patients with advanced hepatocellular carcinoma., Cancer Sci, 101, 2606, 2611,   2010 , 10.1111/j.1349-7006.2010.01730.x
• Characterization of intra-abdominal lesions of undetermined origin by contrast-enhanced harmonic EUS (with videos)., Gastrointest Endosc, 72, 637, 642,   2010 , 10.1016/j.gie.2010.04.013
• EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle., Am J Gastroenterol, 105, 2599, 2606,   2010 , 10.1038/ajg.2010.339
• The challenge of prognosis and staging for hepatocellular carcinoma., Oncologist, 4, 23, 33,   2010
• Radiofrequency ablation of hepatocellular carcinoma: Current status., World J Radiol, 2, 11, 417, 424,   2010
• Report of the 18th follow-up survey of primary liver cancer in Japan., Hepatol Res, 40, 1043, 1059,   2010 , 10.1111/j.1872-034X.2010.00731.x
• Liver cancer working group report., Jpn J Clin Oncol, 40, i19, i27,   2010 , 10.1093/jjco/hyq123
• Hepatitis C virus core protein induces homotolerance cross-tolerance to Toll-like receptor ligands by activation of Toll-like receptor 2., J Infect Dis, 202, 6, 853, 861,   2010 , 10.1086/655812
• Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2cm., World J Gastroenterol, 16, 33, 4187, 4192,   2010 , 10.3748/wjg.v16.i33.4187
  Summary:Mita K, Kim SR, Kudo M, Imoto S, Nakajima T, Ando K, Fukuda K, Matsuoka T, Maekawa Y, Hayashi Y: 16: 4187-4192, 2010.
• Hepatic malignancies: Correlation between sonographic findings and pathological features., World J Radiol, 2, 249, 256,   2010
• Endoscopic findings of intestinal Behcet’s disease complicated with toxic megacolon., Endoscopy, 42, 173, 174,   2010 , 10.1055/s-0028-1103446
• Pancreatic ductal drainage by endoscopic ultrasound-assisted rendezvous technique for pain caused by ductal stricture with chronic pancreatitis., Digest Endosc, 22, 3, 217, 219,   2010 , 10.1111/j.1443-1661.2010.00980.x
• Response evaluatin criteria in cancer of the liver (RECICL) proposed by the liver cancer study group of Japan (2009 revised version)., Hepatol Res, 40, 686, 692,   2010 , 10.1111/j.1872-034X.2010.00674.x
• Management of hepatocellular carcinoma: Report of consensus meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)., Hepatol Res, 40, 667, 685,   2010 , 10.1111/j.1872-034X.2010.00673.x
• Local ablation therapy., Heppatol Res, 40, S1, 113, 119,   2010
• Clinical practice guidelines for hepatocellular carcinoma ?The Japan Society of Hepatology 2009 update., Heppatol Res, 40, S1, 1, 144,   2010
• Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C., Intern Med, 49, 12, 1119, 1122,   2010 , 10.2169/internalmedicine.49.3413
• Cecal intussusception in an adult with cronkhite-Canada syndrome relieved by colonoscopy., Intern Med, 49, 12, 1123, 1126,   2010 , 10.2169/internalmedicine.49.2813
• Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress., Oncology, 78, 180, 188,   2010 , 10.1159/000315740
• Positioning of a molecular-targeted agent, Sorafenib, in the treatment algorithm for hapatocellular carcinoma and implication of many complete remission cases in Japan., Oncology, 78, 154, 166,   2010 , 10.1159/000315245
• Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma., Oncology, 78, 148, 153,   2010 , 10.1159/000315244
• Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010., Oncology, 78, 113, 124,   2010 , 10.1159/000315239
• Radiofrequency ablation for hepatocellular carcinoma: assistance techniques for difficult cases., Oncology, 78, 94, 101,   2010 , 10.1159/000315236
• Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?, Oncology, 78, 87, 93,   2010 , 10.1159/000315235
• Contrast-enhanced ultrasound techniques for guiding and assessing response to locoregional treatments for hepatocellular carcinoma., Oncology, 78, 68, 77,   2010 , 10.1159/000315233
• Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma., Oncology, 78, 60, 67,   2010 , 10.1159/000315232
• Usefulness of the post-vascular phase of contrast-enhanced ultrasonography with Sonazoid in the evaluation of gross types of Hepatocellular carcinoma., Oncology, 78, 53, 59,   2010 , 10.1159/000315231
• Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using Sonazoid in the management of hepatocellular carcinoma., Oncology, 78, 40, 45,   2010 , 10.1159/000315229
• Management of hepatocellular carcinoma: from the prevention to molecular targeted therapy., Oncology, 78, 1, 6,   2010 , 10.1159/000315222
• Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice., Int J Clin Oncol, 15, 242, 255,   2010 , 10.1007/s10147-010-0089-y
• Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study., Int J Clin Pract, 64, 8, 1034, 1041,   2010 , 10.1111/j.1742-1241.2010.02414.x
• A novel biomarker TERTmRNA is applicable for early detection of hepatoma., BMC Gastroenterology, 10, 46, 57,   2010 , 10.1186/1471-230X-10-46
• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma., Hepatol Int, 4, 2, 439, 474,   2010 , 10.1007/s12072-010-9165-7
• Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis., Intervirology, 53, 76, 81,   2010 , 10.1159/000252789
• PEG-IFN α/RBV combination therapy for choronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate., Intervirology, 53, 60, 65,   2010 , 10.1159/000252786
• Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks., Intervirology, 53, 55, 59,   2010 , 10.1159/000252785
• Changing trends in hepatitis C interfection over the past 50 years in Japan., Intervirology, 53, 39, 43,   2010 , 10.1159/000252782
• Viral hepatitis A to E: An update in 2010., Intervirology, 53, 5, 9,   2010 , 10.1159/000252777
• Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience., Liver Int, 30, 5, 759, 764,   2010 , 10.1111/j.1478-3231.2010.02226.x
• Diagnosis of pancreatic tumors by endoscopic ultrasonography, World J Radiol, 2, 8, 122, 134,   2010
• The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy., J Gastroenterol Hepatol, 25, 439, 452,   2010 , 10.1111/j.1440-1746.2009.06207.x
• Management of hepatitis C: Report of the consensus meeting at the 45th annual meeting of the Japan Society of Hepatology (2009)., Hepatol Res, 40, 347, 368,   2010 , 10.1111/j.1872-034X.2010.00642.x
• Overall survival after transarterial lipiodol infusion chemotherapy with and without embolization for unresectable hepatocellular carcinoma: propensity score analysis., AJR Am J Roentgenol, 194, 830, 837,   2010 , 10.2214/AJR.09.3308
• Single HCC between 2 and 5cm: the grey zone: Hepatologist’s perspective., J Hepatobiliary-Pancreat Surg, 17, 434, 437,   2010 , 10.1007/s00534-009-0242-z
• EUS-guided in vivo microdialysis of the pancreas: a novel technique with potential diagnostic and therapeutic application., Gastrointest Endosc, 71, 1, 176, 179,   2010 , 10.1016/j.gie.2009.05.040
• Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis., Intervirology, 53, 76, 81,   2010 , 10.1159/000252789
• JSH Consensus Kobe 2009 ; Diagnosis and Treatment of NASH, OKANOUE Takeshi, SAIBARA Toshiji, ONO Masafumi, SUMIDA Yoshio, HASHIMOTO Etsuko, TAMURA Shinji, YAMADA Gotaro, KAWADA Sumio, KUDO Masatoshi, Kanzo, 50, 12, 741, 747,   2009 12 25 , 10.2957/kanzo.50.741, http://ci.nii.ac.jp/naid/10026101017
• Molecular targeted therapy for advanced hepatocellular carcinoma, KUDO Masatoshi, Nippon Shokakibyo Gakkai Zasshi, 106, 12, 1712, 1726,   2009 12 05 , 10.11405/nisshoshi.106.1712, http://ci.nii.ac.jp/naid/10026134405
• JSH Consensus Kobe 2009 : Diagnosis and Treatment of Hepatitis C, NISHIGUCHI Shuhei, IZUMI Namiki, HINO Keisuke, SUZUKI Fumitaka, KUMADA Hiromitsu, ITO Yoshito, ASAHINA Yasuhiro, TAMORI Akihiro, HIRAMATSU Naoki, HAYASHI Norio, KUDO Masatoshi, Kanzo, 50, 11, 665, 677,   2009 11 25 , 10.2957/kanzo.50.665, http://ci.nii.ac.jp/naid/10026100794
• Consensus report of the 2nd International Forum for Liver MRI., Eur Radiol Suppl, 19, 5, S975, S989,   2009 10
• Panel discussion : Management of hepatocellular carcinoma, ARII Shigeki, MISHIRO Shunji, MATSUI Osamu, IZUMI Namiki, KUDO Masatoshi, KOKUDO Norihiro, Kanzo, 50, 8, 407, 426,   2009 08 25 , 10.2957/kanzo.50.407, http://ci.nii.ac.jp/naid/10025137244
• Transgastric EUS guided gallbladder drainage for acute cholecystitis., Endoscopy, 41, E315, 316,   2009 , 10.1055/s-0029-1215225
• Identification and characterization of IgG4-associated autoimmune hepatitis., Liver Int, 30, 2, 222, 231,   2009 , 10.1111/j.1478-3231.2009.02092.x
• Age and immunoglobulin G4-associated autoimmune hepatitis: author’s response., Liver Int, 333,   2009 , 10.1111/j.1478-3231.2009.02165.x
• PEG-IFN α/RBV combination therapy for choronic hepatitis C patients increases serum ferritin level and improves sustained viral response rate., Intervirology, 53, 60, 65,   2009 , 10.1159/000252786
• Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks., Intervirology, 53, 55, 59,   2009 , 10.1159/000252785
• Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b., Intervirology, 53, 44, 48,   2009
• Double-filtration plasmapheresis plus IFN for non-sustained virological response to previous combination therapy: early viral dynamics., Intervirology, 53, 44, 48,   2009 , 10.1159/000252783
• Changing trends in hepatitis C interfection over the past 50 years in Japan., Intervirology, 53, 39, 43,   2009 , 10.1159/000252782
• Viral hepatitis A to E: An update in 2010., Intervirology, 53, 5, 9,   2009 , 10.1159/000252777
• Association of genetic polymorphisms with interferon-induced hematologic adverse effects in chronic hepatitis C patients., J Viral Hepat, 16, 388, 396,   2009 , 10.1111/j.1365-2893.2009.01095.x
• Acute pancreatitis associated with pegylated interferon and ribavirin treatment of chronic hepatitis C, genotype 1b with high viral load., Case Rep Gastroenterol, 3, 372, 376,   2009
• Consensus report of the 2nd international forum for liver MRI., Eur Radiol, 19, 975, 989,   2009
• Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocelular carcinoma., World J Radiol, 31, 86, 91,   2009
• Transgastric EUS guided gallbladder drainage for acute cholecystitis., Endoscopy, 41, 316, 316,   2009
• The burden of HCC in Asia-Pacific., LIVER MRI, 4, 1, 2,   2009
• Comparison of an ecabet sodium and proton pump inhibitor(PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection(ESD) ?induced ulcers in early gastric cancer: prospective randomized study., Hepatogastroenterol, 56, 1270, 1273,   2009
• Endoscopic findings of intestinal Behcet’s disease complicated with toxic megacolon., Endoscopy, 41, E1, E2,   2009
• Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience., AJR Am J Roentgenol, 193, 1540, 1545,   2009 , 10.2214/AJR.08.1681
• Small invasive ductal carcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasm. Case Report., World J Gastroetenrol, 15, 43, 5489, 5492,   2009 , 10.3748/wjg.15.5489
• Hepatectomy versus radiofrequency ablation for early hepatocelullar carcinoma: Reply., J Hepatol, 50, 1051, 1056,   2009 , 10.1016/j.jhep.2009.02.003
• Present status and future perspective of EUS-guided drainage., Digest Endosc, 21, 66, 70,   2009 , 10.1111/j.1443-1661.2009.00868.x
• Campylobacter fetus meningitis in a patient with Crohn’s disease., Inflamm Bowel Dis, 15, 645, 646,   2009 , 10.1002/ibd.20686
• Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies., World J Gastroenterol, 15, 2296, 2299,   2009 , 10.3748/wjg.15.2296
  Summary:233. 2009 Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Fukuda K, Nishikawa R, Koma Y, Matsuoka T, Kudo M, Hayashi Y: 15: 2296-2299, 2009.
• Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses., J Gastroen Hepatol, 24, 3, 384, 390,   2009 , 10.1111/j.1440-1746.2008.05636.x
• Crohn’s disease with gastroduodenal mucosa lesions that are similar to the lesions caused by ulcerative colitis., Inflamm Bowel Dis, 15, 5, 646, 648,   2009 , 10.1002/ibd.20685
• Well-differentiated hepatocellular carcinoma smaller than 15mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation., Hepatol Int, 3, 411, 415,   2009 , 10.1007/s12072-009-9128-z
• Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis., Digestion, 79, 36, 39,   2009 , 10.1159/000203639
• Value of liver parenchymal phase contrast-enhanced sonography to diagnose the premalignant and borderline lesions and overt hepatocellular carcinoma., AJR Am J Roentgenol, 192, 698, 705,   2009 , 10.2214/AJR.07.3282
• Multistep human hepatocarcinogenesis: correlation of imaging with pathology., J Gastroenterol, 44, 112, 118,   2009 , 10.1007/s00535-008-2274-6
• Interventional EUS for pancreatic diseases, KITANO Masayuki, SAKAMOTO Hiroki, KUDO Masatoshi, 35, 6, 663, 670,   2008 11 15 , 10.3179/jjmu.35.663, http://ci.nii.ac.jp/naid/10023914387
• Prevention of Recurrence of Liver Cancer, Kudo Masatoshi, Nihon Naika Gakkai Zasshi, 97, 7, 1681, 1689,   2008 07 10 , 10.2169/naika.97.1681, http://ci.nii.ac.jp/naid/10021930747
• Pegylated interferon α-2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b, KIM Soo Ryang, IMOTO Susumu, FUKI Shuichi, KIM Ke Ih, TANIGUCHI Miyuki, NAGANO Motoko, HOTTA Hak, SHOUJI Ikuo, KANBARA Yoshihiro, MAEKAWA Yoko, KUDO Masatoshi, HAYASHI Yoshitake, Kanzo, 49, 4, 145, 152,   2008 04 25 , 10.2957/kanzo.49.145, http://ci.nii.ac.jp/naid/10021938805
  Summary:The patients (n=75) in this study had chronic hepatitis C with high viral loads of serum HCV-RNA genotype 1b. All the patients received a regimen of pegylated interferon α-2b plus ribavirin (PEG IFN α-2b/RBV) for 48 weeks. Comparative analysis was done by dividing these patients into two groups by age: Elderly group (over 65 years old, 23 patients) and Non-Elderly group (under 65 years old, 52 patients). The sustained viral response (SVR) rate in the Elderly (37.5%, 6/16) was not different significantly from that in the Non-Elderly (50%, 20/40). The response ratio of 2´-5´-oligoadenylate synthetase (2-5AS), the viral dynamics and the rate of discontinuation of therapy were not different between the two groups. Interestingly, however, the mean α-fetoprotein (AFP) values decreased significantly in the Elderly irrespective of SVR or non-SVR (from 10.1±9.55 ng/ml before treatment to 5.18±4.52 ng/ml after treatment, P<0.05), but did not in the Non-Elderly. It was thus suggested that Peg IFN α-2b/RBV would be useful in the prevention of HCC in elderly patients including non-SVR cases.
• Contrast-enhanced harmonic EUS with Sonazoid, KITANO Masayuki, SAKAMOTO Hiroki, KUDO Masatoshi, 35,   2008 04 15 , http://ci.nii.ac.jp/naid/10023914537
• Joint Research for the Objective Rating of Hepatic Tissue Characterization Using Real-time Tissue Elastography (3rd report), FUJIMOTO Kenji, TATSUMI Chie, UESHIMA Kazuomi, MAEKAWA Kiyoshi, KATO Michio, KUDO Masatoshi, TONOMURA Akiko, YAMAKAWA Makoto, SHIINA Tsuyoshi, 35,   2008 04 15 , 10.1179/174313408X322741, http://ci.nii.ac.jp/naid/10023914657
• Study of Ablated valome after RFA using CE-US with Sonazoid, Defect-reinjection-test and new imaging, MAEKAWA Kiyoshi, HATANAKA Kinuyo, YOKOGAWA Mika, MAENO Tomoko, ICHIJIMA Mayumi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, KUDO Masatoshi, 35,   2008 04 15 , http://ci.nii.ac.jp/naid/10023915007
• Contrast enhanced sonography for hepatic malignancies : value of Defect Re-injection Test, HATANAKA Kinuyo, MINAMI Yasunori, KITAI Satoshi, TATSUMI Chie, TAKAHASHI Syunsuke, INOUE Tatsuo, HAGIWARA Satoru, CHUNG Hobyung, UESHIMA Kazuomi, KUDO Masatoshi, 35,   2008 04 15 , http://ci.nii.ac.jp/naid/10023915255
• Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey., J Hepatol, 49, 589, 594,   2008 , 10.1016/j.jhep.2008.05.018
• Long-term follow-up of atypical progressive focal nodular hyperplasia increasing in size and number implicates its pathogenesis., Am J Gastroenterol, 103, 2153, 2155,   2008 , 10.1111/j.1572-0241.2008.01982_14.x
• Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma., Hepato?Gastroenterol, 55, 1454, 1457,   2008
• Focal nodular hyperplasia-like lesion with venous washout in alcoholic liver cirrhosis., Internal Med, 47, 1899, 1903,   2008 , 10.2169/internalmedicine.47.1221
• Intracystic hemorrhage in a patient of polycystic kidney with renocolic fistula diagnosed by contrast-enhanced ultrasonography., Intern Med, 47, 1977, 1979,   2008 , 10.2169/internalmedicine.47.1184
• In situ carcinoma of pancreas diagnosed by EUS-FNA., Endoscopy, 40, E15, E16,   2008 , 10.1055/s-2007-966708
• Multistep progression from a hypovascular nodule to a nodule-in-nodule type hepatocellular carcinoma in hepatitis C-related cirrhosis., Indian J Gastroenterol, 27, 176,   2008
• Foreign body granuloma mimicking disseminated tumor reccurence after radiofrequency ablation for hepatocellular carcinoma., Liver Int, 28, 414, 415,   2008 , 10.1111/j.1478-3231.2007.01607.x
• Defect reperfusion imaing, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma, J Med Ultrasound, 16, 169, 176,   2008 , 10.1016/S0929-6441(08)60045-4
• Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis., World J Gastroenterol, 14, 5316, 5321,   2008 , 10.3748/wjg.14.5316
• The clinical characteristics, endscopic treatment and prognosis for patients presenting with duodenal varices., Hepato?Gastroenterol, 55, 959, 962,   2008
• Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC., J Hepatol, 49, 223, 232,   2008 , 10.1016/j.jhep.2008.04.013
• Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumors., J Med Ultrasound, 16, 130, 139,   2008 , 10.1016/S0929-6441(08)60014-4
• Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotye 1b., Intervirology, 51, S70, S75,   2008 , 10.1159/000122601
• Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas., Ultrasound Med Biol, 34, 525, 532,   2008 , 10.1016/j.ultrasmedbio.2007.09.018
• Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan), and real-time tissue., Intervirology, 51, S27, S33,   2008 , 10.1159/000122602
• A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score., Intervirology, 51, S86, S94,   2008 , 10.1159/000122599
• Elevated serum ALT levels during pegylated interferon monotherapy may be caused by hepatic iron overload., Intervirology, 51, S76, S85,   2008 , 10.1159/000122604
• Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis., Intervirology, 51, S17, S26,   2008 , 10.1159/000122595
• Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid., Intervirology, 51, S61, S69,   2008 , 10.1159/000122600
• Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation., AJR Am J Roentgenol, 190, 1, W7,   2008
• Effects of decorin on the expression of α-smooth muscle actin in a human myofibroblast cell line., Mol Cell Biochem, 308, 201, 207,   2008 , 10.1007/s11010-007-9629-9
• Preliminary study of contrast-enhanced harmonic endosonography with second-generation contrast agents., J Med Ultrasonics, 35, 11, 18,   2008 , 10.1007/s10396-007-0167-6
• A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video)., Gastrointest Endscopy, 67, 141, 150,   2008 , 10.1016/j.gie.2007.07.045
• Mixed intestinal-and diffuse-type histology is a risk factor for lymph node metastasis of submucosal invasive gastric cancer, Digestive Endoscopy, 20, 1, 17, 21,   2008 01 , 10.1111/j.1443-1661.2007.00770.x
• Dissemination of clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists and liver surgeons, KOKUDO Norihiro, MAKUUCHI Masatoshi, NAKAYAMA Takeo, ARII Shigeki, OMATA Masao, KUDO Masatoshi, KOJIRO Masamichi, SAKAMOTO Michiie, TAKAYASU Ken-ichi, HAYASHI Norio, MONDEN Morito, Kanzo, 48, 11, 562, 570,   2007 11 25 , 10.2957/kanzo.48.562, http://ci.nii.ac.jp/naid/10020121530
  Summary:"Clinical practice guidelines for hepatocellular carcinoma (HCC)," the first evidence-based guidelines for the treatment of HCC in Japan (the J-HCC Guidelines) have been compiled and English translation has just been completed (http://www.jsh.or.jp/). In March 2006, approximately a year after publication of the J-HCC Guideline Book, a questionnaire survey was conducted to investigate the level of awareness and influence of the guidelines among 2,279 members of the Liver Cancer Study Group of Japan. Of the 843 responders (37.0%), the J-HCC Guidelines have been acknowledged by 72% and 78.8% considered the guidelines useful for their daily practice. Algorithm for the treatment was most commonly used. After the introduction of the guidelines, only 20.8% of the responders changed their practice pattern; 40.3% did not change and were convinced that their choice of treatment was similar to the recommendations in the guidelines. In conclusion, one year after their publication, the J-HCC Guidelines have become well disseminated among specialists for HCC in Japan. As expected, these guidelines have begun to be applied at every level of clinical decision-making for HCC.
• ENDOSCOPIC ULTRASOUND-GUIDED BILIARY DRAINAGE FOR OBSTRUCTIVE JAUNDICE, SAKAMOTO Hiroki, KITANO Masayuki, SUETOMI Yoichiro, SHIOMI Mikio, KOMAKI Takahiro, NODA Kazu, TATUMI Chie, UESHIMA Kazuomi, KUDO Masatoshi, Gastroenterol Endosc, 49, 8, 1844, 1847,   2007 08 20 , 10.11280/gee1973b.49.1844, http://ci.nii.ac.jp/naid/10019818396
• A Proposal of Novel Treatment-assist Technique for Hepatocellular Carcinoma in the Sonazoid-enhanced Ultrasonography : Value of Defect Re-Perfusion Imaging, KUDO Masatoshi, HATANAKA Kinuyo, CHUNG Hobyung, MINAMI Yasunori, MAEKAWA Kiyoshi, Kanzo, 48, 6, 299, 301,   2007 06 20 , 10.2957/kanzo.48.299, http://ci.nii.ac.jp/naid/10019510868
  Summary:We have innovated new imaging technique, Defect Re-perfusion Imaging, in the Sonazoid-enhanced contrast ultrasonography (US) for hepatocellular carcinoma (HCC), which is not clearly demonstrated on B mode US. Firstly, perfusion defect can be detected on post-vascular phase imaging 10 min after intravenous injection of Sonazoid. Second, re-injection of Sonazoid clearly shows arterial hypervascularity within the defect portion if the nodule is typical HCC. Since this technique is extremely useful in the detection, treatment guidance and evaluation of treatment response for ultrasound ill-defined HCC nodules, we propose this technique should be widely used in the clinical practice of HCC.
• New Situation of Contrast Enhanced Sonography, MINAMI Yasunori, KUDOU Masatoshi, 34,   2007 04 15 , http://ci.nii.ac.jp/naid/10019999381
• Invention of Contrast-enhanced Harmonic Endosonography and Its Application to Clinical Investigations, KITANO Masayuki, SAKAMOTO Hiroki, MATSUI Uwe, ITO Yasuhiro, MAEKAWA Kiyoshi, VON SCHRENCK Tammo, KUDO Masatoshi, 34,   2007 04 15 , http://ci.nii.ac.jp/naid/10019999415
• Joint Research for the Objective Rating of Hepatic Tissue Characterization Using Real-time Tissue Elastography, FUJIMOTO Kenji, TATSUMI Chie, UESHIMA Kazuomi, MAEKAWA Kiyoshi, TONOMURA Akiko, MITAKE Tsuyoshi, YAMAKAWA Makoto, KATO Michio, KUDOU Msatoshi, SHIINA Tsuyoshi, 34,   2007 04 15 , http://ci.nii.ac.jp/naid/10019999595
• Study of Hepatic Tumors Using Contrast-enhanced Ultrasonography with Sonazoid, MAEKAWA Kiyoshi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, HUKUNAGA Toyokazu, KUDOU Masatoshi, 34,   2007 04 15 , http://ci.nii.ac.jp/naid/10019999856
• Radiofrequency ablation combined with reduction of hepatic blood flow: effect of lipiodol on coagulation diameter and ablation time in normal pig liver., Hepato-Gastroenterol, 54, 701, 704,   2007 03
• Contrast harmonoc sonographic-guided radiofrequency ablation theraph Versus B-mode sonography in Hepatocellular Carcinoma: prospective randomized controlled trial., AJR, 188, 489, 494,   2007 02 , 10.2214/AJR.05.1286
• Contrast harmonic sonography-guided radiofrequency ablation therapyversus B-mode sonography in hepatocellular carcinoma:prospectiverandomized controlled trial., Am J Roentgenol, 188, 489, 494,   2007 , 10.2214/AJR.05.1286
• Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumor cell growth in nude mice by apoptosis of p53., Brit J Cancer, 97, 1532, 1537,   2007 , 10.1038/sj.bjc.6604058
• Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation: a matched case-control study., Oncology, 72, 132, 138,   2007 , 10.1159/000111719
• Percutaneous radiofrequency ablation of sonographically unidentifiable liver tumors: Feasibility and usefulness of a novel guiding technique with an integrated system of computed tomography and sonographic images., Oncology, 72, 111, 116,   2007 , 10.1159/000111716
• Initial treatment response is essential to improve survival in patients with heptocellular carcinoma who underwent curative radiofrequency ablation therapy., Oncology, 72, 98, 103,   2007 , 10.1159/000111714
• What is the best time to evaluate treatment response after radiofrequency ablation of hepatocellular carcinoma using contrast-enhanced sonography?, Oncology, 72, 92, 97,   2007 , 10.1159/000111713
• Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients., Oncology, 72, 72, 75,   2007 , 10.1159/000111710
• Superiority of CT arterioportal angiography to contras-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2cm., Oncology, 72, 58, 66,   2007 , 10.1159/000111708
• Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma., Oncology, 72, 45, 51,   2007 , 10.1159/000111706
• Natural course of small nodular lesions with intranodular preserved portal supply in cirrhotic liver., Oncology, 72, 24, 29,   2007 , 10.1159/000111704
• Management of heepatocellular carinoma in Japan: Consensus-based clinical practice manual proposed by the Japan Society of Hepatology., Oncology, 72, 2, 15,   2007 , 10.1159/000111702
• Case of rapidly progressed sarcomatoid hepatocellular carcinoma in young female without risk factor., Liver Int, 27, 10, 1428, 1430,   2007 , 10.1111/j.1478-3231.2007.01584.x
• Small hepatocellular carcinoma presenting with massive metastasis in the peritoneum, mimicking sarcomatous tumor., Hepatol Res, 37, 885, 889,   2007 , 10.1111/j.1872-034X.2007.00134.x
• Well- to moderately-differentiated HCC manifesting hyperattenuation on both CT during arteriography and arterial portography., World J Gastroenterol, 13, 43, 5775, 5778,   2007
• Outcomes of non-trasplant potentially curative therapy for early-stage hepatocellular carinoma in child-pugh stage A cirrhosis is comparable with liver transplantation., Digest Dis, 25, 4, 303, 309,   2007 , 10.1159/000106909
• Role of tumor markers in assesment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma., Hepatol Res, 37, S166, S171,   2007
• New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma., Hepatol Res, 37, S193, S199,   2007 , 10.1111/j.1872-034X.2007.00184.x
• International camparision of treatment outcomes based on staging systems., Hepatol Res, 37, S216, S222,   2007
• Review of current staging systems for hepatocellular carcinoma., Hepatol Res, 37, S210, 215,   2007
• Hepatocellular carcinoma: international consensus and controversies., Hepatol Res, 37, S83, S87,   2007
• Report of the 17th follow-up survey of primary liver cancer in Japan., Hepatol Res, 37, 676, 691,   2007 , 10.1111/j.1872-034X.2007.00119.x
• First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma., Jpn J Clin Oncol, 37, 376, 381,   2007 , 10.1093/jjco/hym039
• Endoscopic ultrasonography with three miniature probes of different frequency is an accurate diagnostic tool for endoscopic submucosal dissection., Hepato-Gastenterol, 54, 325, 328,   2007
• Multistep hepatocarcinogenesis from dysplastic nodule to well-differentiated hepatocelllular carcinoma in a patient with alcohol-related liver cirrhosis., World J Gastroenterol, 13, 8, 1271, 1274,   2007
• Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study., Ann Intern Med, 146, 649, 656,   2007
• Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonography., Ultrasound Med Biol, 33, 353, 361,   2007 , 10.1016/j.ultrasmedbio.2006.09.003
• Endoscopic ultrasound-guided pancreatico-gastrostomy reconstruction., Endoscopy, 39, E1, E2,   2007 , 10.1055/s-2007-966150
• Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update., J Hepatol, 46, 521, 527,   2007 01 , 10.1016/j.jhep.2006.12.007
• Consensus on extra-hepatic portal vein obstruction., Liver Int, 26, 512, 519,   2006 06 , 10.1111/j.1478-3231.2006.01269.x
• Case of adult genotype CHBV carrier after acute hepatitis B, losing HBsAg and acquiring HBsAb after IFN and lamivudine treatment., Hepatol Res, 36, 149, 152,   2006 , 10.1016/j.hepres.2006.06.013
• Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma., J Gastroenterol, 41, 1214, 1219,   2006 , 10.1007/s00535-006-1950-7
• Staging hepatocellular carcinoma by a novel scoring system (BALAD Score) based on serum markers., Clinical Gastroenterol and Hepatol, 4, 1528, 1536,   2006 , 10.1016/j.cgh.2006.09.021
• Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis., Hepato-Gastenterol, 53, 879, 882,   2006
• Hepatocellular carcinoma metastasizing to the skull base involving multiple cranial nerves., World J Gastroenterol, 12, 6727, 6729,   2006
• Clinical characteristics of nonBnonC HCC: comparison with HBV and HCV related HCC., Intervirology, 50, 24, 31,   2006 , 10.1159/000096309
• Wegener’s granulomatosis complicated with aphthoid colitis: a case report., Digestive Endoscopy, 18, 221, 224,   2006 , 10.1111/j.0915-5635.2006.00605.x
• Value of computed tomography for evaluating the injection site in endosonography-guided celiac plexus neurolysis., Digestive Endoscopy, 18, 206, 211,   2006 , 10.1111/j.0915-5635.2006.00611.x
• What is the best staging system for hepatocellular carcionoma?, J Gastroenterol, 41, 3, 290, 291,   2006
• Clinical significance of the genotype and core promoter/pre-core mutations in hepatitis B virus carriers., Intervirology, 49, 200, 206,   2006 , 10.1159/000090789
• Hemodynamic and morphologic changes of peripheral hepatic vasculare in cirrhotic liver disease: a preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography., World of Gastroenterol, 11, 6348, 6353,   2006
• Imaging findings of biliary hamartomas., World of Gastroenterol, 11, 6354, 6359,   2006
• Cecal necrosis due to ischemic colitis mimicking an abscess on songraphy, J Ultrasound Med, 25, 393, 396,   2006
• Comparison of standard-dose and low-dose regimens of gemcitabine for patients with pancreatic adenocarcinoma: a preliminary prospective randomized trail., J Gastroenterol, 41, 70, 76,   2006 , 10.1007/s00535-005-1724-7
• Hepatocellular carcinoma and NASH., J Gastroenterol, 39, 409, 411,   2006 , 10.1007/s00535-004-1332-y
• A proposal of the modified liver damage classification for hepatocellular carcinoma., Hepatology Research, 34, 124, 129,   2006 , 10.1016/j.hepres.2005.10.009
• Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography, AJR, 181, 57, 63,   2006
  Summary:. 2003; : -.
• Stage IV hepatocellular carcinoma with portal venous tumor thrombus: complete response after combined therapy of repeated arterial chemoembolization and radiofreqnency ablation, J Gastroenterol, 38, 406, 409,   2006 , 10.1007/s005350300073
• Vascularity of Gastric Carcinoma : Evaluation using Color Doppler Ultrasonography, KUWAGUCHI Ai, KUDO Masatoshi, KAWASAKI Toshihiko, MAENO Tomoko, ICHIZIMA Mayumi, MAEKAWA Kiyoshi, INOUE Tatuo, ITOU Tatuki, 32, 6, 539, 545,   2005 11 15 , http://ci.nii.ac.jp/naid/10020456646
• Vascularity of Gastric Carcinoma : Evaluation using Color Doppler Ultrasonography, KUWAGUCHI Ai, KUDO Masatoshi, KAWASAKI Toshihiko, MAENO Tomoko, ICHIZIMA Mayumi, MAEKAWA Kiyoshi, INOUE Tatuo, ITOU Tatuki, 32, 6, 539, 545,   2005 11 15 , http://ci.nii.ac.jp/naid/10021787421
• Serologic test for the diagnosis of subclinical gastric anisakiasis, Gastrointestinal Endoscopy, 61, 7, 931,   2005 07
• Forefront of radiofrequency ablation treatment of hepatic cancer. 1. Treatment indication (positioning of the treatment)., Kudo Masatoshi, Kanzo, 46, 4, 160, 164,   2005 04 25 , 10.2957/kanzo.46.160, http://ci.nii.ac.jp/naid/10015684084
• Usefullness of contrast-enhanced ultrasonography for diagnosis and evaluation of response to chemotherapy in pancreatic ductal carcinomas, SAKAMOTO Hiroki, KITANO Masayuki, KUDOU Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456000
• Estimation of the Malignant Potential of Gastrointestinal Stromal Tumors, FUKUTA Nobuhiro, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456013
• Evaluation of microcirculation in digestive organs by EUS probe, KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, MINAMI Yasunori, NAKAOKA Ryousuke, NAKATANI Tatsuya, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456015
• Usefulness and manipulation of EUS-FNAB for diagnosis of pancreatic tumors, SAKAMOTO Hiroki, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456023
• Usefulness and indication of EUS-guided celiac plexus neurolysis, KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456024
• Real-time Virtual Sonography, an integrated system of computer tomography with ultrasound images : Value in radiofrequency ablation guidance, MINAMI Yasunori, KUDO Masatoshi, TEI Hiroshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456028
• Detect of early arterial phase in Coded Harmonic Angio mode with Levovist used accumulation and time intensity courve, MAEKAWA Kiyoshi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, HUKUNAGA Toyokazu, KUDOU Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10020456305
• Usefullness of contrast-enhanced ultrasonography for diagnosis and evaluation of response to chemotherapy in pancreatic ductal carcinomas, SAKAMOTO Hiroki, KITANO Masayuki, KUDOU Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021786775
• Estimation of the Malignant Potential of Gastrointestinal Stromal Tumors, FUKUTA Nobuhiro, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021786788
• Evaluation of microcirculation in digestive organs by EUS probe, KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, MINAMI Yasunori, NAKAOKA Ryousuke, NAKATANI Tatsuya, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021786790
• Usefulness and manipulation of EUS-FNAB for diagnosis of pancreatic tumors, SAKAMOTO Hiroki, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021786798
• Usefulness and indication of EUS-guided celiac plexus neurolysis, KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, KUDO Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021786799
• Real-time Virtual Sonography, an integrated system of computer tomography with ultrasound images : Value in radiofrequency ablation guidance, MINAMI Yasunori, KUDO Masatoshi, TEI Hiroshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021786803
• Detect of early arterial phase in Coded Harmonic Angio mode with Levovist used accumulation and time intensity courve, MAEKAWA Kiyoshi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, HUKUNAGA Toyokazu, KUDOU Masatoshi, 32,   2005 04 15 , http://ci.nii.ac.jp/naid/10021787080
• Staging system for hepatocellular carcinoma : it concept and clinical impact, KUDO Masatoshi, Kanzo, 46, 2, 53, 63,   2005 02 25 , 10.2957/kanzo.46.53, http://ci.nii.ac.jp/naid/10015445985
  Summary:In this article, the concept and clinical impact of the staging systems for hepatocellular carcinoma (HCC) were reviewed. Among the several scoring systems so far available, such as Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), and Japan Integrated Staging (JIS) systems, the JIS system is extremely efficient in the stratification ability of the HCC patients from the very early stage through highly advanced stage of HCC: particularly in the areas like Japan, where small HCC less than 2 cm in diameter can be diagnosed based on the screening program for early detection of HCC. This efficiency of the JIS system is due to an excellent tumor-node-metastasis (TNM) staging system developed by Liver Cancer Study Group of Japan (LCSGJ). JIS system is an integated staging system between child-Pugh stage and the TNM stage by LCSGJ. Therefore, the TNM stage by LCSGJ and the JIS score is expected to be used as a global standard staging system in the near future.
• Multiple hypervascular liver nodules in a heavy drinker of alcohol., J Gastroenterol Hepatol, 20, 795, 799,   2005 , 10.1111/j.1440-1746.2005.03244.x
• Vascularity of gastric carcinoma: evaluation using color Doppler ultrasonography., J Med Ultrasonics, 32, 23, 28,   2005 , 10.1007/s10396-005-0029-z
• Low-dose, long-term, intermittent interferon-alpha 2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus related hepatocellular carcinoma., Intervirology, 48, 64, 70,   2005 , 10.1159/000082097
• Reply "Staging for hepatocellular carcinoma: treatment strategy matters.", Hepatology, 41, 678, 679,   2005 , 10.1002/hep.20583
• Response., Gastrointest Endosc, 61, 931,   2005
• Early detection and curative treatment of early-stage hepatocellular carcinoma., Clin Gastroenterol Hepatol, 3, 144, 148,   2005 , 10.1016/S1542-3565(05)00712-3
• Hepatic angiomyolipoma: identification of an efferent vessel to be hepatic vein by contrast-enhanced harmonic ultrasound., Br J Radiol, 78, 956, 960,   2005
• Hepatic angiomyolipma-identification of an efferent vessel to be hepatic vein by contrast-enhanced harmonic ultrasonography., J Med Ultrasonics, 32, 191, 196,   2005 , 10.1007/s10396-005-0052-0
• Imaging findings of biliary hamartomas (von Meyenburg complexes)., J Med Ultrasonics, 32, 205, 212,   2005 , 10.1007/s10396-005-0051-1
• Hemodynamic and morphologic changes of peripheral hepatic vasculature in chronoic liver disease: a preliminary study by contrast-enhanced coded phase-inversion harmonic sonography., J Med Ultrasonics, 32, 197, 204,   2005 , 10.1007/s10396-005-0053-z
• Multiple metastases from a meningeal hemangiopericytoma associated with severe hypoglycemia., J Med Ultrasonics, 32, 187, 190,   2005 , 10.1007/s10396-005-0049-8
• A case of central retinal vein occlusion during combination therapy of IFNα-2b and rivabirin for chronic hepatitis C, FUKI Syuichi, KIM Soo Ryang, NINOMIYA Tosiaki, MAEKAWA Yoko, KIM Ke Ih, IMOTO Susumu, KUDO Masatoshi, Kanzo, 45, 12, 666, 670,   2004 12 25 , 10.2957/kanzo.45.666, http://ci.nii.ac.jp/naid/10014497458
• Mucin phenotypic expression and background mucosa of esophagogastric junctional adenocarcinoma, Gastric Cancer, 7, 97, 103,   2004 06
• Precut sphincterotomy from the pancreatic orifice using a standard papillotome, MIZUNO Shigeto, HONJO Hajime, KUDO Masatoshi, 18, 1, 23, 28,   2004 03 19 , 10.11210/tando1987.18.1_23, http://ci.nii.ac.jp/naid/10030924384
• Diagnosis of acute cholecystitis in patients with liver cirrhosis: waveform analysis of cystic artery by color Doppler imaging., J Medical Ultrasonics, 31, 21, 28,   2004 , 10.1007/s10396-003-0001-8
• Estimation of the malignant potential of gastrointestinal stromal tumors: The value of contrast-enhanced coded phase-inversion harmonic US., J Gastroenterol, 40, 247, 255,   2004 , 10.1007/s00535-004-1531-6
• Validation of a New Prognostic Staging System for Hepatocellular Carcinoma, the JIS Score as Compared with CLIP Score., Hepatology, 40, 1396, 1405,   2004 , 10.1002/hep.20486
• Detection of the intratumoral vascularity in small hepatocellular carcinoma by coded phase inversion harmonics., Intervirology, 47, 169, 178,   2004 , 10.1159/000078469
• Atypical large well-differentiated hepatocellular carcinoma with benign nature: a new clinical entity., Intervirology, 47, 227, 237,   2004 , 10.1159/000078475
• Differentiation of hepatic tumors by color Doppler imaging: role of the maximum velocity and the pulsatility index of the intratumoral blood flow signal., Intervirology, 47, 154, 161,   2004 , 10.1159/000078467
• Hepatocellular carcinoma with nodule in nodule appearance: demonstration by contrast-enhanced coded phase-inversion harmonic imaging., Intervirology, 47, 184, 190,   2004 , 10.1159/000078471
• Afferent and efferent vessel of premalignant and overt hepatocellular carcinoma: Observation by color Doppler imaging., Intervirology, 47, 144, 153,   2004 , 10.1159/000078466
• Atypical focal spared area in fatty liver: evaluation by color Doppler ultrasonography., J Med Ultrasonics, 31, 131, 134,   2004 , 10.1007/s10396-004-0013-z
• Hepatocellular carcinoma ruptured during radiofrequency ablation therapy., J Gastroenterol, 39, 10, 1015, 1016,   2004 , 10.1007/s00535-003-1437-8
• Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography., AJR, 183, 153, 156,   2004
• Dynamic imaging of pancreatic diseases by contrast-enhanced coded phase- inversion harmonic US., Gut, 53, 6, 854, 859,   2004
• Multiple tuberculous abscesses of the liver and the brain in a patient with acute leukemia., J Gastroenterol, 39, 497, 499,   2004 , 10.1007/s00535-003-1327-0
• Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artifical pleural effusion for hepatocellular carcinoma in the hepatic dome., AJR, 182, 5, 1224, 1226,   2004
• Comparison of argon plasma coagulation and paravariceal injection sclerotherapy of 1 % polidocanol in the mucosa-fibrosing therapy for esophageal varices., J Gastroenterol, 39, 397, 401,   2004 , 10.1007/s00535-003-1309-2
• Characterization of hepatic tumors: value of contrast-enhanced coded phase inversion harmonic US., AJR, 182, 4, 1019, 1026,   2004
• Local ablation therapy for hepatocellular carcinoma: current status and future perspective., J Gastroenterol, 39, 205, 214,   2004 , 10.1007/s00535-003-1280-y
• The present condition of radiofrequency ablation : A retreospective multicenter study (38 institutions), KASUGAI Hiroshi, OSAKI Yukio, OKA Hiroko, KUDO Masatoshi, SEKI Toshihito, Osaka liver cancer study group, Kanzo, 44, 12, 632, 640,   2003 12 25 , 10.2957/kanzo.44.632, http://ci.nii.ac.jp/naid/130000875257
  Summary:This study was undertaken to obtain the information about the present condition of radiofrequency ablation (RFA) for hepatocellular carcinoma.The data of 2614 patients, who underwent RFA between January 1999 and May 2002, were gathered and analyzed in this study.RFA was performed percutaneously in 2542, raparoscopically in 23 and operatively in 49 patients.The complication rate was 7.8% (204 patients). Most popular complications were pleural effusion, ascites, biliary injury, portal thrombus, intraperitoneal hemorrhage, burn of the abdominal wall and liver abscess. The mortality rate was 0.3% (9 patients).The complication rate and mortality rate were lower in institutions which have some device for safe and accurate treatment or have much experience in RFA.
• Natural history of untreated hepatocellular carcinoma : A retrospective multicenter study of 195 patients, OKA Hiroko, OSAKI Yukio, KASUGAI Hiroshi, KUDO Masatoshi, SEKI Toshihito, Osaka liver cancer study group, Kanzo, 44, 11, 546, 551,   2003 11 25 , 10.2957/kanzo.44.546, http://ci.nii.ac.jp/naid/130000875247
  Summary:The present study deals with the natural history of 195 patients with hepatocellular carcinoma who were seen from 1990 to 2000. One-year survival of overall patients was 31%, 3-year was 10%, and 5-year was 3%. The 1-, 3-, 5-yr survival for 13 patients with the liver damage score A/B and the imaging stage I was 82%, 56%, 56%, respectively. The 1-, 3-, 5-yr survival for 20 patients with the liver damage score A/B and the imaging stage III was 42%, 8%, 0%, respectively. The tumor stage and clinical stage were correlated to the prognosis.
• 2.Local ablation therapy, KUDO M, Kanzo, 44, 6, 250, 258,   2003 06 25 , 10.2957/kanzo.44.250, http://ci.nii.ac.jp/naid/10011223733
• Hepatobiliary and pancreatic: fatty liver, spared areas and aberrant gastric venous drainage., J Gastroenterol Hepatol, 18, 1423,   2003 , 10.1046/j.1440-1746.2003.03293.x
• Percutaneous ultrasound-guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome, J Gastroenterol, 38, 1066, 1070,   2003 , 10.1007/s00535-003-1197-5
• Detection of tumor vascularity in hepatocellular carcinoma with contrast enhanced Dynamic Flow imaging: comparison with contrast enhanced power Doppler imaging., J Medical Ultrasonics, 30, 141, 151,   2003 , 10.1007/BF02481219
• Hepatocellular carcinoma associated with secondary hemochromatosis in non-cirrhotic liver, Hepatol Res, 26, 254, 258,   2003 , 10.1016/S1386-6346(03)00109-8
• Hepatobiliary and pancreatic: arterioportal fistula causing portal hypertension., J Gastroenterol Hepatol, 18, 873,   2003 , 10.1046/j.1440-1746.2003.03116.x
• Value of new contrast harmonic technique for detecting tumor vascularity in hepatocellular carcinoma: preliminary results, J Medical Ultrasonics, 30, 85, 92,   2003 , 10.1007/BF02481368
• Contrast-enhnaced Agent Detection Imaging: early experience in hepatocellular carcinoma, J Med Ultrasonics, 30, 77, 84,   2003 , 10.1007/BF02481367
• Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors, Springer Verlag, 1, 253,   2003
• Radiofrequency ablation therapy under harmonic imaging guidance for the recurring cancer after local therapy for HCC: a randomized controlled study with RFA under B-mode guidance, Ultrasound Med Biol, 29, 145,   2003
• Hepagocellular carcinoma mimicking cavernous hemangioma on angiography and contrast enhanced harmonic ultrasonography. A case report., Hepatol Res, 25, 202, 212,   2003 , 10.1016/S1386-6346(02)00249-8
  Summary:2003; : -
• Spontaneous regurgitation of portal blood flow normalized by meal intake in a patient with alcoholic liver cirrhosis, Hepatol Res, 25, 143, 148,   2003 , 10.1016/S1386-6346(02)00206-1
• Hepatic nodular lesions caused by abnormal hepatic circulation: etiological and clinical aspects, J Gastroenterol, 38, 308, 309,   2003 , 10.1007/s005350300056
• Prognostic staging system for hepatocellular carcinoma (CLIP score): value, limitation and a proposal of new prognostic system, Japan Integrated Staging Score (JIS Score), J Gastroenterol, 38, 207, 215,   2003 , 10.1007/s005350300038
• Assessment of image quality of contrast-enhanced power Doppler imaging in hepatocellular carcinoma with a personal ultrasound imager: comparison with conventional machine, J Medical Ultrasonics, 30, 31, 38,   2003
• Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography, AJR, 180, 703, 708,   2003
• Transient portal vein thrombosis caused by radiofrequency ablation for hepatocellular carcinoma, J Gastroenterol, 28, 101, 103,   2003 , 10.1007/s005350300015
• Contrast advanced dynamic flow imaging and contrast pulse subtraction imaging: preliminary results in hepatic tumors, J Medical Ultrasonics, 29, 195, 204,   2003
• Impact Factor and Stock Market, KUDO Masatoshi, 29, 6, J535, J536,   2002 11 15 , http://ci.nii.ac.jp/naid/10012281371
• The efferent blood flow of early hepatocellular carcinoma and borderline lesions: demonstration by color Doppler imaging., J Med Ultrasonics, 29, 205, 209,   2002
• Evaluation of image quality of personal ultrasound imager: comparison with the conventional machine, J Med Ultrasonics, 29, 41, 46,   2002
• Contrast harmonic imaging in the characterization of hepatic tumors, J Society Ultrasound Med ROC, 18, 52, 53,   2002
• Radiofrequency ablation for HCC under contrast-harmonic imaging, J Society Ultrasound Med ROC, 18, 48, 50,   2002
• Hepatocellular carcinoma treated with radiofrequency ablation: Evaluation of therapeutic response by contrast-enhanced Coded Harmonic Angio, Chinese Journal of Ultrasound in Medicine, 18, 6, 452, 455,   2002
• Endoscopic band ligation for control of nonvariceal upper GI hemorrhage: comparison with bipolar electrocoagulation, Gastrointest Endoscopy, 55, 214, 218,   2002 , 10.1067/mge.2002.121337
• Application of contrast-enhanced ultrasonography to the local treatment of hepatocellular carcinoma, Kudo Masatoshi, Journal of Microwave Surgery, 20, 17, 25,   2002 , 10.3380/jmicrowavesurg.20.17, http://ci.nii.ac.jp/naid/130000066744
  Summary:Areas of residual tumors after RFA or PEI therapy are not distinguishable from necrotic tissues on US. The sonographic findings of gray-scale, color Doppler and power Doppler scanning after RFA or PEI therapy do not correlate well with the overall necrotic shape, or with the volume or extent of coagulation necrosis induced. Therefore, contrast-enhanced CT or MRI is generally necessary to assess the efficacy of the treatment. The absence of intensified areas on contrast-enhanced CT indicates the disappearance of the blood supply and, by inference, a successful treatment. Conversely, focal areas of persistent contrast enhancement usually indicate viable tumor cells, and, therefore, warrant further treatment to achieve a complete tumor necrosis.Harmonic gray-scale images can extract only the blood flow echoes created by destruction of microbubbles, whilst echoes from tissue are effectively cancelled. This mode makes it possible to clearly depict residual blood flow in tumors after therapy. Because contrast-enhanced harmonic sonography is easy to perform and provides real-time needle insertion guidance, it may be favored in monitoring response to localized therapies, obviating unnecessary CT and treatment sessions.Although contrast-enhanced CT can clearly depict residual areas of tumors after RFA or PEI therapy, it does not make possible real-time guidance in percutaneous therapies. Furthermore, the retention of lipiodol in HCC lesions sometimes makes it difficult to distinguish the hyperattenuating area of contrast enhancement from that of lipiodol when the retention of iodized oil in tumors is incomplete.Contrast-enhanced harmonic gray-scale images can reveal the tumor vascularity in patients with HCC, after transcatheter arterial embolization and percutaneous therapies, with high sensitivity and accuracy in comparison with dynamic CT. This capability of harmonic imaging for depicting residual cancer cells in HCCs after treatment facilitates a correct guidance for the insertion of a needle on US monitoring, which cannot be achieved by any other imaging modalities including CT and MRI.The noninvasive vascular technique of contrast-enhanced harmonic imaging is an extremely sensitive tool for detecting the intranodular blood flow in hepatic tumors. This method is drastically changing the diagnostic and therapeutic strategy of hepatic tumors, especially HCC, resulting in an eventual improvement in the prognosis of patients with HCC.
• Imaging diagnosis of hepatocellular carcinoma : recent progress, KUDO Masatoshi, Nippon Shokakibyo Gakkai Zasshi, 98, 7, 795, 808,   2001 07 01 , 10.11405/nisshoshi1964.98.795, http://ci.nii.ac.jp/naid/10007031629
• The usefulness of Harmonic Imaging of liver tumors, TEI H, KUDO M, MAEKAWA K, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356038
• Therapeutic application of the contrast enhanced harmonic ultrasound, MINAMI Y, WEN YL, SUETOMI Y, TEI H, ONDA H, KAWASAKI T, KUDO M, KUWAGUCHI A, MAEKAWA K, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356045
• Hemodynamic and morphologic analysis of hepatic tumors using high resolution contrast enhanced ultrasongraphy, KAWASAKI T, KUDO M, MAEKAWA K, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356099
• Hepatic hemangiomas : Levovist^【○!R】enhancement patterns with coded harmonic angio, KAWASAKI T, WEN Y, MINAMI Y, SUETOMI Y, TEI H, ONDA K, KUDO M, EGUCHI M, MAEKAWA K, DING H, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356332
• Classification of hemodynamic patterns of Hepatic Tumor on Coded Harmonic Angio mode, MAEKAWA K, OTANI M, WEN Y, DING H, SUETOMI Y, TEI H, MINAMI Y, ONDA H, KAWASAKI T, KUDO M, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356335
• Experience of EUS using micro comvex array, SUETOMI Y, KAWASAKI T, MINAMI Y, WEN YL, DING H, TEI H, ONDA H, KUDO M, MAEKAWA K, KUWAGUCHI A, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356357
• Value of Contrast Harmonic Imaging in the Diagnosis of Hepatic Focal Nodular Hyperplasia. H. Ding, MAEKAWA K, KUWAGUCHI A, MINAMI Y, WEN Y, TEI H, SUETOMI Y, ONDA H, KAWASAKI T, KUDO M, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356377
• Comparision of Enhanced Fundamental Power Doppler with Contrast Harmonic Power Doppler Imaging in the Detection of Intratumoral Flow of Hepatocellular Carcinoma, WEN Y, TEI H, MINAMI Y, SUETOMI Y, ONDA H, KAWASAKI T, KUDO M, OHTANI M, MAEKAWA K, DING H, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356378
• Contrast enhanced harmonic ultrasound of hepatic nodules which maintain portal flow as much as surrounding parenchyma, TEI H, WEN Y, MINAMI Y, SUETOMI Y, ONDA K, KAWASAKI T, KUDO M, OTANI M, MAEKAWA K, DING H, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356382
• Assessment of the effectafter Lipiodol TAE for HCC : usefulness of the contrast enhancedharmonic ultrasound, MINAMI Y, WEN Y L, DING H, SUETOMI Y, TEI H, ONDA H, KAWASAKI T, KUDO M, KUWAGUCHI A, MAEKAWA K, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356396
• RFA thrapy against the residual HCC after local therapy assisted by Contrast enhanced ultrasonography, TEI H, WEN Y, MINAMI Y, SUETOMI Y, ONDA K, KAWASAKI T, KUDO M, EGUCHI M, MAEKAWA K, DING H, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356397
• Evaluation of Image Quality of Sonosite 180 : Comparison with Toshiba PV 8000, WEN Y, TEI H, MINAMI Y, SUETOMI Y, ONDA H, KAWASAKI T, KUDO M, EGUCHI M, MAEKAWA K, DING H, 28, 3,   2001 04 15 , http://ci.nii.ac.jp/naid/10012356408
• Intrahepatic portosystemic venous shunt in liver cirrhosis: is it congenital or acquired?, AJR Am J Roentgenol, 160, 421, 422,   2001
• Intrahepatic spontaneous retrograde portal flow in liver cirrhosis can be reversed by meal intake., AJR, 177, 1109, 1112,   2001
• Agenesis of the left lobe of the liver: radiologic features, J Medical Ultrasonics, 28, 181, 183,   2001
• Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT, Radiology, 221, 3, 721, 730,   2001
• Has vascular enhancement with Levovist changed diagnosis of liver tumors?, Proceedings of 3rd International Kyoto Symposium on Ultrasound Contrast Imaging, 54, 56,   2001
• Contrast harmonic ultrasound is a breakthrough technology in the diagnosis and treatment of hepatocellular carcinoma, J Medical Ultrasonics, 28, 79, 81,   2001
• Detection of tumor parenchymal blood flow in hepatic tumors: value of second harmonic imaging with a galactose-based contrast agent, Hepatology Research, 21, 242, 251,   2001 , 10.1016/S1386-6346(01)00106-1
• Imaging blood flow characteristics of hepatocellular carcinoma, Oncology, 61, 48, 56,   2001
• Cerebral vascular resistence in hepatic insufficiency, J Gastroenterol Hepatol, 16, 845, 847,   2001 , 10.1046/j.1440-1746.2001.02552.x
• Sonographic findings of wandering spleen, J Gastroenterol, 36, 9, 643, 644,   2001 , 10.1007/s005350170051
• Color Doppler observation of efferent blood flow in liver tumors, Proceeding of the Hepatic Hemodynamic Imaging Study Group Special Symposium, Miura K, Itai Y, eds., 97, 103,   2001
• Intrahepatic portal vein anomaly: a duplicated portal vein, J Gastroenterol Hepatol, 16, 821, 824,   2001
• Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual display mode, Radiology, 220, 349, 356,   2001
• Recent advances in the imaging and ablation of hepatocellular carcinoma, Proceedings of 4th Korean Liver Cancer Study Group, 35, 44,   2001
• Hepatic peribiliary cysts: clinically harmless disease with potential risk due to increase in size and number, J Gastroenterol, 36, 286, 288,   2001 , 10.1007/s005350170119
• Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma, AJR, 176, 3, 661, 666,   2001
• Hepatocellular adenoma in type Ia glycogen storage disease, J Gastroenterol, 36, 65, 66,   2001 , 10.1007/s005350170157
• Proximal Bifurcation of Hepatic Artery : Novel Findings on Hepatic Arteries Demonstrated by Ultrasound Doppler Imaging , B-Flow and US Angiography, TOCHIO Hitoshi, IWASAKI Nobuhiro, NAKAMURA Hitomi, NAKAYAMA Keiko, SOGA Toshiko, NISHIUMA Shinichi, FUKUNAGA Toyokazu, OKABE Yoshihiro, KASHIDA Hiroshi, HIRASA Masahiro, IBUKI Yasuyoshi, FUJIMOTO Toshiaki, MORIMOTO Yoshito, KUDO Masatoshi, TOMITA Syusuke, KONISHI Yutaka, ORINO Akio, 27, 10, 1303, 1310,   2000 10 15 , http://ci.nii.ac.jp/naid/10007873017
• Laparoscopic splenopexy for adult wandering spleen : Sandwich method with two sheets of absorbable kintted mesh, Surgical Laparoscopy Endoscopy ＆ Percutaneous techniques, 10, 5, 332, 334,   2000 10
• Clinical Potential of Contrast-enhanced Ultrasonography in Hepatobiliary and Pancreatic Disease., KUDO M, DING H, ONDA H, MAEKAWA K, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182208
• Demonstration of Tumor Efferent Blood Flow by Levovist-enhanced Color Doppler Imaging in a case of Hepatocellular Carcinoma., DING H, ONDA H, YAMAMOTO K, INOUE T, UMEHARA Y, EGUCHI M, YAMAMOTO M, ONDA Y, MAEKAWA K, KUDO M, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182329
• Usefulness of Intermittent Imaging of Second Harmonic Power Doppler Mode using Intravenous Injection of Levovist., DING H, ONDA H, NAKAOKA R, MATSUI S, YAMAMOTO K, EGUCHI M, YAMAMOTO M, ONDA Y, MAEKAWA K, KUDO M, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182330
• Usefulness of Levovist-enhanced Intermittent Second Harmonic Imaging with a Use of Multi-shot Digital Subtraction Technique in the Diagnosis of Liver Tumors., DING H, ONDA H, YAMAMOTO K, YUTANI I, SHIOMI M, EGUCHI E, YAMAMOTO M, ONDA Y, MAEKAWA K, KUDO M, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182331
• Enhanced Color Doppler Imaging of Liver Tumors: Detection of Tumor Parenchymal Flow by Intermittent Imaging., MAEKAWA K, EGUCHI M, YAMAMOTO M, ONDA Y, DING H, ONDA H, TANIIKE D, KAMEYAMA C, YAMAMOTO K, KUDO M, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182334
• Usefulness of B Flow Imaging in Liver Disease., EGUCHI M, YAMAMOTO M, ONDA Y, MAEKAWA K, DING H, KATO R, ONDA H, MATSUI S, YAMAMOTO K, KUDO M, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182350
• US Guided Radio-frequency Abration Therapy for Hepatocellular Carcinoma: Initial Experience, ONDA H, DING J.H, NAKAOKA R, TANIIKE S, KAMEYAMA C, MATSUI S, YUTANI I, YAMAMOTO K, SHIOMI M, KUDO M, 27, 4,   2000 04 15 , http://ci.nii.ac.jp/naid/10006182438
• Therapeutic results of different treatments for single hepatocellular carcinoma : a retroapective multicenter study (18 institutions), SEKI Toshihito, OSAKI Yukio, KASUGAI Hiroshi, OKA Hiroko, KUDO Masatoshi, OSAKA LIVER CANCER, STUDY GROUP, Kanzo, 41, 3, 169, 182,   2000 03 25 , 10.2957/kanzo.41.169, http://ci.nii.ac.jp/naid/10005251463
  Summary:This retrospective study was undertaken to obtain information relevant to the therapeutic strategy and therapeutic results in single hepatocellular carcinoma. Eighteen institutions located mainly in the Kinki District of Japan took part in this study.<BR>The data of 3489 patients, who underwent different treatments between January 1, 1987 to March 31, 1998 were gathered and analyzed in this study.<BR>The results are shown follows. (The end-point of clinical observation was July 31, 1998)<BR>(1) Surgical resection was mainly performed for HCC of clinical stage I or II regardless of the tumor size.<BR>(2) The difference in survival of patients with HCC measuring 2.0cm or less in diameter of clinical stage I or II between surgical resection and PEIT or PMCT was not statistically significant.<BR>(3) Among patients treated with PEIT, ten-year survivors were observed in patients with HCC measuring 3.0cm or less in diameter.<BR>(4) In patients with HCC measuring more than 3.0 cm in diameter and of clinical stage I or II, survival rates of surgical resection were superior to those of other treatments except two groups (TAE+PEIT, 3<tumor size≤5cm, clinical stage I and TAE, 5cm<tumor size, clinical stage II).<BR>(5) Of ten-year survivors, 87% had been treated with surgical resection as a first treatment.<BR>(6) Of patients with HCC measuring 5.0cm or less in diameter, approximately 40% died of causes other than HCC progression.<BR>(7) There was a statistically significant difference in survival rates between institutions having 100 cases or more, and those with fewer than 100 cases.
• A case of gastrointestinal stromal tumor(GIST) in the stomach, YUTANI Itsuro, SHIOMI Mikio, KAWABATA Kazuhito, OHNO Yasuhiro, INOUE Ryoichi, KUDO Masatoshi, AOKI Norihiko, YAMAZUMI Toshiaki, YOSHIKAWA Hideto, OKUNO Kiyotaka, Nippon Shokakibyo Gakkai Zasshi, 97, 3, 331, 336,   2000 03 05 , 10.11405/nisshoshi1964.97.331, http://ci.nii.ac.jp/naid/10005557850
• Repeated hepatic arterial chemoembolization therapy for management of a patient with metastatic carcinoid tumors of the liver, Am J Gastroenterol, 95, 7, 1842, 1843,   2000 , 10.1016/S0002-9270(00)00942-4
• Repeated hepatic arterial chemoembolization therapy for management of a patient with metastatic carcinoid tumors of the liver., Am J Gastroenterol, 95, 1842, 1843,   2000 , 10.1016/S0002-9270(00)00942-4
• The Efferent Blood Flow of Early Hepatocellular Carcinoma and Borderline Lesions : Demonstration by Color Doppler Imaging, TOCHIO Hitoshi, TOMITA Syusuke, KUDO Masatoshi, IWASAKI Nobuhiro, TAMURA Syuji, NAKAMURA Hitomi, SOGA Toshiko, FUKUNAGA Toyokazu, OKABE Yoshihiro, KASHIDA Hiroshi, HIRASA Masahiro, IBUKI Yasuyosi, MORIMOTO Yoshito, ORINO Akio, 26, 6, 781, 785,   1999 06 15 , http://ci.nii.ac.jp/naid/10007875957
• The Draining Vessel of Advanced Hepatocellular Carcinoma: Assessment of Color Doppler Findings in Comparison with Histopathological Findings, TOCHIO Hitoshi, TOMITA Syusuke, UDO Masatoshi, OKABE Yoshihiro, FUKUNAGA Kazutoyo, KASHIDA Hiroshi, HIRASA Masahiro, IBUKI Yasuyoshi, ORINO Akio, Kanzo, 40, 4, 243, 252,   1999 04 25 , 10.2957/kanzo.40.243, http://ci.nii.ac.jp/naid/10005255627
  Summary:Efferent flow signal, which shows continuous waveform, adjacent to afferent pulsatile wave signal is often detected within hepatocellular carcinoma (HCC) by color Doppler imaging. It is hypothesized that this signal may reflect the draining efferent blood flow within the preexisting portal vein, which remained in the advanced stage HCC nodule. In order to clarify whether this hypothesis is correct, 11 resected advanced HCC with such signals were analyzed histopathologically. The size of tumor ranged 1.2-5.1cm (Mean±SD=2.5±1.3cm). In 8 out of 11 (73%), Glisson sheath including patent portal vessel were observed within the tumor. These portal veins were located within entire tumor in small, well-differentiated HCC, where as those were located in the periphery of the tumor in large, relatively poorly differentiated HCC. These results suggested that the portal vein, which remained within the advanced HCC, may act as a draining vessel in some advanced HCCs. Furthermore, portal vein is an efferent draining vessel already in small, well-differentiated HCC.
• Diagnosis of Hepatic Nodular Lesions : Role of Ultrasonography, Especially of Color Doppler Imaging, in the Next Century, KUDO M, 26, 4,   1999 04 15 , http://ci.nii.ac.jp/naid/10013820478
• Hepatic Hemangioma with Arterio-portal Shunt : A cause of Focal Sparing in Fatty Liver, ONDA H, KUDO M, AOKI N, YAMAMOTO M, HASEGAWA Y, MAEKAWA K, TOCHIO H, OKABE Y, TOMITA S, ORINO A, 26, 4,   1999 04 15 , http://ci.nii.ac.jp/naid/10013820539
• Clinical Usefulness of 3-Dimensional Ultrasonographic Imaging obtained by Fusion 3D technique, MAEKAWA K, KUDO M, ONDA H, TANIIKE S, KAMEYAMA C, AOKI N, HASEGAWA Y, YAMAMOTO M, HASHIMOTO S, YAMAGATA H, 26, 4,   1999 04 15 , http://ci.nii.ac.jp/naid/10013820588
• Association between a focal spared area in the fatty liver and intrahepatic efferent blood flow from the gallbladder wall: evaluation by color Doppler sonography., AJR, 172, 1249, 1253,   1999
• Riedel's lobe of the liver and its clinical implications, Internal Medicine, 39, 2, 87, 88,   1999 , 10.2169/internalmedicine.39.87
• Imaging diagnosis of hepatocellular carcinoma and premalignant /borderline lesions, Seminors in Liver Disease, 19, 297, 309,   1999
• Blood flow and disease state of hepatoma. Advance and significance of the ultrasonic wave blood flow image., Kanzo, 39, 12, 885, 894,   1998 12 25 , 10.2957/kanzo.39.885, http://ci.nii.ac.jp/naid/10005576256
• The Draining Vessel of Advanced Hepatocellular Carcinoma : Assessment by Color Doppler Imaging in Comparison with Histopathological Findings, TOCHIO H, IWASAKI N, NAKAMURA H, TAMURA S, SOGA T, MORIMOTO Y, OKABE Y, KASHIDA H, KUDO M, TOMITA S, 25, 4,   1998 04 15 , http://ci.nii.ac.jp/naid/10016336119
• Regenerative nodule of alcoholic cirrhosis revealing hyperperfusion at CT during arterial portography (CTAP) and hyperperfus at CT during arteriography (CTA), KIM Soo Ryan, MATSUOKA Toshiyuki, HAYASHI Yoshitake, KUDO Masatoshi, SHINTANI Shigeyuki, SASAKI Kazunori, KIM Jung Hyo, IMOTO Susumu, KIM Ke Ih, Kanzo, 39, 175, 180,   1998 03 25 , 10.2957/kanzo.39.175, http://ci.nii.ac.jp/naid/10005574316
• Morphological diagnosis of hepatocellular carcinoma: special emphais on intranodular hemodynamic imaging, Hepato-Gastroenterology, 45, 1226, 1231,   1998
• Acute portal hypertension due to gastroduodenal aneurysm rupturing and communicating to the superior mesenteric vein, Japanese Journal of Portal Hypertension and Esophageal Varices, 4, 4, 368, 373,   1998 , 10.11423/jsph1995.4.4_368, http://ci.nii.ac.jp/naid/130001930026
• Association Between Focal Spared Area at the Gallbladder Bed in the Fatty Liver and Intrahepatic Efferent Blood Flow From the Gallbladder Wall : Evaluation With Color Doppler Imaging, TOCHIO Hitoshi, OKABE Yoshihiro, TOMITA Syusuke, KUDO Masatoshi, KASHIDA Hiroshi, IWASAKI Nobuhiro, MINOWA Kazushi, TAMURA Syuji, SOGA Toshiko, MORIMOTO Yoshito, WATANABE Tomohiro, FUKUNAGA Toyokazu, HIRASA Masahiro, IBUKI Yasuyoshi, ORINO Akio, TODO Akio, 24, 10, 43, 53,   1997 10 15 , http://ci.nii.ac.jp/naid/10007874670